

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
6 July 2006 (06.07.2006)

PCT

(10) International Publication Number
WO 2006/071983 A2

(51) International Patent Classification:
A61K 39/00 (2006.01) A61P 35/00 (2006.01)

(74) Agent: DELANEY, Karoline, A.; Knobbe, Martens, Olson & Bear, LLP, 2040 Main Street, 14th Floor, Irvine, California 92614 (US).

(21) International Application Number:
PCT/US2005/047407

(22) International Filing Date:
29 December 2005 (29.12.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/640,598 29 December 2004 (29.12.2004) US

(71) Applicant (for all designated States except US):
MANNKIND CORPORATION [US/US]; 28903 North Avenue Paine, Valencia, California 91355 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): CHIANG, Chih-Sheng [US/US]; 10339 Oakdale Avenue, Chatsworth, California 91311 (US). SIMARD, John, J.L. [CA/CA]; 2960 Altamont Crescent, West Vancouver, British Columbia V7V 3C1 (CA). DIAMOND, David, C. [US/US]; 23135 Schoenborn Street, West Hills, California 91304 (US). BOT, Adrian, Ion [RO/US]; 24406 West Gable Ranch Lane, Valencia, California 91354 (US). LIU, Xiping [US/US]; 6035 Camellia Avenue, Temple City, California 91780 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report


[Continued on next page]

(54) Title: COMBINATIONS OF TUMOR-ASSOCIATED ANTIGENS IN COMPOSITIONS FOR VARIOUS TYPES OF CANCERS

Schedule of immunization with plasmids (pCBP expressing SSX2 41-49; and pSEM expressing Melan A)

Schedule of immunization

Immunization Schedule:



Experimental Setup:

Group 1: Plasmids separately (pCBP, pSEM)
Group 2: Plasmids admixed (pCBP+pSEM)

WO 2006/071983 A2

(57) Abstract: Disclosed herein are methods and compositions for inducing an immune response against various combinations of tumor-associated antigens, which can promote effective immunologic intervention in pathogenic processes. Embodiments of the invention disclosed herein are directed to the use of effective combinations of TuAAs for the immunotherapy of patients with various types of cancer. Both immunogenic compositions for inducing an immune response to these combinations of antigens and methods for their use are disclosed.



For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

COMBINATIONS OF TUMOR-ASSOCIATED ANTIGENS IN COMPOSITIONS FOR VARIOUS TYPES OF CANCERS

Cross Reference to Related Applications

[0001] This application claims priority under 35 U.S.C. § 119(e) to U.S. Provisional Application No. 60/640,598, filed on December 29, 2004, entitled COMBINATIONS OF TUMOR-ASSOCIATED ANTIGENS IN COMPOSITIONS FOR VARIOUS TYPES OF CANCERS; the disclosure of which is hereby expressly incorporated by reference in its entirety.

Background of the Invention

Field of the Invention

[0002] Disclosed herein are methods and compositions for inducing an immune response against various combinations of tumor-associated antigens, which can promote effective immunologic intervention in pathogenic processes.

Description of the Related Art

[0003] The American Cancer Society has estimated that over one million people get cancer each year, and that approximately one out of every two American men and one out of every three American women will have some type of cancer at some point during their lifetime.

[0004] Cancer generally develops when cells in a part of the body begin to grow out of control. Although there are many kinds of cancer, they typically begin with out-of-control growth of abnormal cells.

[0005] Normal body cells grow, divide, and die in an orderly fashion. Cancer cells are different in that they continue to grow and divide. Instead of dying, they outlive normal cells and continue to form new abnormal cells.

[0006] Usual treatment options for cancer include surgery, radiation therapy, and chemotherapy. A fourth branch of treatment is developing, which is referred to as immunotherapy. Immunotherapies attempt to help the immune system recognize cancer cells, and/or to strengthen a response against cancer cells in order to destroy the cancer.

Immunotherapies include active and passive immunotherapies. Active immunotherapies attempt to stimulate the body's own immune system to fight the disease. Passive immunotherapies generally do not rely on the body to attack the disease; instead, they use immune system components (such as antibodies) created outside of the body.

[0007] A continuing need exists for additional treatment options.

Summary of the Invention

[0008] Embodiments of the invention disclosed herein are directed to the use of effective combinations of tumor-associated antigens (TuAAs) for the immunotherapy of patients with various types of cancer. In some embodiments, the TuAAs are antigens expressed by the cancer cell itself. In some embodiments, the TuAAs are antigens associated with non-cancerous components of the tumor, such as tumor-associated neovasculature or other stroma. In some embodiments, the combinations further include a tumor growth factor and/or a signal transduction protein. Both immunogenic compositions for inducing an immune response to these combinations of antigens and methods for their use are disclosed.

[0009] Some embodiments relate to methods of treating neoplastic diseases. The methods can include the step of immunizing a patient against, for example, PRAME and at least one other tumor associated antigen. To immunize a patient against an antigen such as, for example, PRAME means in preferred embodiments to administer to the patient some portion of the antigen, or some other immunogenic product that is capable of inducing a specific immune response directed against the antigen. Accordingly, in some embodiments, immunizing against PRAME includes administering a complete and intact PRAME antigen to the patient. In some embodiments, immunizing against PRAME includes administering one or more epitopes, one or more epitope clusters, one or more fragments, and the like, of PRAME, and/or administering, for example, a nucleic acid encoding any of the foregoing epitope(s), cluster(s), fragment(s), and the like. Although PRAME is used as a representative antigen for the purpose of discussion, any antigen against which a patient can be immunized can be used.

[0010] Some embodiments relate to methods of treating ovarian or colorectal cancer. The methods can include the step of immunizing a patient against, for example, PRAME and/or PSMA and at least one other tumor associated antigen. In some embodiments, the at least one other tumor associated antigen can include, for example,

SSX-2, NY-ESO-1, PSMA, PRAME, mesothelin, a MAGE protein, MAGE-3, Melan-A, PLK1, VEGF-A, VEGFR2, Tie-2, and the like, or subsets thereof. Preferably, the methods include immunizing against PRAME, NY-ESO-1 and/or SSX-2, for example. More preferably, the methods include immunizing against PRAME, NY-ESO-1, SSX-2, and PSMA, for example. The methods can further include the step of immunizing against at least one antigen associated with tumor neovasculature. The antigen associated with tumor neovasculature can be, for example, PSMA, VEGFR2, and/or Tie-2. The methods can further include immunizing against a growth factor, such as VEGF-A, and/or a signal transduction protein, such as PLK1. In preferred embodiments, the methods induce a cytolytic T cell response.

[0011] In some embodiments, methods of inducing an anti-cancer immune response in the treatment of ovarian or colorectal cancer are disclosed. The methods can include, for example, the step of immunizing a patient against PRAME and/or PSMA and at least one tumor-associated antigen. In some embodiments, the at least one other tumor-associated antigen can be, for example, SSX-2, NY-ESO-1, PSMA, PRAME, mesothelin, a MAGE protein, MAGE-3, Melan-A, PLK1, VEGF-A, VEGFR2, Tie-2, and the like, or subsets thereof. For example, in some embodiments, the methods can include immunization against PRAME, NY-ESO-1, and/or SSX-2. The methods can further include immunizing against PSMA. The methods can further include the step of immunizing against at least one antigen associated with tumor neovasculature. The antigen associated with tumor neovasculature can be, for example, PSMA, VEGFR2, and/or Tie-2. The methods can further include immunizing against a growth factor, such as VEGF-A, and/or a signal transduction protein, such as PLK1. In preferred embodiments, the anti-cancer immune response is a CTL response.

[0012] Other embodiments relate to methods of treating pancreatic cancer. The methods can include the step of immunizing against, for example, PRAME and/or PSMA and at least one other tumor-associated antigen. In an embodiment, the methods further include immunizing against at least one antigen selected from an antigen associated with tumor neovasculature, a growth factor and a signal transduction protein. The at least one other tumor-associated antigen can be, for example, PRAME, PSMA, mesothelin, SSX-2 and/or NY-ESO-1, a MAGE protein, MAGE-3, Melan-A, PLK1, VEGF-A, VEGFR2, Tie-2, and the like, or subsets thereof. For example, the methods can include immunizing against PSMA, NY-ESO-1, and/or SSX-2. In some embodiments,

the methods can include immunizing against PRAME, NY-ESO-1, and/or SSX-2. In some embodiments, the methods can include immunizing against PRAME, PSMA, NY-ESO-1, and SSX-2. The methods can further include the step of immunizing against at least one antigen associated with tumor neovasculature. The antigen associated with tumor neovasculature can be, for example, PSMA, VEGFR2 and/or Tie-2. In some embodiments, the growth factor is VEGF-A. In some embodiments, the signal transduction protein is PLK1. In a preferred embodiment, the methods induce a cytolytic T cell response.

[0013] Further, in some embodiments, methods of inducing an anti-cancer immune response in the treatment of pancreatic cancer are disclosed. The methods can include, for example, the step of immunizing a patient against PRAME and/or PSMA and at least one tumor-associated antigen. In an embodiment, the methods further include immunizing against at least one antigen selected from an antigen associated with tumor neovasculature, a growth factor and a signal transduction protein. In some embodiments, the at least one other tumor-associated antigen can be, for example, PRAME, PSMA, SSX-2, NY-ESO-1, mesothelin, a MAGE protein, MAGE-3, Melan-A, PLK1, VEGF-A, VEGFR2, Tie-2, and the like, or subsets thereof. For example, the methods can include immunization against PSMA and NY-ESO-1, and/or SSX-2. In some embodiments, the methods can include immunizing against PRAME and NY-ESO-1 and/or SSX-2. In some embodiments, the methods can include immunizing against PRAME, PSMA and NY-ESO-1 and/or SSX-2. The methods can further include the step of immunizing against at least one antigen associated with tumor neovasculature. The antigen associated with tumor neovasculature can be, for example, PSMA, VEGFR2 and/or Tie-2. In some embodiments, the growth factor is VEGF-A. In some embodiments, the signal transduction protein is PLK1. In preferred embodiments, the anti-cancer immune response is a CTL response.

[0014] Still other embodiments relate to methods of treating non-small cell lung cancer. The methods can include the step of immunizing a patient against, for example, PSMA and at least one other tumor associated antigen. For example, the tumor-associated antigen can be a MAGE protein, MAGE-3, Melan-A, mesothelin, SSX-2, NY-ESO-1, PRAME, PSMA, VEGF-A, PLK1, VEGFR2, Tie-2, and the like, or subsets thereof. Preferably, the methods can include immunizing against PSMA, NY-ESO-1 and/or SSX-2. More preferably, the methods can include immunization against PSMA,

NY-ESO-1, SSX-2, and/or MAGE-3, for example. The methods can further include the step of immunizing against at least one antigen associated with tumor neovasculature. The antigen associated with tumor neovasculature can be, for example, PSMA, VEGFR2 and/or Tie-2. The methods can further include immunizing against a growth factor, such as VEGF-A, and/or a signal transduction protein, such as PLK1. In a preferred embodiment, the methods can induce a cytolytic T cell response.

[0015] In a further embodiment, methods of inducing an anti-cancer immune response in the treatment of non-small cell lung cancer are disclosed. The methods can include, for example, the step of immunizing a patient against PSMA and at least one tumor-associated antigen. The at least one other tumor-associated antigen can be, for example, a MAGE protein, MAGE-3, Melan-A, mesothelin, SSX-2, NY-ESO-1, PRAME, PSMA, VEGF-A, PLK1, VEGFR2, Tie-2, and the like, or subsets thereof. For example, the methods can include immunization against PSMA, NY-ESO-1, and/or SSX-2. The methods can further include immunization against PSMA, NY-ESO-1, SSX-2, and/or MAGE-3. In an embodiment, the methods can further include the step of immunizing against at least one antigen associated with tumor neovasculature. The antigen associated with tumor neovasculature can be, for example, PSMA, VEGFR2 and/or Tie-2. The methods can further include immunizing against a growth factor, such as VEGF-A, and/or a signal transduction protein, such as PLK1. In preferred embodiments, the anti-cancer immune response is a CTL response.

[0016] Other embodiments relate to methods of treating renal cell carcinoma. The methods can include the step of immunizing a patient against, for example, PSMA and/or PRAME and at least one other tumor associated antigen. The at least one other tumor-associated antigen can be, for example, PRAME, PSMA, SSX-2, NY-ESO-1, a MAGE protein, MAGE-3, Melan-A, mesothelin, VEGF-A, VEGFR2, Tie-2, and the like, or subsets thereof. Preferably, the methods can include immunizing against PSMA, PRAME, and/or SSX-2, for example. The methods can further include the step of immunizing against at least one antigen associated with tumor neovasculature. The antigen associated with tumor neovasculature can be, for example, PSMA, VEGFR2 and/or Tie-2. In a preferred embodiment, the methods induce a cytolytic T cell response.

[0017] Further, in some embodiments, methods of inducing an anti-cancer immune response in the treatment of renal cell carcinoma are disclosed. The methods can include, for example, the step of immunizing a patient against PSMA and at least one

other tumor-associated antigen. In some embodiments, the tumor-associated antigen can be PRAME, PSMA, SSX-2, NY-ESO-1, a MAGE protein, MAGE-3, Melan-A, mesothelin, VEGF-A, VEGFR2, Tie-2, and the like, or subsets thereof. For example, the methods can include immunization against PSMA, PRAME, and/or SSX-2. The methods can further include the step of immunizing against at least one antigen associated with tumor neovasculature. The antigen associated with tumor neovasculature can be, for example, PSMA, VEGFR2 and/or Tie-2. In preferred embodiments, the anti-cancer immune response is a CTL response.

[0018] Some embodiments relate to methods of treating melanoma. The methods can include the step of immunizing a patient against, for example, at least one tumor-associated antigen selected from each of two groups. The first group can include, for example, tyrosinase, Melan-A, and the like. The second group can include, for example, SSX-2, NY-ESO-1, and the like. In some embodiments, the methods can include immunizing against Melan-A, SSX-2, and/or NY-ESO. In some embodiments, the methods can include immunization against Melan-A, SSX-2, and/or tyrosinase, for example. The methods can further include the step of immunizing against at least one antigen associated with tumor neovasculature. The antigen associated with tumor neovasculature can be, for example, PSMA, VEGFR2, and/or Tie-2. The methods can further include immunizing against a growth factor, such as VEGF-A, and/or a signal transduction protein, such as PLK1. In a preferred embodiment, the methods induce a cytolytic T cell response.

[0019] In some embodiments, methods of inducing an anti-cancer immune response in the treatment of melanoma are disclosed. The methods can include, for example, the step of immunizing a patient against at least one tumor-associated antigen selected from each of two groups. The first group can include, for example, tyrosinase, Melan-A, and the like. The second group can include, for example, SSX-2, NY-ESO-1, and the like. For example, the method can include immunization against Melan-A, SSX-2, and/or NY-ESO. Alternatively, the method can include, for example, immunization against Melan-A, SSX-2, and/or tyrosinase. The method can further include the step of immunizing against at least one antigen associated with tumor neovasculature. The antigen associated with tumor neovasculature can be, for example, PSMA, VEGFR2, and/or Tie-2. The methods can further include immunizing against a growth factor, such

as VEGF-A, and/or a signal transduction protein, such as PLK1. In preferred embodiments, the anti-cancer immune response is a CTL response.

[0020] Some embodiments relate to the use of a composition comprising, for example, PRAME and/or PSMA and at least one other tumor associated antigen, in the preparation of a medicament for the treatment of ovarian or colorectal cancer. In some embodiments the at least one other tumor associated antigen can include, for example, SSX-2, NY-ESO-1, PSMA, PRAME, mesothelin, a MAGE protein, MAGE-3, Melan-A, PLK1, VEGF-A, VEGFR2, Tie-2, and the like, or subsets thereof. Thus, the composition can comprise NY-ESO-1 and/or SSX-2, for example. In some embodiments, the composition can comprise NY-ESO-1, SSX-2, and/or PSMA, for example. The composition can further include at least one antigen associated with tumor neovasculature. The antigen associated with tumor neovasculature can be, for example, PSMA, VEGFR2, and/or Tie-2. In a preferred embodiment, the medicament induces a cytolytic T cell response.

[0021] Other embodiments relate to the use of a composition comprising, for example, PRAME and/or PSMA and at least one other tumor-associated antigen in the preparation of medicament for the treatment of pancreatic cancer. The composition can further include an antigen associated with tumor neovasculature, a growth factor, or a signal transduction protein. The at least one other tumor-associated antigen can be, for example, PRAME, PSMA, SSX-2 and/or NY-ESO-1, mesothelin, a MAGE protein, MAGE-3, Melan-A, PLK1, VEGF-A, VEGFR2, Tie-2, and the like, or subsets thereof. In an embodiment, the composition comprises PSMA and NY-ESO-1, and/or SSX-2. In an embodiment, the composition comprises PRAME and NY-ESO-1, and/or SSX-2. The composition can further include at least one antigen associated with tumor neovasculature. The antigen associated with tumor neovasculature can be, for example, PSMA, VEGFR2 and/or Tie-2. The growth factor can be VEGF-A, for example. The signal transduction protein can be, for example, PLK1. In a preferred embodiment, the medicament can induce a cytolytic T cell response. In some embodiments, the medicament is for use in combination with at least one additional medicament comprising a tumor-associated antigen.

[0022] Still other embodiments relate to the use of a composition comprising PSMA and at least one other tumor associated antigen in the preparation of a medicament for the treatment of non-small cell lung cancer. In some embodiments, the tumor-

associated antigen can be a MAGE protein, MAGE-3, Melan-A, mesothelin, SSX-2, NY-ESO-1, PRAME, PSMA, VEGF-A, PLK1, VEGFR2, Tie-2, and the like, or subsets thereof. Preferably, the composition comprises PSMA, NY-ESO-1 and/or SSX-2. More preferably, the composition comprises PSMA, NY-ESO-1, SSX-2, and/or MAGE-3, for example. The composition can further include at least one antigen associated with tumor neovasculature. The antigen associated with tumor neovasculature can be, for example, PSMA, VEGFR2 and/or Tie-2. In a preferred embodiment, the medicament can induce a cytolytic T cell response.

[0023] Alternative embodiments relate to the use of a composition comprising PRAME and/or PSMA and at least one other tumor associated antigen in the preparation of a medicament for the treatment of renal cell carcinoma. The at least one other tumor-associated antigen can be, for example, PSMA, PRAME, SSX-2, NY-ESO-1, a MAGE protein, MAGE-3, Melan-A, mesothelin, VEGF-A, VEGFR2, Tie-2, and the like, or subsets thereof. Preferably, the composition comprises PSMA, PRAME, and/or SSX-2, for example. The composition can further include at least one antigen associated with tumor neovasculature. The antigen associated with tumor neovasculature can be, for example, PSMA, VEGFR2 and/or Tie-2. In a preferred embodiment, the medicament can induce a cytolytic T cell response.

[0024] Still other embodiments relate to the use of a composition comprising at least one tumor-associated antigen selected from each of two groups in the preparation of a medicament for the treatment of melanoma. The first group can include, for example, tyrosinase, Melan-A, and the like. The second group can include, for example, SSX-2, NY-ESO-1, and the like. Preferably, the composition comprises Melan-A, SSX-2, and/or NY-ESO. More preferably, the composition comprises Melan-A, SSX-2, and/or tyrosinase, for example. The method can further include the step of immunizing against at least one antigen associated with tumor neovasculature. The antigen associated with tumor neovasculature can be, for example, PSMA, VEGFR2, and/or Tie-2. The composition can further include a growth factor, such as VEGF-A and/or a signal transduction protein, such as PLK1. In a preferred embodiment, the medicament can induce a cytolytic T cell response.

[0025] Other embodiments relate to immunogenic compositions for inducing an anti-cancer immune response, comprising, individually or in combination, 1) whole antigens, 2) fragments of antigens, 3) epitope clusters derived from antigens, 4) epitopes

derived from antigens, or 5) nucleic acids encoding any of 1 to 4; wherein the antigens comprise a first antigen selected from PRAME, PSMA, and/or tyrosinase; and at least one other tumor-associated antigen. The cancer treated by the immunogenic compositions can be, for example, ovarian cancer, colorectal cancer, pancreatic cancer, non-small cell lung cancer, melanoma, renal cell carcinoma, and the like. In a preferred embodiment, the at least one other tumor-associated antigen is selected from NY-ESO-1, SSX-2, a MAGE protein, MAGE-3, mesothelin, Melan-A, VEGFR2, Tie-2, and the like, or subsets thereof. In some embodiments, the compositions can further include a neovasculature antigen or other stromal cell antigen. In some embodiments, the compositions can also include an extra-cellular factor. In some embodiments, the compositions further include a non-target antigen. In some embodiments, the compositions can include a means for inducing immunity to a factor that promotes the growth, survival, invasiveness, or metastasis of a tumor. The compositions can also include a means for inducing bystander help for the tumor-associated antigens. In some embodiments, the compositions can include a means for causing inflammation in a tumor lesion. The compositions can further include a growth factor and/or a signal transduction protein. The growth factor can be, for example, VEGF-A. The signal transduction factor can be, for example, PLK1.

[0026] Still other embodiments relate to immunogenic compositions for the treatment of cancer. The compositions can include, for example, individually or in combination, 1) whole antigens, 2) fragments of antigens, 3) epitope clusters derived from antigens, 4) epitopes derived from antigens, or 5) nucleic acids encoding any of 1 to 4; wherein the antigens can include PRAME and/or PSMA and/or tyrosinase and at least one other tumor-associated antigen. In a preferred embodiment, the at least one other tumor-associated antigen can be selected from SSX-2 and/or NY-ESO-1, a MAGE protein, MAGE-3, mesothelin, Melan-A, VEGFR2, Tie-2, and the like, or subsets thereof. The cancer treated can be, for example, ovarian cancer, colorectal cancer, pancreatic cancer, non-small cell lung cancer, melanoma, renal cell carcinoma, and the like. The compositions can further include at least one antigen associated with tumor neovasculature or stroma. The antigen associated with tumor neovasculature can be, for example, PSMA, VEGFR2 and/or Tie-2. Thus, in some embodiments, immunogenic compositions comprising a PSMA antigen and further comprising at least one additional antigen selected from PRAME, NY-ESO and SSX-2 are disclosed. In some embodiments, immunogenic compositions comprising a PRAME antigen and further

comprising at least additional antigen selected from PRAME, NY-ESO and SSX-2 are disclosed. In some embodiments, the compositions further include an extra-cellular factor. In some embodiments, the compositions further include a non-target antigen. In some embodiments, the compositions further include a means for inducing immunity to a factor that promotes the growth, survival, invasiveness, or metastasis of a tumor. In some embodiments, the compositions further comprise a means for inducing bystander help for the tumor-associated antigens. In some embodiments, the compositions further comprise a means for causing inflammation in a tumor lesion. The compositions can further include a growth factor and/or a signal transduction protein. The growth factor can be, for example, VEGF-A. The signal transduction factor can be, for example, PLK1.

[0027] Other embodiments relate to immunogenic compositions for the treatment of or for inducing an anti-cancer response against ovarian or colorectal cancer, for example. The compositions can include, for example, individually or in combination, 1) whole antigens, 2) fragments of antigens, 3) epitope clusters derived from antigens, 4) epitopes derived from antigens, 5) nucleic acids encoding any of 1 to 4, and the like; wherein the antigens can include a first antigen selected from PRAME, PSMA, and/or tyrosinase and at least one other tumor-associated antigen. The at least one other tumor-associated antigen can include, for example, SSX-2, NY-ESO-1, a MAGE protein, MAGE-3, Melan-A, mesothelin, VEGF-A, PLK1, PRAME, PSMA, VEGFR2, Tie-2, and the like, or subsets thereof. The compositions can further include at least one antigen associated with tumor neovasculature or stroma. The antigen associated with tumor neovasculature can be, for example, PSMA, VEGFR2 and/or Tie-2. The compositions can further include a growth factor and/or a signal transduction protein. The growth factor can be, for example, VEGF-A. The signal transduction factor can be, for example, PLK1.

[0028] Other embodiments relate to immunogenic compositions for the treatment of, or for inducing an anti-cancer response against, pancreatic cancer. The compositions can include, for example, individually or in combination, 1) whole antigens, 2) fragments of antigens, 3) epitope clusters derived from antigens, 4) epitopes derived from antigens, or 5) nucleic acids encoding any of 1 to 4; wherein the antigens are PRAME and/or PSMA and at least one other tumor-associated antigen. In a preferred embodiment, the at least one other tumor-associated antigen can be selected from PSMA, PRAME, mesothelin, SSX-2, NY-ESO-1, a MAGE protein, MAGE-3, Melan-A, VEGF-

A, PLK1, VEGFR2, Tie-2, and the like, or subsets thereof. In some embodiments, the composition comprises PRAME and NY-ESO-1 and/or SSX-2. In some embodiments, the composition comprises PSMA and NY-ESO-1 and/or SSX-2. In some embodiments, the composition comprises PRAME, PSMA and NY-ESO-1 and/or SSX-2. In some embodiments, the compositions can further include a neovasculature antigen or other stromal cell antigen. The antigen associated with tumor neovasculature can be, PSMA, VEGFR2 and/or Tie-2. In some embodiments, the compositions can also include an extra-cellular factor. In some embodiments, the compositions further include a non-target antigen. In other embodiments, the compositions can include a means for inducing immunity to a factor that promotes the growth, survival, invasiveness, or metastasis of a tumor. The compositions can also include a means for inducing bystander help for the tumor-associated antigens. In some embodiments, the compositions can include a means for causing inflammation in a tumor lesion. The compositions can further include a growth factor and/or a signal transduction protein. The growth factor can be, for example, VEGF-A. The signal transduction factor can be, for example, PLK1.

[0029] Some embodiments relate to immunogenic compositions for the treatment of or for inducing an anti-cancer response against non-small cell lung cancer. The compositions can include, for example, individually or in combination, 1) whole antigens, 2) fragments of antigens, 3) epitope clusters derived from antigens, 4) epitopes derived from antigens, or 5) nucleic acids encoding any of 1 to 4; wherein the antigens can include a first antigen selected from PRAME, PSMA, and/or tyrosinase and at least one other tumor-associated antigen. The at least one other tumor associated antigen can include, for example, a MAGE protein, MAGE-3, Melan-A, PLK1, VEGF-A, SSX-2, NY-ESO-1, mesothelin, PRAME, PSMA, VEGFR2, Tie-2, and the like, or subsets thereof. The compositions can further include at least one antigen associated with tumor neovasculature or stroma. The antigen associated with tumor neovasculature can be, for example, PSMA, VEGFR2 and/or Tie-2. The compositions can further include a growth factor and/or a signal transduction protein. The growth factor can be, for example, VEGF-A. The signal transduction factor can be, for example, PLK1.

[0030] Some embodiments relate to immunogenic compositions for the treatment of or for inducing an anti-cancer response against renal cell carcinoma. The compositions can include, for example, individually or in combination, 1) whole antigens, 2) fragments of antigens, 3) epitope clusters derived from antigens, 4) epitopes derived

from antigens, or 5) nucleic acids encoding any of 1 to 4; wherein the antigens can include a first antigen selected from PRAME, PSMA, and/or tyrosinase and at least one other tumor-associated antigen. In some embodiments, the at least one other tumor associated antigen can be a MAGE protein, MAGE-3, Melan-A, mesothelin, NY-ESO-1, SSX-2, PSMA, PRAME, VEGF-A, VEGFR2, Tie-2, and the like, or subsets thereof. The compositions can further include at least one antigen associated with tumor neovasculature or stroma. The antigen associated with tumor neovasculature can be, for example, PSMA, VEGFR2 and/or Tie-2.

[0031] Still other embodiments relate to immunogenic compositions for the treatment of or for inducing an anti-cancer response against melanoma. The compositions can include, for example, individually or in combination, 1) whole antigens, 2) fragments of antigens, 3) epitope clusters derived from antigens, 4) epitopes derived from antigens, or 5) nucleic acids encoding any of 1 to 4; wherein the antigens can be selected from each of two groups; wherein the first group includes, for example, PRAME, PSMAE and/or tyrosinase; and wherein the second group includes a MAGE protein, MAGE-3, Melan-A, SSX-2 and/or NY-ESO-1, and the like. The compositions can further include at least one antigen associated with tumor neovasculature or stroma. The antigen associated with tumor neovasculature can be, for example, PSMA, VEGFR2 and/or Tie-2. The compositions can further include a growth factor and/or a signal transduction protein. The growth factor can be, for example, VEGF-A. The signal transduction factor can be, for example, PLK1.

[0032] Further embodiments relate to compositions and methods for inducing an anti-cancer response using combinations of tumor-associated antigens, including fragments of tumor-associated antigens, clusters and epitopes. The compositions can include nucleic acid constructs, for example, a single construct that encodes all of the desired antigens. In other embodiments a single construct encodes a single antigen, while in other embodiments one construct can have a combination of epitopes with similar immunogenicity and another construct can have epitopes with similar immunogenicity.

[0033] Still other embodiments relate to methods of designing and preparing immunogenic compositions, which methods can include the steps of determining the presence of one or more antigens on a tumor type, and obtaining the one or more antigens for inclusion in a composition that induces CTL.

[0034] In some embodiments, methods of inducing an anti-cancer immune response are disclosed. The cancer can be, for example, ovarian cancer, colorectal cancer, pancreatic cancer, non-small cell lung cancer, melanoma, and renal cell carcinoma, and the like, or any subset thereof. The methods can include, for example, the step of immunizing against a first antigen and at least one tumor associated antigen. The first antigen can be, for example, PRAME, PSMA, tyrosinase, and the like. For example, in some embodiments, the methods include the step of immunizing against PRAME and at least one tumor-associated antigen and the cancers treated can be ovarian cancer, colorectal cancer, pancreatic cancer, melanoma, and renal cell carcinoma. In some embodiments, the methods include the step of immunizing against PSMA and at least one tumor-associated antigen, and the cancer can be non-small cell lung cancer, ovarian cancer, colorectal cancer, pancreatic cancer, and renal cell carcinoma. The at least one tumor-associated antigen can be, for example, PRAME, PSMA, VEGFR-2, NY-ESO 1, SSX-2, a MAGE protein, MAGE-3, mesothelin, PLK-1, VEGF-A, Melan A, VEGFR2, Tie-2, and the like, or subsets thereof.

[0035] In some embodiments, the methods can further include the step of immunizing against a stromal cell antigen, such as by active immunotherapies, passive immunotherapies, or the like. In some embodiments, the methods can further include a step for causing inflammation in a tumor lesion. In some embodiments, the methods further include immunizing against an extra-cellular factor. The extra-cellular factor can be, for example, an autocrine factor, a paracrine factor, a growth factor, chorionic gonadotropin, gastrin, an NF- κ B activating factor, VEGF-A CXCL1, CXCL8, CCL2 and the like. In some embodiments, the methods can further include immunizing against a factor that promotes the growth, survival, invasiveness, or metastasis of a tumor.

[0036] In another embodiment, the methods can include immunizing against a non-self antigen, such as a B cell epitope or a Th epitope. The methods can also include a step for co-inducing a helper response, such as a B cell response or a Th cell response.

[0037] In some embodiments, the methods can further include administering a treatment such as, for example, chemotherapy, radiotherapy, chemotherapy, biotherapy, passive immunotherapy, antibody therapy, surgery, and the like. In some embodiments, the methods further include a step for tumor debulking. In some embodiments, the methods can include a step for inducing tissue damage, necrosis, or apoptosis within a

tumor. In some embodiments, the methods can include a step for inducing inflammation within a tumor.

Brief Description of the Drawings

[0038] Figure 1 is a timeline depicting the schedule of immunization with two plasmid (pCBP expressing SSX2 41-49 and pSEM expressing Melan A).

[0039] Figure 2 is a bar graph that shows CTL activity obtained using the protocol in Figure 1.

[0040] Figure 3 is a timeline depicting the schedule of immunization of an entrain-and-amplify immunization protocol using plasmids and peptides representing two epitopes.

[0041] Figure 4 is a table showing *in vivo* clearance of epitope-pulsed cells in mice immunized according to the protocol of Figure 3.

[0042] Figures 5A and 5B are timelines depicting preferred immunization protocols for inducing strong multivalent responses. Figure 5A shows the use of peptides for boosting restores multivalent immune responses even if plasmids and peptides are used as mixtures. Figure 5B shows segregation of plasmid and peptide components allows induction of multivalent immune responses.

Detailed Description of the Preferred Embodiment

[0043] The frequency of expression of many tumor-associated antigens (TuAAs) in various types of cancers is known. However, the frequency of appearance of some antigens, and especially certain combinations of TuAAs, in various types of cancers has not been reported. Accurate measurement of the presence of TuAAs in tumor tissues aids in determining which TuAAs will be useful for the treatment of a particular type of cancer.

[0044] Many attempts to develop active immunotherapies for cancer have utilized a single antigen. This can be problematic for two distinct reasons. Firstly, the expression of any particular TuAA in cancer can be mosaic with the antigen expression ranging from high in some cells within a tumor mass to completely absent in others. Moreover, the TuAA may be expressed in some lesions but not others. By directing an immune response against more than a single antigen, if properly selected, the number of tumor cells that can be recognized is maximized. Secondly, some tumors lose expression

of a TuAA following immunization, giving rise to a resistant population. If the immune response is directed against more than one TuAA it becomes much more difficult for a resistant tumor to arise because it must then simultaneously lose expression of each of the antigens in order to escape. Thus, in treating cancer with immunotherapy, it can be advantageous to use a combination of TuAAs both due to more complete coverage of the population of tumor cells, and because there will be less chance of tumor escape through loss of expression of the TuAAs. In preferred embodiments, this technique is employed when the tumor is positive for two, three, or more of the TuAAs of the combination used.

[0045] Multivalent attack can offer another advantage in increasing the sensitivity of the tumor to attack. If more than a single antigen on a tumor cell is targeted, the effective concentration of anti-tumor agent is increased. In addition, attack on stroma associated with the tumor, such as vasculature, can increase the accessibility of the tumor cells to the agent(s) targeting them. Thus, even an antigen that is also expressed on some normal tissue can receive greater consideration as a target antigen, if the other antigens to be targeted in a multivalent attack are not also expressed by that tissue.

[0046] In some embodiments, practice of the methods includes use of at least two different compositions and, especially when there is more than a single target antigen, can involve several compositions to be administered together and/or at different times. Thus, embodiments of the invention include sets and subsets of immunogenic compositions and individual doses thereof. Multivalency can be achieved using compositions comprising multivalent immunogens, combinations of monovalent immunogens, coordinated use of compositions comprising one or more monovalent immunogens or various combinations thereof. Multiple compositions, manufactured for use in a particular treatment regimen or protocol according to such methods, define an immunotherapeutic product. In some embodiments all or a subset of the compositions of the product are packaged together in a kit.

Definitions

[0047] Unless otherwise clear from the context of the use of a term herein, the following listed terms shall generally have the indicated meanings for purposes of this description.

[0048] PROFESSIONAL ANTIGEN-PRESENTING CELL (pAPC) – a cell that possesses T cell co-stimulatory molecules and is able to induce a T cell response. Well characterized pAPCs include dendritic cells, B cells, and macrophages.

[0049] PERIPHERAL CELL – a cell that is not a pAPC.

[0050] HOUSEKEEPING PROTEASOME – a proteasome normally active in peripheral cells, and generally not present or not strongly active in pAPCs.

[0051] IMMUNOPROTEASOME – a proteasome normally active in pAPCs; the immunoproteasome is also active in some peripheral cells in infected tissues or following exposure to interferon.

[0052] EPITOPE – a molecule or substance capable of stimulating an immune response. In preferred embodiments, epitopes according to this definition include but are not necessarily limited to a polypeptide and a nucleic acid encoding a polypeptide, wherein the polypeptide is capable of stimulating an immune response. In other preferred embodiments, epitopes according to this definition include but are not necessarily limited to peptides presented on the surface of cells, the peptides being non-covalently bound to the binding cleft of class I MHC, such that they can interact with T cell receptors (TCR). Epitopes presented by class I MHC may be in immature or mature form. “Mature” refers to an MHC epitope in distinction to any precursor (“immature”) that may include or consist essentially of a housekeeping epitope, but also includes other sequences in a primary translation product that are removed by processing, including without limitation, alone or in any combination, proteasomal digestion, N-terminal trimming, or the action of exogenous enzymatic activities. Thus, a mature epitope may be provided embedded in a somewhat longer polypeptide, the immunological potential of which is due, at least in part, to the embedded epitope; likewise, the mature epitope can be provided in its ultimate form that can bind in the MHC binding cleft to be recognized by TCR.

[0053] MHC EPITOPE – a polypeptide having a known or predicted binding affinity for a mammalian class I or class II major histocompatibility complex (MHC) molecule.

[0054] HOUSEKEEPING EPITOPE – In a preferred embodiment, a housekeeping epitope is defined as a polypeptide fragment that is an MHC epitope, and that is displayed on a cell in which housekeeping proteasomes are predominantly active. In another preferred embodiment, a housekeeping epitope is defined as a polypeptide containing a housekeeping epitope according to the foregoing definition, that is flanked by

one to several additional amino acids. In another preferred embodiment, a housekeeping epitope is defined as a nucleic acid that encodes a housekeeping epitope according to the foregoing definitions. Exemplary housekeeping epitopes are provided in U.S. Patent Application Nos. 10/117,937, filed on April 4, 2002 (Pub. No. 20030220239 A1), 11/067,159 (Pub. No. 2005-0221440 A1), filed February 25, 2005, 11/067,064 (Pub. No. 2005-0142144 A1), filed February 25, 2005, and 10/657,022 (Pub. No. 2004-0180354 A1), filed September 5, 2003, and in PCT Application No. PCT/US2003/027706 (Pub. No. WO 2004/022709 A2), filed 9/5/2003; and U.S. Provisional Application Nos. 60/282,211, filed on April 6, 2001; 60/337,017, filed on November 7, 2001; 60/363,210 filed March 7, 2002; and 60/409,123, filed on September 6, 2002. Each of the listed applications is entitled “EPITOPE SEQUENCES.” Each of the applications mentioned in this paragraph is incorporated herein by reference in its entirety.

[0055] IMMUNE EPITOPE – In a preferred embodiment, an immune epitope is defined as a polypeptide fragment that is an MHC epitope, and that is displayed on a cell in which immunoproteasomes are predominantly active. In another preferred embodiment, an immune epitope is defined as a polypeptide containing an immune epitope according to the foregoing definition, that is flanked by one to several additional amino acids. In another preferred embodiment, an immune epitope is defined as a polypeptide including an epitope cluster sequence, having at least two polypeptide sequences having a known or predicted affinity for a class I MHC. In yet another preferred embodiment, an immune epitope is defined as a nucleic acid that encodes an immune epitope according to any of the foregoing definitions.

[0056] TARGET CELL – In a preferred embodiment, a target cell is a cell associated with a pathogenic condition that can be acted upon by the components of the immune system, for example, a cell infected with a virus or other intracellular parasite, or a neoplastic cell. In another embodiment, a target cell is a cell to be targeted by the vaccines and methods of the invention. Examples of target cells according to this definition include but are not necessarily limited to: a neoplastic cell and a cell harboring an intracellular parasite, such as, for example, a virus, a bacterium, or a protozoan. Target cells can also include cells that are targeted by CTL as a part of an assay to determine or confirm proper epitope liberation and processing by a cell expressing immunoproteasome, to determine T cell specificity or immunogenicity for a desired epitope. Such cells can be

transformed to express the liberation sequence, or the cells can simply be pulsed with peptide/epitope.

[0057] TARGET-ASSOCIATED ANTIGEN (TAA) – a protein or polypeptide present in a target cell.

[0058] TUMOR-ASSOCIATED ANTIGEN (TuAA) – a TAA, wherein the target cell is a neoplastic cell. In alternate embodiments, a TuAA is an antigen associated with non-cancerous cells of the tumor such as tumor neovasculature or other stromal cells within the tumor microenvironment.

[0059] HLA EPITOPE – a polypeptide having a known or predicted binding affinity for a human class I or class II HLA complex molecule.

[0060] ANTIBODY – a natural immunoglobulin (Ig), poly- or monoclonal, or any molecule composed in whole or in part of an Ig binding domain, whether derived biochemically, or by use of recombinant DNA, or by any other means. Examples include *inter alia*, F(ab), single chain Fv, and Ig variable region-phage coat protein fusions.

[0061] SUBSTANTIAL SIMILARITY – this term is used to refer to sequences that differ from a reference sequence in an inconsequential way as judged by examination of the sequence. Nucleic acid sequences encoding the same amino acid sequence are substantially similar despite differences in degenerate positions or minor differences in length or composition of any non-coding regions. Amino acid sequences differing only by conservative substitution or minor length variations are substantially similar. Additionally, amino acid sequences comprising housekeeping epitopes that differ in the number of N-terminal flanking residues, or immune epitopes and epitope clusters that differ in the number of flanking residues at either terminus, are substantially similar. Nucleic acids that encode substantially similar amino acid sequences are themselves also substantially similar.

[0062] FUNCTIONAL SIMILARITY – this term is used to refer to sequences that differ from a reference sequence in an inconsequential way as judged by examination of a biological or biochemical property, although the sequences may not be substantially similar. For example, two nucleic acids can be useful as hybridization probes for the same sequence but encode differing amino acid sequences. Two peptides that induce cross-reactive CTL responses are functionally similar even if they differ by non-conservative amino acid substitutions (and thus may not be within the substantial similarity definition). Pairs of antibodies, or TCRs, that recognize the same epitope can

be functionally similar to each other despite whatever structural differences exist. Testing for functional similarity of immunogenicity can be conducted by immunizing with the “altered” antigen and testing the ability of an elicited response, including but not limited to an antibody response, a CTL response, cytokine production, and the like, to recognize the target antigen. Accordingly, two sequences may be designed to differ in certain respects while retaining the same function. Such designed sequence variants of disclosed or claimed sequences are among the embodiments of the present invention.

[0063] EXPRESSION CASSETTE – a polynucleotide sequence encoding a polypeptide, operably linked to a promoter and other transcription and translation control elements, including but not limited to enhancers, termination codons, internal ribosome entry sites, and polyadenylation sites. The cassette can also include sequences that facilitate moving it from one host molecule to another.

[0064] EMBEDDED EPITOPE – in some embodiments, an embedded epitope is an epitope that is wholly contained within a longer polypeptide; in other embodiments, the term also can include an epitope in which only the N-terminus or the C-terminus is embedded such that the epitope is not wholly in an interior position with respect to the longer polypeptide.

[0065] MATURE EPITOPE – a peptide with no additional sequence beyond that present when the epitope is bound in the MHC peptide-binding cleft.

[0066] EPITOPE CLUSTER – a polypeptide, or a nucleic acid sequence encoding it, that is a segment of a protein sequence, including a native protein sequence, comprising two or more known or predicted epitopes with binding affinity for a shared MHC restriction element. In preferred embodiments, the density of epitopes within the cluster is greater than the density of all known or predicted epitopes with binding affinity for the shared MHC restriction element within the complete protein sequence. Epitope clusters are disclosed and more fully defined in U.S. Patent Application No. 09/561,571, filed April 28, 2000, entitled “EPITOPE CLUSTERS,” which is incorporated herein by reference in its entirety.

[0067] LIBERATION SEQUENCE – a designed or engineered sequence comprising or encoding a housekeeping epitope embedded in a larger sequence that provides a context allowing the housekeeping epitope to be liberated by processing activities including, for example, immunoproteasome activity, N terminal trimming, and/or other processes or activities, alone or in any combination.

[0068] CTLp – CTL precursors are T cells that can be induced to exhibit cytolytic activity. Secondary *in vitro* lytic activity, by which CTLp are generally observed, can arise from any combination of naïve, effector, and memory CTL *in vivo*.

[0069] MEMORY T CELL – A T cell, regardless of its location in the body, that has been previously activated by antigen, but is in a quiescent physiologic state requiring re-exposure to antigen in order to gain effector function. Phenotypically they are generally CD62L⁻ CD44^{hi} CD107a⁻ IGN- γ ⁻ LT β ⁻ TNF- α ⁻ and is in G0 of the cell cycle.

[0070] EFFECTOR T CELL – A T cell that, upon encountering antigen antigen, readily exhibits effector function. Effector T cells are generally capable of exiting the lymphatic system and entering the immunological periphery. Phenotypically they are generally CD62L⁻ CD44^{hi} CD107a⁺ IGN- γ ⁺ LT β ⁺ TNF- α ⁺ and actively cycling.

[0071] EFFECTOR FUNCTION – Generally, T cell activation generally, including acquisition of cytolytic activity and/or cytokine secretion.

[0072] INDUCING a T cell response – Includes in many embodiments the process of generating a T cell response from naïve, or in some contexts, quiescent cells; activating T cells.

[0073] AMPLIFYING a T cell response – Includes in many embodiments, the process or increasing the number of cells, the number of activated cells, the level of activity, rate of proliferation, or similar parameter of T cells involved in a specific response.

[0074] ENTRAINMENT – Includes in many embodiments an induction that confers particular stability on the immune profile of the induced lineage of T cells. In various embodiments, the term “entrain” can correspond to “induce,” and/or “initiate.”

[0075] TOLL-LIKE RECEPTOR (TLR) – Toll-like receptors (TLRs) are a family of pattern recognition receptors that are activated by specific components of microbes and certain host molecules. As part of the innate immune system, they contribute to the first line of defense against many pathogens, but also play a role in adaptive immunity.

[0076] TOLL-LIKE RECEPTOR (TLR) LIGAND – Any molecule capable of binding and activating a toll-like receptor. Examples include, without limitation: poly IC A synthetic, double-stranded RNA known for inducing interferon. The polymer is made of one strand each of polyinosinic acid and polycytidylic acid, double-stranded RNA, unmethylated CpG oligodeoxyribonucleotide or other immunostimulatory sequences

(ISSs), lipopolysaccharide (LPS), β -glucans, and imidazoquinolines, as well as derivatives and analogues thereof.

[0077] IMMUNOPOTENTIATING ADJUVANTS – Adjuvants that activate pAPC or T cells including, for example: TLR ligands, endocytic-Pattern Recognition Receptor (PRR) ligands, quillaja saponins, tucaresol, cytokines, and the like. Some preferred adjuvants are disclosed in Marciani, D.J. *Drug Discovery Today* 8:934-943, 2003, which is incorporated herein by reference in its entirety.

[0078] IMMUNOSTIMULATORY SEQUENCE (ISS) – Generally an oligodeoxyribonucleotide containing an unmethylated CpG sequence. The CpG may also be embedded in bacterially produced DNA, particularly plasmids. Further embodiments include various analogues; among preferred embodiments are molecules with one or more phosphorothioate bonds or non-physiologic bases.

[0079] VACCINE – In preferred embodiments a vaccine can be an immunogenic composition providing or aiding in prevention of disease. In other embodiments, a vaccine is a composition that can provide or aid in a cure of a disease. In others, a vaccine composition can provide or aid in amelioration of a disease. Further embodiments of a vaccine immunogenic composition can be used as therapeutic and/or prophylactic agents.

[0080] IMMUNIZATION – a process to induce partial or complete protection against a disease. Alternatively, a process to induce or amplify an immune system response to an antigen. In the second definition it can connote a protective immune response, particularly proinflammatory or active immunity, but can also include a regulatory response. Thus in some embodiments immunization is distinguished from tolerization (a process by which the immune system avoids producing proinflammatory or active immunity) while in other embodiments this term includes tolerization.

[0081] ENCODE – an open-ended term such that a nucleic acid encoding a particular amino acid sequence can consist of codons specifying that (poly)peptide, but can also comprise additional sequences either translatable, or for the control of transcription, translation, or replication, or to facilitate manipulation of some host nucleic acid construct.

[0082] COVERAGE – the fraction or proportion of tumor cells expressing a particular TuAA or at least one TuAA from a set of selected TuAAs.

[0083] REDUNDANCY – the degree to which a population of tumor cells, or some subset of them, express more than one of a selected set of TuAAs.

[0084] CO-TARGETING – in preferred embodiments, co-targeting involves inducing and/or amplifying an immune response against a target cell, while also inducing an immune response against at least one other agent in the vicinity and/or *milieu* of a tumor. In some embodiments, agents within the vicinity and/or *milieu* of the tumor include, but are not limited to, cancer cells, stromal cells, including those associated with neovasculature, endothelial cells, fibroblasts, inflammatory cells, epithelial cells, autocrine factors, and paracrine factors. In some embodiments, tumor cells and stromal cells are specifically targeted. In other embodiments, an immune response is induced and/or amplified against neovasculature and other non-transformed, non-lymphoid cells within the tumor microenvironment. In still other embodiments, an immune response is induced against cancer cells and autocrine and/or paracrine factors produced by cells in the tumor microenvironment.

Tumor Associated Antigens

[0085] Examples of TuAAs useful in embodiments disclosed herein include tyrosinase (SEQ. ID NO. 1), melan-A, (SEQ. ID NO. 2), SSX-2, (SEQ. ID NO.3), PSMA (prostate-specific membrane antigen) (SEQ. ID NO. 4), MAGE-1, (SEQ. ID NO. 5), MAGE-3 (SEQ. ID NO. 6), NY-ESO-1, (SEQ. ID NO. 7), PRAME, (SEQ. ID NO.8), Her2/Neu (SEQ. ID NO. 9), mesothelin (SEQ. ID NOs. 10 and 11), VEGF-A (SEQ. ID NO. 12), and PLK1 (SEQ. ID NO. 13). The natural coding sequences for these proteins, or any segments within them, can be determined from their cDNA or complete coding (cds) sequences, SEQ. ID NOS. 14-26, respectively. The protein and cDNA sequences are identified by accession number and provided in the sequence listing filed herewith.

Table 1. SEQ. ID NOS.

SEQ. ID NO.	IDENTITY	ACCESSION NUMBER**
1	Tyrosinase protein	P14679
2	Melan-A protein	Q16655
3	SSX-2 protein	NP_003138
4	PSMA protein	NP_004467
5	MAGE-1 protein	P43355

6	MAGE-3 protein	P43357
7	NY-ESO-1 protein	P78358
8	PRAME protein	NP 006106
9	Her2/Neu protein	P04626
10	Mesothelin, isoform 1, protein	NP005814
11	Mesothelin, isoform 2, protein	NP037536
12	VEGF-A protein	P15692
13	PLK1 protein	P53350
14	Tyrosinase cDNA	NM_000372
15	Melan-A cDNA	U06452
16	SSX-2 cDNA	NM_003147
17	PSMA cDNA	NM_004476
18	MAGE-1 cds	M77481
19	MAGE-3 cds	U03735
20	NY-ESO-1 cDNA	U87459
21	PRAME cDNA	NM_006115
22	Her2/Neu cDNA	M11730
23	Mesothelin, isoform 1, cDNA	NM005823
24	Mesothelin, isoform 2, cDNA	NM013404
25	VEGF-A cDNA	NM_001025366
26	Plk1 cDNA	NM_005030

**All accession numbers used here and throughout can be accessed through the NCBI databases, for example, through the Entrez seek and retrieval system on the world wide web.

[0086] Tyrosinase is a melanin biosynthetic enzyme that is considered one of the most specific markers of melanocytic differentiation. Tyrosinase is expressed in few cell types, primarily in melanocytes, and high levels are often found in melanomas. The usefulness of tyrosinase as a TuAA is taught in U.S. Patent No. 5,747,271, entitled "METHOD FOR IDENTIFYING INDIVIDUALS SUFFERING FROM A CELLULAR ABNORMALITY SOME OF WHOSE ABNORMAL CELLS PRESENT COMPLEXES OF HLA-A2/TYROSINASE DERIVED PEPTIDES, AND METHODS FOR TREATING SAID INDIVIDUALS" which is hereby incorporated by reference in its entirety.

[0087] GP100, also known as PMel17, is another melanin biosynthetic protein expressed at high levels in melanomas. GP100 as a TuAA is disclosed in U.S. Patent No. 5,844,075, entitled "MELANOMA ANTIGENS AND THEIR USE IN DIAGNOSTIC

AND THERAPEUTIC METHODS," which is hereby incorporated by reference in its entirety.

[0088] Melan-A, also known as MART-1 (Melanoma Antigen Recognized by T cells), is another melanin biosynthetic protein expressed at high levels in melanomas. The usefulness of Melan-A/MART-1 as a TuAA is taught in U.S. Patent Nos. 5,874,560 and 5,994,523, both entitled "MELANOMA ANTIGENS AND THEIR USE IN DIAGNOSTIC AND THERAPEUTIC METHODS," as well as U.S. Patent No. 5,620,886, entitled "ISOLATED NUCLEIC ACID SEQUENCE CODING FOR A TUMOR REJECTION ANTIGEN PRECURSOR PROCESSED TO AT LEAST ONE TUMOR REJECTION ANTIGEN PRESENTED BY HLA-A2," each of which is hereby incorporated by reference in its entirety.

[0089] SSX-2, also known as Hom-Mel-40, is a member of a family of highly conserved cancer-testis (CT) antigens (Gure, A.O. *et al.*, *Int. J. Cancer* 72:965-971, 1997, which is hereby incorporated by reference in its entirety). Its identification as a TuAA is taught in U.S. Patent No. 6,025,191, entitled "ISOLATED NUCLEIC ACID MOLECULES WHICH ENCODE A MELANOMA SPECIFIC ANTIGEN AND USES THEREOF," which is hereby incorporated by reference in its entirety. Cancer-testis antigens are found in a variety of tumors, but are generally absent from normal adult tissues except testis. Expression of different members of the SSX family has been found in various tumor cell lines. Due to the high degree of sequence identity among SSX family members, similar epitopes from more than one member of the family will be generated and able to bind to an MHC molecule, so that some vaccines directed against one member of this family can cross-react and be effective against other members of this family.

[0090] MAGE-1 (melanoma-associated antigen-1), MAGE-2 (melanoma-associated antigen-2), and MAGE-3 (melanoma-associated antigen-3) are members of another family of cancer-testis antigens originally discovered in melanoma but found in a variety of tumors. The identification of MAGE proteins as TuAAs is taught in U.S. Patent No. 5,342,774, entitled "NUCLEOTIDE SEQUENCE ENCODING THE TUMOR REJECTION ANTIGEN PRECURSOR, MAGE-1," which is hereby incorporated by reference in its entirety, and in numerous subsequent patents. Currently there are 17 entries for (human) MAGE in the SWISS Protein database. There is extensive similarity among these proteins, such that in many cases, an epitope from one can induce a cross-

reactive response to other members of the family. A few members of the MAGE family have not been observed in tumors, most notably MAGE-H1 and MAGE-D1, which are expressed in testes and brain, and bone marrow stromal cells, respectively. The possibility of cross-reactivity on normal tissue is ameliorated by the fact that they are among the least similar to the other MAGE proteins.

[0091] GAGE-1 is a member of the GAGE family of cancer testis antigens (Van den Eynde, B., *et al.*, *J. Exp. Med.* 182: 689-698, 1995; U.S Patent Nos. 5,610,013; 5648226; 5,858,689; 6,013,481; and 6,069,001, each of which is hereby incorporated by reference in its entirety). The PubGene database currently lists 12 distinct accessible members, some of which are synonymously known as PAGE or XAGE. GAGE-1 through GAGE-8 have a very high degree of sequence identity, so most epitopes can be shared among multiple members of the family.

[0092] BAGE is a cancer-testis antigen commonly expressed in melanoma, particularly metastatic melanoma, as well as in carcinomas of the lung, breast, bladder, and squamous cells of the head and neck. Its usefulness as a TuAA is taught in U.S. Patent Nos. 5,683,88, entitled “TUMOR REJECTION ANTIGENS WHICH CORRESPOND TO AMINO ACID SEQUENCES IN TUMOR REJECTION ANTIGEN PRECURSOR BAGE, AND USES THEREOF,” and 5,571,711, entitled “ISOLATED NUCLEIC ACID MOLECULES CODING FOR BAGE TUMOR REJECTION ANTIGEN PRECURSORS,” each of which is hereby incorporated by reference in its entirety.

[0093] NY-ESO-1, also known as CTAG-1 (Cancer-Testis Antigen-1) and CAG-3 (Cancer Antigen-3), is a cancer-testis antigen found in a wide variety of tumors. NY-ESO-1 as a TuAA is disclosed in U.S. Patent 5,804,381, entitled “ISOLATED NUCLEIC ACID MOLECULE ENCODING AN ESOPHAGEAL CANCER ASSOCIATED ANTIGEN, THE ANTIGEN ITSELF, AND USES THEREOF,” which is hereby incorporated by reference in its entirety. A paralogous locus encoding antigens with extensive sequence identity, LAGE-1a/s and LAGE-1b/L, has been disclosed in publicly available assemblies of the human genome, and has been concluded to arise through alternate splicing. Additionally, CT-2 (or CTAG-2, Cancer-Testis Antigen-2) appears to be either an allele, a mutant, or a sequencing discrepancy of LAGE-1b/L. Due to the extensive sequence identity, many epitopes from NY-ESO-1 can also induce immunity to tumors expressing these other antigens. NY-ESO-1 and LAGE are virtually

identical through amino acid 70. From amino acid 71 through 134 the longest run of identity between the two proteins is 6 residues, but potentially cross-reactive sequences are present. From amino acid 135 through 180, NY-ESO and LAGE-1a/s are identical except for a single residue, but LAGE-1b/L is unrelated due to the alternate splice. The CAMEL and LAGE-2 antigens appear to derive from the LAGE-1 mRNA, but from alternate reading frames, thus giving rise to unrelated protein sequences. More recently, GenBank Accession AF277315.5, Homo sapiens chromosome X clone RP5-865E18, RP5-1087L19, complete sequence, reports three independent loci in this region which are labeled as LAGE1 (corresponding to CTAG-2 in the genome assemblies), LAGE2-A and LAGE2-B (both corresponding to CTAG-1 in the genome assemblies).

[0094] PRAME, also known as MAPE, DAGE, and OIP4, was originally observed as a melanoma antigen. Subsequently, it has been recognized as a cancer-testis (CT) antigen, but unlike many CT antigens, such as, MAGE, GAGE and BAGE, PRAME is expressed in acute myeloid leukemias. PRAME is a member of the MAPE family, which consists largely of hypothetical proteins with which it shares limited sequence similarity. The usefulness of PRAME as a TuAA is taught in U.S. Patent No. 5,830,753, entitled "ISOLATED NUCLEIC ACID MOLECULES CODING FOR TUMOR REJECTION ANTIGEN PRECURSOR DAGE AND USES THEREOF," which is hereby incorporated by reference in its entirety.

[0095] PSMA (prostate-specific membranes antigen), a TuAA described in U.S. Patent No. 5,538,866 entitled, "PROSTATE-SPECIFIC MEMBRANES ANTIGEN," which is hereby incorporated by reference in its entirety, is expressed by normal prostate epithelium and, at a higher level, in prostatic cancer. It has also been found in the neovasculature of non-prostatic tumors. PSMA can thus form the basis for vaccines directed to both prostate cancer and to the neovasculature of other tumors. This later concept is more fully described in a provisional U.S. Provisional Patent Application No. 60/274,063, and U.S. Patent Application Nos. 10/094,699 (Pub. No. 20030046714 A1), filed on March 7, 2002, and 11/073,347 (Pub. No. _____), filed June 30, 2005, each entitled "ANTI-NEOVASCULATURE PREPARATIONS FOR CANCER," each of which is hereby incorporated by reference in its entirety. Briefly, as tumors grow they recruit ingrowth of new blood vessels. This is understood to be necessary to sustain growth as the centers of unvascularized tumors are generally necrotic and angiogenesis inhibitors have been reported to cause tumor regression. Such new blood vessels, or

neovasculature, express antigens not found in established vessels, and thus can be specifically targeted. By inducing CTL against neovascular antigens the vessels can be disrupted, interrupting the flow of nutrients to, and removal of wastes from, tumors, leading to regression.

[0096] Alternate splicing of the PSMA mRNA leads to a protein with an apparent start at Met₅₈, thereby deleting the putative membrane anchor region of PSMA as described in U.S. Patent No. 5,935,818, entitled "ISOLATED NUCLEIC ACID MOLECULE ENCODING ALTERNATIVELY SPLICED PROSTATE-SPECIFIC MEMBRANES ANTIGEN AND USES THEREOF," which is hereby incorporated by reference in its entirety. A protein termed PSMA-like protein, Genbank accession number AF261715, is nearly identical to amino acids 309-750 of PSMA, but has a different expression profile. Thus, the most preferred epitopes are those with an N-terminus located from amino acid 58 to 308.

[0097] PSA (prostate specific antigen) is a peptidase of the kallikrein family and a differentiation antigen of the prostate. Expression in breast tissue has also been reported. Alternate names include gamma-seminoprotein, kallikrein 3, seminogelase, seminin, and P-30 antigen. PSA has a high degree of sequence identity with the various alternate splicing products prostatic/glandular kallikrein-1 and -2, as well as kalikrein 4, which is also expressed in prostate and breast tissue. Other kallikreins generally share less sequence identity and have different expression profiles. Nonetheless, cross-reactivity that might be provoked by any particular epitope, along with the likelihood that that epitope would be liberated by processing in non-target tissues (most generally by the housekeeping proteasome), should be considered in designing a vaccine.

[0098] PSCA (prostate stem cell antigen) and also known as SCAH-2, is a differentiation antigen preferentially expressed in prostate epithelial cells, and overexpresssed in prostate cancers. Lower level expression is seen in some normal tissues including neuroendocrine cells of the digestive tract and collecting ducts of the kidney. PSCA is described in U.S. Patent No. 5,856,136, entitled "HUMAN STEM CELL ANTIGENS," which is hereby incorporated by reference in its entirety.

[0099] Synaptonemal complex protein 1 (SCP-1), also known as HOM-TES-14, is a meiosis-associated protein and also a cancer-testis antigen (Tureci, O., *et al.*, *Proc. Natl. Acad. Sci. USA* 95:5211-5216, 1998, which is hereby incorporated by reference in its entirety). As a cancer antigen its expression is not cell-cycle regulated and

it is found frequently in gliomas, breast, renal cell, and ovarian carcinomas. It has some similarity to myosins, but with few enough identities that cross-reactive epitopes are not an immediate prospect.

[0100] The ED-B domain of fibronectin is also a potential target. Fibronectin is subject to developmentally regulated alternative splicing, with the ED-B domain being encoded by a single exon that is used primarily in oncofetal tissues (Matsuura, H. and S. Hakomori *Proc. Natl. Acad. Sci. USA* 82:6517-6521, 1985; Carnemolla, B. *et al.*, *J. Cell Biol.* 108:1139-1148, 1989; Lordin-Rosa, B. *et al.*, *Cancer Res.* 50:1608-1612, 1990; Nicolo, G. *et al.*, *Cell Differ. Dev.* 32:401-408, 1990; Borsi, L. *et al.*, *Exp. Cell Res.* 199:98-105, 1992; Oyama, F. *et al.*, *Cancer Res.* 53:2005-2011, 1993; Mandel, U. *et al.*, *APMIS* 102:695-702, 1994; Farnoud, M.R. *et al.*, *Int. J. Cancer* 61:27-34, 1995; Pujuquet, P. *et al.*, *Am. J. Pathol.* 148:579-592, 1996; Gabler, U. *et al.*, *Heart* 75:358-362, 1996; Chevalier, X. *Br. J. Rheumatol.* 35:407-415, 1996; Midulla, M. *Cancer Res.* 60:164-169, 2000, each of which is hereby incorporated by reference in its entirety).

[0101] The ED-B domain is also expressed in fibronectin of the neovasculature (Kaczmarek, J. *et al.*, *Int. J. Cancer* 59:11-16, 1994; Castellani, P. *et al.*, *Int. J. Cancer* 59:612-618, 1994; Neri, D. *et al.*, *Nat. Biotech.* 15:1271-1275, 1997; Karelina, T.V. and A.Z. Eisen *Cancer Detect. Prev.* 22:438-444, 1998; Tarli, L. *et al.*, *Blood* 94:192-198, 1999; Castellani, P. *et al.*, *Acta Neurochir (Wien)* 142:277-282, 2000, each of which is hereby incorporated by reference in its entirety). As an oncofetal domain, the ED-B domain is commonly found in the fibronectin expressed by neoplastic cells in addition to being expressed by the neovasculature. Thus, CTL-inducing vaccines targeting the ED-B domain can exhibit two mechanisms of action: direct lysis of tumor cells, and disruption of the tumor's blood supply through destruction of the tumor-associated neovasculature. As CTL activity can decay rapidly after withdrawal of vaccine, interference with normal angiogenesis can be minimal. The design and testing of vaccines targeted to neovasculature is described in Provisional U.S. Provisional Patent Application No. 60/274,063, filed on March 7, 2001, and U.S. Patent Application Nos. 10/094,699, (Pub. No. 20030046714 A1), filed March 7, 2002, and 11/073,347 (Pub. No.

_____), filed June 30, 2005, all entitled "ANTI-NEOVASCULATURE PREPARATIONS FOR CANCER," filed on March 7, 2002, each of which is hereby incorporated by reference in its entirety. A tumor cell line is disclosed in U.S. Provisional Application No. 60/363,131, filed on March 7, 2002, entitled "HLA-TRANSGENIC

MURINE TUMOR CELL LINE," which is hereby incorporated by reference in its entirety.

[0102] Carcinoembryonic antigen (CEA) is a paradigmatic oncofetal protein first described in 1965 (Gold and Freedman, *J. Exp. Med.* 121: 439-462, 1965, which is hereby incorporated by reference in its entirety). Fuller references can be found in the Online Mendelian Inheritance in Man; record *114890. It has officially been renamed carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5). Its expression is most strongly associated with adenocarcinomas of the epithelial lining of the digestive tract and in fetal colon. CEA is a member of the immunoglobulin supergene family and the defining member of the CEA subfamily.

[0103] Survivin, also known as Baculoviral IAP Repeat-Containing Protein 5 (BIRC5), is another protein with an oncofetal pattern of expression. It is a member of the inhibitor of apoptosis protein (IAP) gene family. It is widely over-expressed in cancers (Ambrosini, G. *et al.*, *Nat. Med.* 3:917-921, 1997; Velculescu V.E. *et al.*, *Nat. Genet.* 23:387-388, 1999, which is hereby incorporated by reference in its entirety) and its function as an inhibitor of apoptosis is believed to contribute to the malignant phenotype.

[0104] HER2/NEU is an oncogene related to the epidermal growth factor receptor (van de Vijver, *et al.*, *New Eng. J. Med.* 319:1239-1245, 1988, which is hereby incorporated by reference in its entirety), and apparently identical to the c-ERBB2 oncogene (Di Fiore, *et al.*, *Science* 237: 178-182, 1987, which is hereby incorporated by reference in its entirety). The over-expression of ERBB2 has been implicated in the neoplastic transformation of prostate cancer. As with HER2, it is amplified and over-expressed in 25-30% of breast cancers among other tumors where expression level is correlated with the aggressiveness of the tumor (Slamon, *et al.*, *New Eng. J. Med.* 344:783-792, 2001, which is hereby incorporated by reference in its entirety). A more detailed description is available in the Online Mendelian Inheritance in Man; record *164870.

[0105] MESOTHELIN is an antigen originally found in mesotheliomas but also known to be upregulated in many pancreatic and ovarian cancers. Its use as a vaccine target and useful epitopes are described in Thomas, A.M. *et al.*, *J. Exp. Med.* 200:297-306, 2004, which is hereby incorporated by reference in its entirety.

[0106] Vascular Endothelial Growth Factor (VEGF-A or VEGF) is a mitogenic protein structurally related to platelet-derived growth factor, but with narrower

mitogenic activity focused on vascular endothelial cells. The protein and its receptors are important to tumor growth and their potential as targets of cancer therapies has been noted (Folkman, *J. Nature Med.* 1: 27-31, 1995, which is hereby incorporated by reference in its entirety). A more detailed description is available in the Online Mendelian Inheritance in Man; record *192240.

[0107] PLK1 is an intracellular serine/threonine kinase that plays a critical role in cell cycle regulation and in DNA damage responses. Mutation or knock down of PLK1 result in abnormal mitosis, cell cycle arrest and apoptosis (Reagan-Shaw S. and Ahmad N., *FASEB J.* 19:611, 2005). PLK1 belongs to the Polo-like kinase family of structurally conserved kinases. The PLK1 family contains two conserved regions, an N-terminal kinase domain and a C-terminal non-catalytic Polo box region (Lowery DM *et al.*, *Oncogene* 24:248.2005) responsible for subcellular localization. PLK1 is predominantly found in the cytoplasm during interphase and localizes to the nucleus during mitosis (Takai N *et al.*, *Oncogene* 24:2872005). Nuclear localization of PLK1 is essential for its biological function (Lee KS *et al.*, *Proc Natl Acad Sci U S A* 95:9301, 1998). While most classical tumor associated antigens are not known to participate in tumor initiation or disease progression, PLK1 has been shown to drive tumor growth. Thus, in some embodiments, PLK1 can be considered a tumor-associated antigen that can be used as a target for cancer immunotherapy. Based on its expression profile, PLK1 is expressed in proliferating cells, with elevated expression found in most solid tumors. This expression pattern renders PLK1 a valid target for active and passive immunotherapy.

[0108] Further examples of tumor-associated antigens include MelanA (MART-I), gp100 (Pmel 17), tyrosinase, TRP-1, TRP-2, MAGE-1, MAGE-3, BAGE, GAGE-1, GAGE-2, p15(58), CEA, RAGE, NY-ESO (LAGE), SCP-1, Hom/Mel-40, PRAME, p53, H-Ras, HER-2/neu, BCR-ABL, E2A-PRL, H4-RET, IGH-IGK, MYL-RAR, Epstein Barr virus antigens, EBNA, human papillomavirus (HPV) antigens E6 and E7, TSP-180, MAGE-4, MAGE-5, MAGE-6, p185erbB2, p180erbB-3, c-met, nm-23H1, PSA, TAG-72-4, CA 19-9, CA 72-4, CAM 17.1, NuMa, K-ras, β -Catenin, CDK4, Mum-1, p16, TAGE, PSMA, PSCA, CT7, telomerase, 43-9F, 5T4, 791Tgp72, alpha-fetoprotein, β -HCG, BCA225, BTAA, CA 125, CA 15-3 (CA 27.29\BCAA), CA 195, CA 242, CA-50, CAM43, CD68\KP1, CO-029, FGF-5, G250, Ga733 (EpCAM), HTgp-175, M344, MA-50, MG7-Ag, MOV18, NB/70K, NY-CO-1, RCAS1, SDCCAG16, TA-90

(Mac-2 binding protein\cyclophilin C-associated protein), TAAL6, TAG72, TLP, TPS, and the like.

[0109] Additional tumor-associated antigens are described in Chen, YT, "Identification of human tumor antigens by serological expression cloning: an online review on SEREX" *Cancer Immun.* 2004 [updated 2004 Mar 10; cited 2004 Apr 1] at world wide web cancerimmunotherapy.org/SEREX/; and Renkvist, N. *et al.*, "A listing of tumor antigens recognized by T cells," *Cancer Immunology Immunotherapy*, 50:3-15 (2001), each of which is hereby incorporated by reference in its entirety.

[0110] Table 2, adapted from Scanlan *et al.*, "The cancer/testis genes: Review, standardization, and commentary," *Cancer Immunity* 4:1 (January 23, 2004), which is hereby incorporated by reference in its entirety, provides a listing of CT Antigens. Table 3 provides the frequency of mRNA expression in various tumor types for the CT antigens in Table 2. Scanlan *et al.*, "The cancer/testis genes: Review, standardization, and commentary," *Cancer Immunity* 4:1 (January 23, 2004), which is hereby incorporated by reference in its entirety.

Table 2
Listing of CT genes

CT Identifier	Transcript/Transcript family	Family Members/CT Identifier (Synonyms)
CT1	MAGEA	MAGEA1/CT1.1, MAGEA2/CT1.2, MAGEA3/CT1.3, MAGEA4/CT1.4, MAGEA5/CT1.5, MAGEA6/CT1.6, MAGEA7/CT1.7, MAGEA8/CT1.8, MAGEA9/CT1.9, MAGEA10/CT1.10, MAGEA11/CT1.11, MAGEA12/CT1.12
CT2	BAGE	BAGE/CT2.1, BAGE2/CT2.2, BAGE3/CT2.3, BAGE4/CT2.4, BAGE5/CT2.5
CT3	MAGEB	MAGEB1/CT3.1, MAGEB2/CT3.2, MAGEB5/CT3.3, MAGEB6/CT3.4
CT4	GAGE1	GAGE1/CT4.1, GAGE2/CT4.2, GAGE3/CT4.3,

		GAGE4/CT4.4, GAGE5/CT4.5, GAGE6/CT4.6, GAGE7/CT4.7, GAGE8/CT4.8
CT5	SSX	SSX1/CT5.1, SSX2/CT5.2a, SSX2/CT5.2b, SSX3/CT5.3, SSX4/CT5.4
CT6	NY-ESO-1	NY-ESO-1/CT6.1, LAGE-1a/CT6.2a, LAGE-1b/CT6.2b
CT7	MAGEC1	MAGEC1/CT7.1, MAGEC3/CT7.2
CT8	SYCP1	SYCP1/CT8
CT9	BRDT	BRDT/CT9
CT10	MAGEE1	MAGEE1/CT10
CT11	CTp11/SPANX	SPANXA1/CT11.1, SPANXB1/CT11.2, SPANXC/CT11.3, SPANXD/CT11.4
CT12	XAGE-1/GAGED	XAGE-1a/CT12.1a, XAGE-1b/CT12.1b, XAGE-1c/CT12.1c, XAGE-1d/CT12.1d, XAGE-2/CT12.2, XAGE-3a/CT12.3a, XAGE-3b/CT12.3b, XAGE-4/CT12.4
CT13	HAGE	HAGE/CT13
CT14	SAGE	SAGE/CT14
CT15	ADAM2	ADAM2/CT15
CT16	PAGE-5	PAGE-5/CT16.1, CT16.2
CT17	LIP1	LIP1/CT17
CT18	NA88	NA88/CT12
CT19	IL13RA1	IL13RA1/CT19

CT20	TSP50	TSP50/CT20
CT21	CTAGE-1	CTAGE-1/CT21.1, CTAGE-2/CT21.2
CT22	SPA17	SPA17/CT22
CT23	OY-TES-1	OY-TES-1/CT23
CT24	CSAGE	CSAGE/CT24.1, TRAG3/CT24.2
CT25	MMA1/DSCR8	MMA-1a/CT25.1a, MMA-1b/CT25.1b
CT26	CAGE	CAGE/CT26
CT27	BORIS	BORIS/CT27
CT28	HOM-TES-85	HOM-TES-85/CT28
CT29	AF15q14/ D40	D40/CT29
CT30	E2F-like/HCA661	HCA661/CT30
CT31	PLU-1	PLU-1/CT31
CT32	LDHC	LDHC/CT32
CT33	MORC	MORC/CT33
CT34	SGY-1	SGY-1/CT34
CT35	SPO11	SPO11/CT35
CT36	TPX1	TPX-1/CT36
CT37	NY-SAR-35	NY-SAR-35/CT37
CT38	FTHL17	FTHL17/CT38

CT39	NXF2	NXF2/CT39
CT40	TAF7L	TAF7L/CT40
CT41	TDRD1	TDRD1/CT41.1, NY-CO-45/CT41.2
CT42	TEX15	TEX15/CT42
CT43	FATE	FATE/CT43
CT44	TPTE	TPTE/CT44
---	PRAME	(MAPE, DAGE)

Table 3.

CT Family (Member)	Frequency (%) of Expression in Tumor Type										Ref						
	Bla d	Br n	Brst	Co i	Eso	Gas	H/N	Live r	Leuk/ Lymph	Lung (NSCLC)	Me I	O v	Panc r	Pro s	Rena l	Star c	
MAGEA1/CT1.1	22	-	18	2	53	29	28	80	0	49	48	28	-	15	0	14	44
BAGE1/CT2.1	15	-	10	0	-	8	-	0	0	4	26	15	-	0	0	6	44
MAGEB1/CT3.1	0	0	17	0	-	0	0	-	0	14	22	-	-	0	0	9	45
GAGE/CT4.1	12	-	9	0	-	-	19	38 ^b	1	19	28	31	-	10	0	25	44
SSX2/CT5.2	44	6	7	12	-	-	35	9 ^b	36	16	35	-	-	40	5	50	46
NY-ESO-1/CT6.1	80	0	30	0	-	0	-	29	0	17	34	25	0	25	9	0	8
MAGEC1/CT7.1	44	-	30	10	-	-	36	-	-	33	70	-	-	-	-	60	20
SYCP1/CT8	-	47	20	0	-	7	-	28 ^b	0	7	14	0	-	0	8	0	2
BRDT/CT9	0	-	0	0	8	-	8	-	-	25	0	-	-	0	-	0	16
MAGEE1/CT10	44	-	38	0	-	-	36	-	-	24	50	-	-	-	-	0	12
SPANXC/CT11.3	9	-	25	22	0	-	-	-	-	33	70	-	0	-	-	-	14

XAGE-1a/CT12.1a	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	22	47
HAGE/CT13	24	37	5	31	27	-	20	9	32	17	-	-	-	-	-	-	-	22	6	20
SAGE/CT14	12	0	5	0	20	-	17	-	4	22	4	-	-	0	0	5	5	5	13	
ADAM2/CT15	-	-	0	0	-	-	-	-	0	0	0	-	-	-	-	12	-	17		
PAGE-5/CT16	-	-	5	11	-	-	-	-	39	22	0	-	-	-	-	44	-	17		
LIP1/CT17	-	-	5	0	-	-	-	-	0	0	0	-	-	-	-	25	-	17		
NA88/CT18	-	-	-	-	-	-	-	-	-	11	-	-	-	-	-	-	-	-	48	
TSP50/CT20	-	-	28	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	49	
CTAGE-1/CT21.1	-	-	-	-	-	-	-	-	35	-	-	-	-	-	-	-	-	-	50	
SPA17/CT22	-	-	-	-	-	-	-	-	26	-	-	-	-	-	-	-	-	-	51	
OYTES1/CT23	28	-	40	15	-	0	-	40	-	20	-	-	-	-	-	0	-	-	52	
MMA1a/CT25.1a	-	-	0	0	0	-	-	-	-	40	26	-	0	-	-	-	-	18	15	
CAGE/CT26	-	-	-	-	-	89	-	-	-	100	-	-	-	-	-	-	-	-	53	
HOMTES85/CT28	-	35	0	10	-	-	-	19	-	28	36	32	-	0	-	-	-	-	54	

D40/CT29	-	20	-	13	-	0	-	-	-	41	-	36	27	-	-	-	-	55
HCA661/CT30	0	-	-	-	0	0	29	-	-	20	-	-	-	-	-	-	-	56
PLU-1/CT31	-	-	86	-	-	-	-	-	-	-	-	-	-	-	-	-	-	27
LDHC/CT32	-	-	35	15	-	-	-	-	-	47	44	42	-	37	57	-	-	18
MORC/CT33	-	-	0	0	-	-	-	-	-	18	18	14	-	0	0	-	-	18
SGY-1/CT34	-	-	20	0	-	-	-	-	-	12	25	57	-	12	0	-	-	18
SPO11/CT35	-	-	0	0	-	-	-	-	-	0	6	0	-	0	0	-	-	18
TPX1/CT36	-	-	15	0	-	-	-	-	-	-	6	14	-	37	14	-	-	18
NYSAR35/CT37	42	-	23	0	8	-	-	-	-	17	6	8	-	-	0	8	57	
FTHL17/CT38	22	-	14	0	0	-	10	-	0	25	0	-	-	0	0	0	0	58
NXF2/CT39	19	-	0	11	12	-	5	-	0	15	55	-	-	14	0	27	58	
TAF7L/CT40	10	-	0	0	0	-	10	-	0	9	21	-	-	0	0	12	58	
TDRD1/CT41.1	28	-	37	0	10	-	22	-	5	5	0	-	-	38	0	0	58	
TEX15/CT42	21	-	0	0	20	-	11	-	0	21	27	-	-	12	33	28	58	

FATE/CT43	-	-	-	21	-	7	-	66	-	0	-	-	-	-	-	19
TPTE/CT44	-	-	-	0	-	0	-	39	-	36	-	-	-	-	-	19

^aAbbreviations: Blad, bladder; Brn, brain; Brst, breast; Col, colon; Gas, gastric; H/N, head and neck; Leuk, leukemia; Lymph, lymphoma, NSCLC, non-small cell lung carcinoma; Mel, melanoma; Ov, ovarian; Paner, pancreatic; Pros, prostate; Sarc, sarcoma; Ref, reference.
^bReference 52.

Many antigens listed in the tables above have no documented role in maintaining the transformed phenotype of a cell, and thus, a transformed cell may lose expression of such antigens without affecting the viability of the cell or the malignancy of the disease. Although some CT antigens, such as the SSX proteins, are known to be transcriptional regulators, their role, if any, in tumorigenicity remains obscure. It has also recently emerged that PRAME can repress signaling through the retinoic acid receptor to inhibit retinoic acid-induced differentiation, growth arrest, and apoptosis, thereby suggesting that PRAME over-expression can impart tumor cells with a growth or survival advantage. It would be advantageous to target an antigen, the loss of which necessarily would affect viability of the cell or the malignancy of the disease. Such antigens are included in preferred embodiments of the combinations of tumor and/or tumor and stromal antigens disclosed herein.

However, many genes involved in the regulation of proliferation are important in oncogenesis primarily in mutated form so that specific immune attack on the mutated form depends on the mutation being appropriately placed within an epitope. Furthermore, epitopes present in the wild type molecule (whether or not the targeted molecule is wild type or mutant) will generally only be considered if there is a substantial difference in expression level between transformed and normal cells, or at least the normal cells of vital organs. Thus appropriate antigens have been difficult to recognize.

The expression of PLK1 is regulated during cell cycle progression as well as throughout the various disease stages. PLK1 expression is minimal during the initial phases of cell division, begins to increase during G2 and peaks at M phase. PLK1 is targeted for degradation by the proteasome pathway after cells exit from mitosis. In normal tissues, PLK1 is expressed in adult organs containing highly proliferative cells, such as in the spleen, placenta, ovary, and testis. Its expression is undetected in vital organs such as heart, lung, liver, brain, intestines, smooth muscle, and skin. Wild type PLK1 is overexpressed in tumor tissues, including breast, prostate, ovarian, non-small cell lung, head/neck, colon, pancreatic, endometrial, and esophageal carcinomas (Table 4). Importantly, the level of PLK1 expression often correlates with more advanced stages of tumor progression and poor prognosis (Wolf G *et al*, *Oncogene* 14:543, 1997; Takai N *et al*, *Cancer Lett.* 164:41, 2001). This has been specifically demonstrated in the case of NSCLC, esophageal, and head/neck carcinomas. Thus, PLK1 is a viable target for cancer immunotherapy for those tumors in which it is overexpressed.

Table 4. Plk-1 Expression Profile

Tumor	Penetrance	Expression Level	Reference
Lung (NSCLC)	> 90 %	Med/strong	Wolf G <i>et al</i> , <i>Oncogene</i> 14:543, 1997.
Ovarian	> 85 %	Low/strong	Takai N <i>et al</i> , <i>Cancer Lett.</i> 164:41, 2001
Breast	43 %	Med/strong	Weichert W <i>et al</i> , <i>Virchows Arch</i> , 446: 442, 2005.
Prostate	53 %	Med/strong	Weichert W <i>et al</i> , <i>Curr. Biol.</i> 101:4419, 2004.
Colorectal	73 %	Med/strong	Takahashi T <i>et al</i> , <i>Cancer Sci.</i> 94:148 2003.
Pancreatic	48 %	Med/strong	Gray JP <i>et al</i> , <i>Mol Cancer Ther.</i> 3:641,2004.
Head & Neck	72 %	Med/strong	Knecht R <i>et al</i> , <i>Cancer Res.</i> 59:2794, 1999.
Melanoma	53 %	Med	Strebhardt K <i>et al</i> , <i>JAMA</i> 283:479, 2000.
Esophageal	96 %	Med	Tokumitsu Y <i>et al</i> , <i>Int J Oncol.</i> 15:687, 1999.

[0111] Each reference listed in this table is incorporated herein by reference in its entirety.

[0112] Additional antigens associated with tumor neovasculature are VEGFR2 (vascular endothelial growth factor receptor 2) described in U.S. Patent No. 6,342,221, which is hereby incorporated by reference in its entirety; and Tie-2, an endothelium specific receptor tyrosine kinase, which is described in WO 99/43801, and which is hereby incorporated by reference in its entirety.

[0113] In addition to disrupting blood flow to tumors that can be achieved using anti-neovasculature agents such as those recited above, co-targeting molecules expressed on cancer cells as well as molecules expressed on underlying non-transformed stromal cells (including neovasculature as well as interstitial tissue, for example) can also improve the

effectiveness of the disclosed methods and compositions in limiting tumor growth and promoting cancer regression by other mechanisms. Stroma encompasses neovasculature as well as fibroblasts, and in general, all non-transformed, non-lymphoid cells within a tumor microenvironment. For example, immune mediated attack of the endothelial cells (via cytotoxic T lymphocytes (CTLs) or antibody dependent cytotoxic cells (ADCC) can result in neovasculature permeabilization and initiation of inflammatory events that result in recruitment and translocation of immune effectors, such as CTLs, targeting the neoplastic cells within primary tumor and metastatic lesions. Moreover, as attacks based, for example, on T cell recognition of endothelial cell MHC-peptide complexes occur in the luminal environment, any immune suppressive influence of the tumoral environment is minimized. Compared to strategies targeting only cancer cells, methods to co-target associated stromal tissue thus improve the efficacy of the former. In some embodiments, the efficacy is synergistically enhanced. Similarly, compared to strategies targeting neovasculature only, methods to co-target cancer cells improve the overall therapeutic effect by attacking lesions, including those of limited size and vascularization, especially those adversely located within vital organs. With regard to neovasculature, co-targeting VEGFRs (such as II), CD55 and PSMA as well as other molecules expressed by neovasculature, can be accomplished by generating CTL or antibodies with capability to initiate ADCC or complement activated cell injury. Alternatively, initial endothelial injury can be brought about though passive immunotherapy using available anti-angiogenic antibodies.

[0114] In addition or alternatively, co-targeting target-associated antigens, together with growth, metastasis, or survival promoting factors produced by cancer cells or non-transformed cells that are found in the extracellular compartment (diffusing or associated with the extracellular matrix), can also result in a more substantial therapeutic effect. By co-targeting antigens expressed within or on cancer cells as well as factors that exert autocrine or paracrine effects (growth, survival, and/or invasiveness), the pathogenic process can be slowed or disrupted to a significant degree. Co-targeting autocrine or paracrine factors (such as, but not limited to, NF- κ B activating molecules - CXCL1, CXCL8, CCL2; or growth factors such as, but not limited to, chorionic-gonadotropic hormone gastrin, and VEGF-A) can be carried out by co-induction of neutralizing antibodies or secondarily, by CTLs recognizing cells that produce such factors.

[0115] The interaction between transformed and stromal cells is mediated by VEGF-A. VEGF-A has been shown to play a key role in the establishment and functionality of tumor neovasculature; thus, deprival of VEGF-A by using specific passive immunotherapy (via anti-VEGF-A antibodies such as bevacizumab (AVASTIN®) resulted in control of tumor progression and metastatic disease for colorectal, lung, breast, ovarian carcinoma and other cancers. The mechanism of action likely involves direct neutralization of VEGF-A, thereby slowing down the establishment and progression of neovasculature. Neutralization of VEGF-A by passive immunotherapy can be combined with the active immunotherapies disclosed herein. VEGF-A can also be used as the target antigen for active or T-cell based immunotherapy directed against cells that produce VEGF-A in excess (most likely a subpopulation of tumoral cells, and most often the transformed cancer cells within the tumor environment). Such a strategy can be more effective in controlling a tumoral process both by mediating immune damage of cancer cells that express VEGF-A and by depriving the tumor neovasculature of an essential growth factor.

[0116] Overall, co-targeting multiple elements of biological importance for tumor growth and metastasis can limit progression of the malignant process by impacting the processes of clonal selection, immune evasion and escape. Thus, co-targeting stroma-associated antigens provides an additional mode of attack in that such activities are inhibited and/or disrupted.

[0117] One of skill in the art will appreciate that any other antigen or protein associated with vascular or other tumor-associated stromal cells can be a target for the immunogenic compositions, including those that are presently known and those yet to be identified.

Compositions

[0118] Immunogenic compositions, including, for example, vaccines, can be prepared using whole antigen or an epitopic peptide. Peptide immunogens can be readily prepared using standard peptide synthesis means known in the art, for example. Immunogens can be prepared commercially by one of numerous companies that do chemical synthesis. An example such a company is American Peptides, Inc., where the distributor is CLINALFA AG (Laufelfingen, Switzerland). The antigens or immunogens can be prepared in accordance with GMP standards and purity can be assessed by analytical

HPLC. The product can be characterized by amino-acid analysis and tested for sterility and the absence of pyrogens.

[0119] The immunogenic compositions can also include adjuvants or other biological response modifiers (BRMs). Particularly advantageous methods of using adjuvants and BRMs are disclosed in U.S. provisional patent application 60/640,727, filed December 29, 2004 and U.S. Application No. ____/____, (Pub. No. _____) (Attorney Docket No. MANNK.046A), filed on even date with this application, both entitled, "METHODS TO TRIGGER, MAINTAIN AND MANIPULATE IMMUNE RESPONSES BY TARGETED ADMINISTRATION OF BIOLOGICAL RESPONSE MODIFIERS INTO LYMPHOID ORGANS," each of which is hereby incorporated by reference in its entirety.

[0120] An antigen can be delivered to an animal's system either directly or indirectly. For example, a polypeptide can be delivered directly as the polypeptide, or it can be delivered indirectly, for example, using a DNA construct or vector, or a recombinant virus that codes for the desired antigen. Any vector driving expression in a professional antigen presenting cell can be suitable for this purpose. In indirect delivery, the antigen is expressed in the cell, then presented by the MHC Class I on the surface of the cell to stimulate a CTL response. Expression of a secreted form of the antigen can be useful to induce an antibody response recognizing antigens that are membrane proteins.

[0121] In a preferred embodiment, an encoded antigen can be delivered in the form of a naked plasmid expression vector. Particularly useful constructs are disclosed in U.S. Patent Application Nos. 09/561,572, filed April 28, 2000, 10/225,568 (Pub No. 2003-0138808), filed August 20, 2002; and PCT Application No. PCT/US2003/026231 (Pub. No. WO 2004/018666); all entitled "EXPRESSION VECTORS ENCODING EPITOPES OF TARGET-ASSOCIATED ANTIGENS;" U.S. Patent Application Nos. 10/292,413 (Pub. No. 2003-0228634 A1), filed November 7, 2002, 10/777,053 (Pub. No. 2004-0132088 A1), filed February 10, 2004, and 10/837,217 (Pub. No. _____), filed April 30, 2004, all entitled "EXPRESSION VECTORS ENCODING EPITOPES OF TARGET-ASSOCIATED ANTIGENS AND METHODS FOR THEIR DESIGN;" U.S. Patent No. 6,709,844, and U.S. Patent Application No. 10/437,830 (Pub. No. 2003-0180949 A1), filed May 13, 2003, both entitled "AVOIDANCE OF UNDESIRABLE REPLICATION INTERMEDIATES IN PLASMID PROPAGATION," and in U.S. Patent Application Nos. 10/026,066 (Pub. No. 2003-0215425 A1), filed December 7, 2001, 10/895,523 (Pub.

No. 2005-0130920 A1), filed July 20, 2004, 10/896,325 (Pub. No. _____), filed July 20, 2004, all entitled "EPITOPE SYNCHRONIZATION IN ANTIGEN PRESENTING CELLS," each of which is hereby incorporated by reference in its entirety. Additional methodology, compositions, peptides, and peptide analogues are disclosed in U.S. Provisional Application No. 60/581,001, filed June 17, 2004, and U.S. Patent Application No. 11/156,253 (Pub. No. _____), filed on June 17, 2005, both entitled "SSX-2 PEPTIDE ANALOGS;" U.S. Provisional Patent Application No. 60/580,962, filed June 17, 2004, and U.S. Patent Application No. 11/155,929 (Pub. No. _____), filed on June 17, 2005, both entitled "NY-ESO PEPTIDE ANALOGS;" U.S. Patent Application No. 09/999,186, filed November 7, 2001, entitled "METHODS OF COMMERCIALIZING AN ANTIGEN"; U.S. Provisional Patent Application No. 60/640,402, filed on December 29, 2004 and U.S. Patent Application No. ____/____ (Pub. No. _____), (Attorney Docket No. MANNK.047A), filed on even date as the instant application, both entitled, "METHODS TO ELICIT, ENHANCE AND SUSTAIN IMMUNE RESPONSES AGAINST MHC CLASS I- RESTRICTED EPITOPES, FOR PROPHYLACTIC OR THERAPEUTIC PURPOSES"; and U.S. Provisional Patent Application No. 60/640,821, filed on December 29, 2004 and U.S. Patent Application No. ____/____ (Pub. No. _____), (Attorney Docket No. MANNK.048A), filed on even date as the instant application, both entitled "METHODS TO BYPASS CD4+ CELLS IN THE INDUCTION OF AN IMMUNE RESPONSE," and U.S. Provisional Patent Application Nos. 60/691,579, filed June 17, 2005, entitled "METHODS AND COMPOSITIONS TO ELICIT MULTIVALENT IMMUNE RESPONSES AGAINST DOMINANT AND SUBDOMINANT EPITOPES EXPRESSED ON CANCER CELLS AND TUMOR STROMA," and 60/691,581, filed June 17, 2005, entitled "MULTIVALENT ENTRAIN-AND-AMPLIFY IMMUNOTHERAPEUTICS FOR CARCINOMA," each of which is hereby incorporated by reference in its entirety. The feasibility of and general procedures related to the use of naked DNA for immunization are described in U.S. Patent No. 5,589,466, entitled "INDUCTION OF A PROTECTIVE IMMUNE RESPONSE IN A MAMMAL BY INJECTING A DNA SEQUENCE" and in U.S. Patent No. 5,679,647, entitled "METHODS AND DEVICES FOR IMMUNIZING A HOST AGAINST TUMOR-ASSOCIATED ANTIGENS THROUGH ADMINISTRATIONS OF NAKED POLYNUCLEOTIDES WHICH ENCODE TUMOR-ASSOCIATED ANTIGENIC PEPTIDES," each of which is hereby incorporated by reference in its entirety. The former

teaches only intramuscular or intradermal injection while the latter teaches only administration to skin or mucosa.

[0122] In a preferred embodiment, the antigen can be administered directly to the lymphatic system. Intranodal administration for the generation of CTL is taught in U.S. Patent Application No. 09/380,534, filed September 1, 1999, and U.S. Patent No. 6,977,074, and in PCT Application No. PCTUS98/14289 (Pub. No. WO 99/02183 A2) each entitled "METHOD OF INDUCING A CTL RESPONSE," each of which is hereby incorporated by reference in its entirety. Single bolus injection intra lymph node (i.ln.) required only 0.1% of the dose required in order to obtain a similar level of CTL response by intramuscular (i.m.) injection. Therefore a protective response can be established against systemic viral infection with a single bolus delivered i.ln., but not with a dose nearing the practical limit delivered i.m. Repeated bolus injections i.m. failed to establish a protective response against a peripheral virus infection or transplanted tumor, whereas lower doses administered i.ln. were completely effective. Particularly useful intranodal immunization protocols are taught in Provisional U.S. Patent Application No. 60/479,393, filed June 17, 2003, entitled "METHODS TO CONTROL MHC CLASS I-RESTRICTED IMMUNE RESPONSE," and in U.S. Patent Application No. 10/871,707, (Pub. No. 20050079152 A1), filed June 17, 2004, entitled "METHODS TO ELICIT, ENHANCE AND SUSTAIN IMMUNE RESPONSES AGAINST MHC CLASS I-RESTRICTED EPITOPES, FOR PROPHYLACTIC OR THERAPEUTIC PURPOSE," each of which is hereby incorporated by reference in its entirety.

[0123] A class of epitopes that can be advantageous in anti-cancer immunogenic compositions are housekeeping epitopes. These are produced through the action of the housekeeping (or standard) proteasome. Housekeeping epitopes can be liberated from the translation product of expression vectors through proteolytic processing by the immunoproteasome of professional antigen presenting cells (pAPC). In one embodiment of the invention, sequences flanking the housekeeping epitope(s) can be altered to promote cleavage by the immunoproteasome at the desired location(s). Housekeeping epitopes, their uses, and identification are described in U.S. Patent Application Nos. 09/560,465 filed on April 28, 2000, and 10/026,066 (Pub. No. 2003-0215425 A1), filed on December 7, 2001, 10/895,523 (Pub No. 2005-0130920 A1), filed July 20, 2004, 10/896,325 (Pub. No. _____), filed July 20, 2004, all entitled "EPITOPE SYNCHRONIZATION IN ANTIGEN PRESENTING CELLS," and U.S.

Patent No. 6,861,234 and U.S. Patent Application No. 10/956,401 (Pub. No. 2005-0069982 A1), filed October 1, 2004, both entitled “METHOD OF EPITOPE DISCOVERY,” each of which is hereby incorporated by reference in its entirety.

[0124] Examples of housekeeping epitopes are disclosed in Provisional U.S. Patent Applications Nos. 60/282,211, filed on April 6, 2001; 60/337,017, filed on November 7, 2001; 60/363,210 filed March 7, 2002; and 60/409,123, filed on September 6, 2002; U.S. Patent Application Nos. 10/117,937 (Publication No. 20030220239 A1), filed on April 4, 2002; and 10/657,022 (Pub. No. 2004-0180354), filed September 5, 2003, and PCT Application No. PCT/US2003/027706 (Pub. No. WO 04/022709 A2), filed September 5, 2003, all entitled “EPITOPE SEQUENCES,” each of which is hereby incorporated by reference in its entirety.

[0125] In other embodiments of the invention, the housekeeping epitope(s) can be flanked by arbitrary sequences or by sequences incorporating residues known to be favored in immunoproteasome cleavage sites. As used herein the term “arbitrary sequences” refers to sequences chosen without reference to the native sequence context of the epitope, their ability to promote processing, or immunological function. In further embodiments of the invention multiple epitopes can be arrayed head-to-tail. These arrays can be made up entirely of housekeeping epitopes. Likewise, the arrays can include alternating housekeeping and immune epitopes. Alternatively, the arrays can include housekeeping epitopes flanked by immune epitopes, whether complete or distally truncated. Further, the arrays can be of any other similar arrangement. There is no restriction on placing a housekeeping epitope at the terminal positions of the array. The vectors can additionally contain authentic protein coding sequences or segments thereof containing epitope clusters as a source of immune epitopes. The term “authentic” refers to natural protein sequences.

[0126] Epitope clusters and their uses are described in U.S. Patent Application Nos. 09/561,571, entitled “EPITOPE CLUSTERS,” filed on April 28, 2000; 10/005,905, filed on November 7, 2001; 10/026,066 (Pub. No. 2003-0215425 A1), filed on December 7, 2001; 10/895,523 (Pub. No. 2005-0130920 A1), filed July 20, 2004, and 10/896,325 (Pub. No. _____), filed July 20, 2004, all entitled “EPITOPE SYNCHRONIZATION IN ANTIGEN PRESENTING CELLS,” each of which is hereby incorporated by reference in its entirety.

[0127] In another embodiment of the invention an encoded antigen can be delivered in the form of a viral vector. A wide array of viruses with modified genomes adapted to express interposed reading frames but often no, or at least a reduced number of, viral proteins are known in the art, including without limitation, retroviruses including lentiviruses, adenoviruses, parvoviruses including adeno-associated virus, herpesviruses, and poxviruses including vaccinia virus. Such viral vectors facilitate delivery of the nucleic acid component into the cell allowing for expression. A subset of these vectors, such as retroviruses and parvoviruses, promote integration of their nucleic acid component into the host genome, whereas others do not.

[0128] Bacteria can also serve as vectors, that is, they can be used to deliver a nucleic acid molecule capable of causing expression of an antigen. For example, a strain of *Listeria monocytogenes* has been devised that effects its own lysis upon entering the cytosol of macrophages (its normal target), thereby releasing plasmid from which antigen is subsequently expressed (Dietrich, G. *et al.*, *Biotechnology* 16:181-185, 1998, which is hereby incorporated by reference in its entirety). *Shigella flexneri* and *Escherichia coli* have been similarly used (Sizemore, D.R. *et al.*, *Science* 270:299-302, 1995, and Courvalin, P. *et al.*, *Life Sci.* 318:1207-1212, 1995, respectively, each of which is hereby incorporated by reference in its entirety).

[0129] The use of microbial vectors for nucleic acid delivery can be complicated by the immune reactions the vectors themselves provoke. When prolonged or repeated administration is required, antibody elicited by the earlier treatment can prevent useful quantities of the vector from ever reaching its intended host. However, by direct administration intra lymph node, for example, the combination of proximity to host cells and the much reduced effective dose makes it possible to administer a dose capable of evading or overwhelming an existing antibody titer.

[0130] The word vector has been used, here and elsewhere, in reference to several modalities and variously modified (*e.g.*, expression vector, viral vector, delivery vector, etc.). The underlying principle is that a nucleic acid capable of causing expression of an antigen, rather than the antigen itself, ultimately arrives in an APC. Unless modified, explicitly or by local context, in preferred embodiments, the term vector as used herein is intended to encompass all such possibilities.

[0131] The techniques discussed above are distinct from the approach of modifying the microbial genome, including extra-chromosomal DNA, such that the antigen

is produced as a component of the microbe, which is then itself administered as the immunogen. Examples of microbes used in the genomic modification approach include viruses, bacteria, fungi, and protozoa. In embodiments of the invention described herein, the compositions, including the vaccines, can include the already synthesized antigen or a nucleic acid capable of causing an APC to express the antigen *in vivo*. In alternative embodiments, combinations of these two techniques are used. For example, one embodiment contemplates the use of a virus vector as discussed above that also incorporates a target epitope into a capsid or envelope protein.

[0132] Antigens may be used alone or may be delivered in combination with other antigens or with other compounds such as cytokines. Cytokines that are known to enhance immune stimulation of CTL responses, include, for example, GM-CSF, IL-12, IL-2, TNF, IFN, IL-18, IL-3, IL-4, IL-8, IL-9, IL-13, IL-10, IL-14, IL-15, G-CSF, IFN alpha, IFN beta, IFN gamma, TGF alpha, TGF beta, and the like. Cytokines are known in the art and are readily available in the literature or commercially. Many animal and human tumors have been shown to produce cytokines, such as IL-4, IL-10, TGF-B, that are potent modulators of the immune response and that protect tumors from immune-mediated destruction. The production of IL-4, IL-10 or TGF-B by tumors may achieve this protective effect by suppressing the induction of cellular immunity, including the elaboration of CTL responses. Alternatively, cytokines that support CTL responses can be exogenously added to help in the balance between induction of anti-tumor cell mediated and non-tumor-destructive humoral responses. Several such exogenous cytokines show utility in experimental mouse vaccination models which are known to enhance CTL responses, including GM-CSF, IFN and IL-2. An example of an effective exogenous cytokine that can be used is GM-CSF. GM-CSF is reported to enhance the expression of the so called "co-stimulatory" molecules, such as B7-1 or B7-2 on antigen presenting cells (APC). These co-stimulatory molecules are important players in the variety of interactions that occur during stimulation of CTL by APC. Moreover, GM-CSF is known to induce activation of APCs and to facilitate growth and differentiation of APCs, thereby making these APCs important CTL stimulating cells available both in greater numbers and potency.

[0133] Immunogenic compositions can additionally contain non-target antigens in order to improve the response to the target antigen. Thus, co-induction of a helper response, such as Th and/or B cell immunity against non-self or foreign antigens not expressed within the tumoral process or in the body, can result in a substantial

improvement in the magnitude and quality of the immune response to the "self" or "self-modified" target antigens expressed within the tumor or underlying stroma. For example, co-initiating a Th immune response against a non-target antigen such as tetanus toxoid can result in the generation of helper cells with bystander effect relative to generation of CTL or B cell responses against the target tumor or self antigens. Any defined sequence expressing or encompassing peptide motifs that bind to at least one class II MHC protein expressed by recipient, where such sequences are non-homologous or contain non-homologous segments relative to self antigens, can be used. Preferably, such sequences are of microbial origin and shown to be immunogenic in HLA-defined or broader populations. In addition to tetanus toxoid (whole or portions, including, but not limited to, portions that are 90%, 80%, 75%, 70%, 60%, 50%, 40%, 30%, 25%, 20%, 15%, 10%, or 5% of a whole toxoid), further examples include, but are not limited to, sequences derived from HBVcore, influenza hemagglutinin, Plasmodium circumsporozoite antigen, and HTLV-1 envelope protein, and fragments of these sequences that are 90%, 80%, 75%, 70%, 60%, 50%, 40%, 30%, 25%, 20%, 15%, 10%, or 5% of the respective full-length sequences. In some embodiments, the tetanus toxoid portion is 5% to 90% of a whole toxoid, in other embodiments, the portion is 15% to 80% of a whole toxoid, in still other embodiments, the toxoid portion is 25% to 70% of a whole toxoid, in yet other embodiments, the toxoid portion is 35% to 60% of a whole toxoid, in still other embodiments, the toxoid portion is 45% to 55% of a whole toxoid. Similarly, co-administration of a strongly immunogenic B cell epitope (a non-self antigen) with or without a Th epitope (a non-self antigen) with target epitopes (self, tumoral) in a cognate fashion (that is, within the same molecule), can result in improved immune response, or even break of tolerance (T cell) against the therapeutic target, via immune antibody-antigen complexes and bystander T cell help.

Delivery of the Antigen

[0134] While not wanting to be bound by any particular theory, it is thought that T cells do not have a functional memory that is long-lived. Antibody-mediated B-cell memory, on the other hand, appears to have a long-lived effector memory. Thus, delivering an antigen that induces a CTL response is most preferably done over time to keep the patient's immune system appropriately stimulated to attack the target cells. In one approach the presence of antigen is maintained virtually continuously within the lymphatic system to maintain effector CTL function as disclosed in U.S. Patent No. 6,977,074, entitled

“METHOD OF INDUCING A CTL RESPONSE,” which is hereby expressly incorporated by reference. In another approach T cell memory is repeatedly induced, and re-amplified and reactivated as described in Provisional U.S. Patent Application No. 60/479,393, filed June 17, 2003, entitled “METHODS TO CONTROL MHC CLASS I-RESTRICTED IMMUNE RESPONSE,” and in U.S. Patent Application No. 10/871,707 (Pub. No. 20050079152 A1), filed June 17, 2004, both entitled “METHODS TO ELICIT, ENHANCE AND SUSTAIN IMMUNE RESPONSES AGAINST MHC CLASS I-RESTRICTED EPITOPES, FOR PROPHYLACTIC OR THERAPEUTIC PURPOSE,” each of which is hereby incorporated by reference in its entirety. While it has been suggested that antigens and adjuvants can be prepared as biodegradable microspheres or liposomes, none of these preparations have thus far provided a CTL response that is useful for attacking cancer cells or pathogens on a long term basis. Preferably, delivery of the antigen is sustained over the desired period of time at a level sufficient to maintain the antigen level to obtain the desired response. In one embodiment, a reservoir having fluid antigen composition can be used to deliver the antigen such that it reaches the animal's lymphatic system. While much of the following discussion focuses on the use of infusion to deliver the antigen it is also possible to use bolus injections directly into the lymphatic system, the number and frequency of which will depend on the persistence of antigen conferred by the particular form and formulation of antigen used.

[0135] Ultimately antigen finds its way into the lymphatic system in order to most efficiently stimulate CTL. Delivery of antigen can involve infusion into various compartments of the body, including but not limited to subcutaneous, intravenous, intraperitoneal and intralymphatic, the latter being preferred. While each of these points of infusion results in antigen uptake into the lymphatic system, the relative amounts of antigen needed to induce a beneficial CTL response varies according to the site of infusion. In general, direct infusion of antigen into the lymph system is deemed to be the most efficient means of inducing a CTL response, however, any delivery route can be used. Pump systems are capable of delivering material quantities of antigen in a range that is suitable for inducing a CTL response through delivery to all compartments of the body. CTL stimulation following delivery of antigen via the various routes will vary depending on the properties of different antigens, including factors that influence antigen behavior in the body and its rate of equilibration to (or longevity in) the lymph, such as antigen stability in

the body fluid, solubility of antigen in body fluid, binding affinity for HLA and potency as a stimulator of CTL.

[0136] In a preferred embodiment, introduction of the antigen is done as directly as possible to the lymphatic system to avoid the destruction of the antigen by metabolism in the body. When introduction of a fluid antigen composition occurs subcutaneously, larger quantities of antigen are needed to assure enough antigen reaches the lymphatic system. Such subcutaneous injection is contemplated by the invention disclosed herein, depending on factors such as cost, stability of the antigen, how quickly the antigen gets to the lymph system, how well it equilibrates with the lymph, and other factors that the attending doctor or specialist will recognize. Subcutaneous delivery generally can require 100 to 1000 times more antigen than direct delivery to the lymph system. It is preferable, therefore, that the antigen composition is introduced through a device for local administration to the lymphatic system, *e.g.*, the spleen, a lymph node, or a lymph vessel. The device for local administration can be positioned outside the patient or implanted into the patient. In either case, the device can have a reservoir to hold the fluid antigen-containing composition, a pump to transfer the composition, and a transmission channel leading from the reservoir to be directed to the preferred region of administration in the patient's body. In either case it is preferably portable.

[0137] For the device positioned outside the patient's body (the external device), there are numerous devices used for delivering insulin to diabetic patients that are useful in delivering antigen according to the embodiments described herein. Generally these devices can be comprised of a reservoir for holding the antigen composition (instead of insulin), a programmable pump to pump the composition out of the reservoir, a transmission channel or line for transmitting the composition, and a means to introduce the composition into the animal's body to ultimately reach the lymphatic system.

[0138] Preferably, the reservoir for the antigen composition should be large enough for delivery of the desired amount of antigen over time and easily refillable or replaceable without requiring the user to reinsert the means for introducing the antigen composition to the lymph system.

[0139] In preparing the antigen compositions of embodiments of the invention disclosed herein, a composition (preferably aqueous) can be prepared to be compatible with the lymph system and physiologically acceptable to the animal being treated. Relevant considerations include, for example, the physicochemical properties of the antigen, such as

the isoelectric point, molecular weight, glycosylation or other post-translational modification, and overall amino acid composition. These properties along with any known behavior of the drug in different solutions (e.g., different buffers, cofactors, etc.) as well as its *in vivo* behavior can help guide the choice of formulation components. One parameter that impacts all the major degradation pathways is the solution pH. Thus, the initial formulations also assess the pH dependence of the degradation reactions and the mechanism for degradation, which can often be determined from the pH dependence to determine the stability of the protein in each solution. Rapid screening methods usually involve the use of accelerated stability at elevated temperatures (e.g., 40° C) using techniques known in the art.

[0140] In general the antigen compositions useful in embodiments described herein can be suitable for parenteral injection, in very small quantities. As such a composition should be free of contamination and have a pH compatible with the lymphatic system. However, because very small quantities of the antigenic composition will be delivered it need not be the same pH as blood or lymph, and it need not be aqueous-based. The preferable pH range that is compatible is from about 6.7-7.3 and can be prepared using water for injection to meet USP specifications (see Remington: *The Science and Practice of Pharmacy*, Nineteenth Edition; Chapters 86-88, which is hereby incorporated by reference in its entirety). For antigens that are less soluble, a suitable cosolvent or surfactant can be used, such as dimethyl sulfoxide (DMSO) or PLURONIC brand surfactants. Generally, a standard saline solution that is buffered with a physiologically acceptable weak acid and its base conjugate, e.g., a phosphate or citrate buffering system, will be the basis of the antigen composition. In some cases, a small amount of an antioxidant may be useful to stabilize the composition and prevent oxidation. Factors to consider in preparing the antigen compositions can be found in the 1994 American Chemical Society book entitled *Formulation and Delivery of Proteins and Peptides* (Acs Symposium Series, No. 567) by Jeffery L. Cleland and Robert Langer (Editor), which is hereby incorporated by reference in its entirety.

[0141] For nucleic acid encoded antigens similar considerations can apply, although the variety of physico-chemical properties encountered with polypeptides is absent, so that acceptable formulations will have nearly universal applicability. As seen in Examples 6-10, plasmid DNA in standard phosphate buffered saline (PBS) is an acceptable and effective formulation. In some embodiments of the invention, DNA is administered

continuously or intermittently at short intervals, from a reservoir worn on, or implanted in, the patient's body. It is preferable that the DNA be maintained in a soluble, stable form at or near body temperature over a period of time measured minimally in days. In such applications where the formulated nucleic acid will be delivered from a reservoir over a period of several days or longer, the stability of the nucleic acid at room or body temperature for that period of time, as well as its continued sterility, take on increased importance. The addition of bacteriostatic agents (*e.g.*, benzyl or ethyl alcohol) and chelating agents (*e.g.*, EDTA) is useful toward these ends. Formulations containing about 0.5-2 % ethyl alcohol, 0.25-0.5mM EDTA generally perform well. Such formulations are also appropriate for bolus injections.

[0142] Generally the amount of the antigen in the antigen composition will vary from patient to patient and from antigen to antigen, depending on such factors as the activity of the antigen in inducing a response and the flow rate of the lymph through the patient's system. In general the antigen composition may be delivered at a rate of from about 1 to about 500 microliters/hour or about 24 to about 12000 microliters/day. The concentration of the antigen is such that about 0.1 micrograms to about 10,000 micrograms of the antigen will be delivered during 24 hours. The flow rate is based on the knowledge that each minute approximately about 100 to about 1000 microliters of lymph fluid flows through an adult inguinal lymph node. The objective is to maximize local concentration of vaccine formulation in the lymph system. A certain amount of empirical investigation on patients will be necessary to determine the most efficacious level of infusion for a given vaccine preparation in humans.

[0143] To introduce the antigen composition into the lymphatic system of the patient the composition is preferably directed to a lymph vessel, lymph node, the spleen, or other appropriate portion of the lymphatic system. Preferably, the composition is directed to a lymph node such as an inguinal or axillary node by inserting a catheter or needle to the node and maintaining the catheter or needle throughout the delivery. Suitable needles or catheters are available made of metal or plastic (*e.g.*, polyurethane, polyvinyl chloride (PVC), TEFLO, polyethylene, and the like). In inserting the catheter or needle into the inguinal node for example, the inguinal node is punctured under ultrasonographic control using a Vialon™ Insyte-W™ cannula and catheter of 24G3/4 (Becton Dickinson, USA) which is fixed using Tegaderm™ transparent dressing (Tegaderm™ 1624, 3M, St. Paul, MN 55144, USA). This procedure is generally done by an experienced radiologist. The

location of the catheter tip inside the inguinal lymph node is confirmed by injection of a minimal volume of saline, which immediately and visibly increases the size of the lymph node. The latter procedure allows confirmation that the tip is inside the node. This procedure can be performed to ensure that the tip does not slip out of the lymph node and can be repeated on various days after implantation of the catheter. In the event that the tip does slip out of location inside the lymph node, a new catheter can be implanted.

Formulation and Treatment protocol

[0144] There are several approaches to utilizing the combination of TuAAs with DNA vaccines. A first approach is to include all the antigens or epitopes from all the antigens in a given combination into a single DNA expression vector. This approach has the advantages of simplicity for manufacturing and administration to patients. However, in some instances, epitope competition can limit the usefulness of this approach. That is, it is possible that only the most immunogenic epitope will elicit an immune response when a vaccine with several epitopes representing all TuAAs in the combination is given to patients. It is also more difficult to design and construct a DNA vaccine in which all epitopes are expressed at high efficiencies. Nevertheless, because the procedure for treating patients is simple and uniform within each type of cancer, the cost is likely to be lower than for the other approaches described below.

[0145] An alternate approach is to include only one antigen or epitopes of one antigen in a DNA expression vector. This approach has the advantages of simplicity in designing and constructing the DNA vector, flexibility, and customized administration to patients. If a large number of individual TuAA vaccines are available, then one can customize treatment for each individual patient based on the TuAA expression profile of his or her tumor. For example, if the standard combination for treating a given type of cancer is TuAA A, B, and C (where A, B, and C designate different tumor associated antigens), but a patient's tumor expresses TuAA A, C, and Z (but not B), then the patient can be treated with separate vaccines for each of A, C, and Z. This flexibility and customizability improves the success rate of immunotherapy because antigen redundancy can be achieved for each patient. However, the procedure of treating the patient can be more complex. For example, delivery using this approach can include a sequential administration scheme (one antigen at a time), or injection into multiple, anatomically separate sites of the patient at about the same time.

[0146] Still another approach is to combine epitopes from multiple TuAAs that have similar immunogenicity into a DNA expression vector (more than one vector may be used for some combinations). This approach can have some of the advantages of the above two approaches but also can suffer from the disadvantages of the previous two.

[0147] A profile of the antigen expression of a particular tumor can be used to determine which antigen or combination of antigens to use. Exemplary methodology is found in U.S. Provisional Application No. 60/580,969, filed June 17, 2004, U.S. Patent Application No. 11/155,288 (Publication No. _____), filed June 17, 2005, and U.S. Patent Application No. ____/____, ____ (Publication No. _____) (Attorney Docket No. MANNK.050CP1), filed on the same date as the instant application, all entitled "COMBINATIONS OF TUMOR-ASSOCIATED ANTIGENS IN DIAGNOSTICS FOR VARIOUS TYPES OF CANCERS," and which is hereby incorporated by reference in its entirety. Specific antigenic combinations of particular benefit in directing an immune response against particular cancers are disclosed in U.S. Provisional Patent Application No. 60/479,554, filed on June 17, 2003, U.S. Patent Application No. 10/871,708 (Publication No. 2005-0118186 A1), filed on June 17, 2004, both entitled "COMBINATIONS OF TUMOR-ASSOCIATED ANTIGENS IN COMPOSITIONS FOR VARIOUS TYPES OF," and PCT Patent Application No. PCT/US2004/019571 (Pub. No. WO 2004/112825 A1), filed June 17, 2004, each of which is hereby incorporated by reference in its entirety.

[0148] Patients that can benefit from such methods of immunization can be recruited using methods to define their MHC protein expression profile and general level of immune responsiveness. In addition, their level of immunity can be monitored using standard techniques in conjunction with access to peripheral blood. Finally, treatment protocols can be adjusted based on the responsiveness to induction or amplification phases and variation in antigen expression. For example, repeated entrainment doses preferably can be administered until a detectable response is obtained, and then administering the amplifying peptide dose(s), rather than amplifying after some set number of entrainment doses. Similarly, scheduled amplifying or maintenance doses of peptide can be discontinued if their effectiveness wanes, antigen-specific regulatory T cell numbers rise, or some other evidence of tolerization is observed, and further entrainment can be administered before resuming amplification with the peptide. The integration of diagnostic techniques to assess and monitor immune responsiveness with methods of immunization is discussed more fully in U.S. Provisional Patent Application No. 60/580,964, filed on June

17, 2004, and U.S. Patent Application No. 11/155,928 (Pub. No. _____), filed on June 17, 2005, both entitled "IMPROVED EFFICACY OF ACTIVE IMMUNOTHERAPY BY INTEGRATING DIAGNOSTIC WITH THERAPEUTIC METHODS," each of which is hereby incorporated by reference in its entirety.

[0149] Combination of active immunotherapies, as disclosed herein, with other treatment modalities can increase the susceptibility of tumoral processes to the elicited immune response and thereby result in increased therapeutic benefit. In some embodiments, the therapeutic benefit is synergistically enhanced. Tumor debulking prior to or during active immunotherapy increases the potential for any particular level of immune response to slow or halt disease progression or to bring about tumor regression or elimination. Additionally, tissue damage, necrosis, or apoptosis initiated with antibody therapy, radiotherapy, biotherapy, chemotherapy, passive immunotherapy (including treatment with mono- and/or polyclonal antibodies, recombinant TCR, and/or adoptive transfer of CTL or other cells of the immune system) or surgery, can facilitate the active immunotherapeutic approach via general inflammation resulting in recruitment of immune effector cells including antigen-specific effectors. In general, any method to induce a transient or more permanent general inflammation within one or multiple tumors / metastatic lesions can facilitate the active immunotherapy. Alternatively or in addition to enabling recruitment of effectors, general inflammation can also increase the susceptibility of target cells to immune mediated attack (e.g., as interferons increase expression of target molecules on cancer cells and underlying stroma). Still other strategies to increase susceptibility of tumor cells to immune mediated attack - by providing factors that interfere with the "stress response" or increase target molecules on cancer cells or stromal cells – can synergize with active immunotherapy.

[0150] Many variations and alternative elements of the invention have been disclosed. Still further variations and alternate elements will be apparent to one of skill in the art. Various embodiments of the invention can specifically include or exclude any of these variations or elements.

[0151] In some embodiments, the numbers expressing quantities of ingredients, properties such as molecular weight, reaction conditions, and so forth used to describe and claim certain embodiments of the invention are to be understood as being modified in some instances by the term "about." Accordingly, in some embodiments, the numerical

parameters set forth in the written description and attached claims are approximations that may vary depending upon the desired properties sought to be obtained by a particular embodiment. In some embodiments, the numerical parameters should be construed in light of the number of reported significant digits and by applying ordinary rounding techniques. Notwithstanding that the numerical ranges and parameters setting forth the broad scope of some embodiments of the invention are approximations, the numerical values set forth in the specific examples are reported as precisely as practicable. The numerical values presented in some embodiments of the invention may contain certain errors necessarily resulting from the standard deviation found in their respective testing measurements.

[0152] In some embodiments, the terms “a” and “an” and “the” and similar referents used in the context of describing a particular embodiment of the invention (especially in the context of certain of the following claims) may be construed to cover both the singular and the plural. The recitation of ranges of values herein is merely intended to serve as a shorthand method of referring individually to each separate value falling within the range. Unless otherwise indicated herein, each individual value is incorporated into the specification as if it were individually recited herein. All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g. “such as”) provided with respect to certain embodiments herein is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention otherwise claimed. No language in the specification should be construed as indicating any non-claimed element essential to the practice of the invention.

[0153] Groupings of alternative elements or embodiments of the invention disclosed herein are not to be construed as limitations. Each group member may be referred to and claimed individually or in any combination with other members of the group or other elements found herein. It is anticipated that one or more members of a group may be included in, or deleted from, a group for reasons of convenience and/or patentability. When any such inclusion or deletion occurs, the specification is herein deemed to contain the group as modified thus fulfilling the written description of all Markush groups used in the appended claims.

[0154] Preferred embodiments of this invention are described herein, including the best mode known to the inventors for carrying out the invention. Variations on those preferred embodiments will become apparent to those of ordinary skill in the art upon

reading the foregoing description. It is contemplated that skilled artisans may employ such variations as appropriate, and the invention may be practiced otherwise than specifically described herein. Accordingly, many embodiments of this invention include all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. Moreover, any combination of the above-described elements in all possible variations thereof is encompassed by the invention unless otherwise indicated herein or otherwise clearly contradicted by context.

[0155] Furthermore, numerous references have been made to patents and printed publications throughout this specification. Each of the above cited references and printed publications are herein individually incorporated by reference in their entirety.

[0156] In closing, it is to be understood that the embodiments of the invention disclosed herein are illustrative of the principles of the present invention. Other modifications that may be employed may be within the scope of the invention. Thus, by way of example, but not of limitation, alternative configurations of the present invention may be utilized in accordance with the teachings herein. Accordingly, the present invention is not limited to that precisely as shown and described.

[0157] Each of the references cited herein is hereby incorporated herein by reference in its entirety.

[0158] The following examples are for illustrative purposes only and are not intended to limit the scope of the embodiments in any way.

Examples

TuAA analysis and selection of combinations

[0159] The presence of TuAAs was measured by Real-Time PCR (RT-PCR). Briefly, total RNA was isolated from tumor specimens by standard methods and cDNA was made with standard reverse transcription procedures. Complementary DNA (cDNA) was amplified with specially designed, gene specific, primers that anneal only to cDNA but not genomic DNA. TuAA expression patterns of 12 ovarian and 7 colorectal tumor specimens were analyzed by RT-PCR. The results are summarized in the Table 5 below.

Table 5

	Total #	PRAME	NY-ESO-1	SSX-2	PSMA	MAGE1	MAGE3
Ovarian	12	12	5	6	6	4	3
Colorectal	7	5	1	2	5	0	1

Example 1Ovarian Cancer

[0160] In the case of ovarian cancer, all samples analyzed were positive for PRAME. Thus the inclusion of PRAME in the combination improves coverage of the cases with ovarian cancer.

[0161] In order to achieve antigen redundancy and improve coverage in a large population, combinations of other antigens in addition to PRAME were considered. SSX-2 as well as PSMA were present in 6 of the 12 cases individually, but the combination of SSX-2 and PSMA provided coverage in 9 of 12 cases. Although NY-ESO-1 and SSX-2 were only present in 5 and 6 of the 12 cases, respectively, either NY-ESO-1 or SSX-2 was detected in 7 of the 12 cases.

[0162] Thus, the combination of PRAME, SSX-2, and PSMA or PRAME, NY-ESO-1, and SSX-2 provided preferable coverage and redundancy compared to the combination of PRAME and PSMA or the combination of PRAME and SSX-2. The combination of PRAME, SSX-2, and PSMA provided excellent coverage of cases and good antigen redundancy because the majority of ovarian tumor samples analyzed had at least two of the four TuAA in the combination present. The combination of PRAME, SSX-2, PSMA, and NY-ESO-1 provided more preferred antigen redundancy, and thus, lower possibility of tumor escape.

Example 2Colorectal cancer

[0163] In the case of colorectal cancer, PRAME and PSMA were each detected in 5 of the 7 samples analyzed. In 6 of the 7 cases, either PRAME or PSMA was detected. Although SSX-2 was only detected in 2 of 7 cases, both SSX-2-PRAME and SSX2-PSMA combinations increased coverage to 6 of 7. Similarly, although NY-ESO-1 was detected in only 1 of 7 cases, the combination of NY-ESO-1-PRAME as well as the NY-ESO-1-PSMA combination increased coverage to 6 of 7. The addition of SSX-2 or NY-ESO-1 to the

PRAME and PSMA combination improved coverage to 7 of 7. Thus, the combination of PRAME, PSMA, and NYESO-1, or the combination of PRAME, PSMA, and SSX-2 provided good coverage of cases and redundancy of antigens for a majority of patients. The combination of PRAME, PSMA, NY-ESO-1, and SSX-2 provided further redundancy.

Example 3

Pancreatic Cancer

[0164] Real-Time PCR (RT-PCR) was utilized to determine the presence of PRAME, SSX2, NY-ESO-1, and PSMA. Briefly, total RNA was isolated from 5 pancreatic tumor specimens by standard methods and cDNA was made with standard reverse transcription procedures. Complementary DNA (cDNA) was amplified with specially designed, gene-specific primers that anneal only to cDNA but not genomic DNA.

[0165] In the pancreatic cancer specimens, the presence of PRAME, NYESO-1, SSX-2, and PSMA was detected in 100%, 40%, 20%, and 100% of the specimens, respectively (see Table 6). Elsewhere, PSMA and over-expression of HER2/neu were reported to be present in 100% and 21% of pancreatic tumors, respectively (Chang SS *et al.*, *Cancer Res* 1999, 59:3192; Safran H *et al.*, *Am J Clin Oncol*. 2001, 24:496, each of which is hereby incorporated by reference in its entirety). Although over-expression of HER2/neu may render the cancer tissue a preferred target, thus providing some specificity for immunotherapy, low level expression of HER2/neu in normal tissues remains a concern. Thus, the combination of NYESO-1, SSX-2, plus PRAME or PSMA provides excellent coverage and some redundancy for treating pancreatic cancer. Inclusion of both PRAME and PSMA significantly improves redundancy.

Table 6

TAA	PRAME	SSX2	NY-ESO-1	PSMA
Detection Freq.	5/5	1/5	2/5	5/5
% positive	100	20	40	100

Example 4

Non-small cell lung cancer

[0166] For non-small cell lung cancer, the reported presence of NYESO-1, SSX-2, MAGE-3, BAGE, over-expression of Her2/neu, and PSMA was 21, 15, 60, 6, 16, and 100%, respectively (Scanlan MJ *et al.*, *Cancer lett* 2000, 150:155; Chang SS *et al.*, *Cancer Res* 1999, 59:3192; Selvaggi G *et al.*, *Cancer* 2002, 94:2669, each of which is

hereby incorporated by reference in its entirety). Thus, the combination of NYESO-1, SSX-2, MAGE-3, and PSMA provides coverage and antigen redundancy for the immunotherapy of non-small cell lung cancer.

Example 5

Renal cell carcinoma

[0167] For renal cell carcinoma, SSX-2, PSMA and PRAME were detected with frequencies of 5, 100 and 40%, respectively (Sahin, U *et al.*, *Clin Cancer Res.* 2000, 6:3916; Chang SS *et al.*, *Urology* 2001, 57:801; Neumann E *et al.*, *Cancer Res.* 1998, 58:4090, each of which is hereby incorporated by reference in its entirety). Thus, the combination of PSMA and PRAME provides excellent coverage and redundancy for renal cell carcinoma. Adding SSX-2 to the combination of PSMA and PRAME improves redundancy.

Example 6

Melanoma

[0168] For melanoma, Melan A, Tyrosinase, NYESO-1, and SSX-2 were reported to be present in 92, 92, 41, and 35% of tumor specimens, respectively (Fetsch PA, *et al.*, *Cancer* 1999, 87:37; Fetsch PA, *et al.*, *Cancer* 2000, 90:252; Schultz-Thater E *et al.*, *Br J Cancer* 2000, 83:204; Sahin, U *et al.*, *Clin Cancer Res.* 2000, 6:3916). Therefore, the combination of Melan A, Tyrosinase, NYESO-1, and SSX-2 provides excellent coverage and antigen redundancy for the immunotherapy of melanoma. Significant redundancy is achieved using tyrosinase and melan-A together, or by combining NY-ESO-1 and SSX-2 with either of tyrosinase or melan-A.

Example 7

[0169] Further studies involving the foregoing tumor types confirmed the observed expression patterns and preferred panels of TuAA. A total of 34 ovarian, 44 colon, 18 renal, and 13 pancreatic tissue samples obtained from various vendors were analyzed for tumor-associated antigen expression using qRT-PCR. The results of these assays demonstrated that PRAME and PSMA were expressed frequently (ranging from 68% to 100%) in all four types of tumors studied. NY-ESO-1 and SSX2 were expressed in 20% to 40% of ovarian and pancreatic tumors.

Table 7:
Overall Expression Profiles for Tumor Associated Antigens
From RTPCR analysis of Primary Tumors and Metastases

Tumor- Associated Antigen	% Samples Expressing a Given Antigen			
	Ovarian ^a	Renal ^b	Pancreatic ^c	Colorectal ^d
SSX2	36	6	20	8
NY-ESO-1	30	6	40	12
PRAME	97	83	80	76
PSMA	91	100	100	68
MAGE-1	27	6	33	8
MAGE-3	30	22	42	20
SCP-1	30	11	0	0
CEA	30	0	58	92

^a 33 samples (27 primary tumors and 6 metastases)

^b 18 samples (18 primary tumors)

^c 15 samples (14 primary tumors and 1 metastasis; PSMA on 10 samples)

^d 25 samples (13 primary tumors and 12 metastases)

Example 8

Schedule of immunization with plasmids expressing epitopes from two antigens

[0170] Two groups of HHD mice (n=4) were immunized via intra lymph node injection with either pSEM expressing Melan-A₂₆₋₃₅A27L (ELA) and pCBP expressing SSX-2₄₁₋₄₉ as a mixture; or with pSEM in the left inguinal lymph node and pCBP in the right inguinal lymph node, twice, at day 0 and 4 as shown in Figure 1. The amount of the plasmid was 25 μ g/plasmid/dose. Two weeks later, the animals were sacrificed, and cytotoxicity was measured against T2 cells pulsed or not with peptide.

Example 9

Co-administration of different vectors carrying distinct antigens

[0171] The animals immunized as described in Example 8, were sacrificed and splenocytes from each group pooled and stimulated with the two peptides (ELA or SSX-2₄₁₋₄₉) in parallel. The cytotoxicity was measured by incubation with Cr⁵¹-tagged, peptide

loaded T2 target cells. Data in Figure 2 show mean of specific cytotoxicity (n=4/group) against various target cells.

[0172] The results show that use of plasmid mixture interferes with the response elicited by pCBP plasmid; however, segregating the two plasmids relative to site of administration rescues the activity of pCBP. Thus, the co-administration of different vectors carrying distinct antigens can result in establishment of a hierarchy with regard to immunogenicity. Vector segregation can rescue the immunogenicity of the less dominant component, resulting in a multivalent response.

Example 10

Rescue of Multivalent Response by Addition of Peptide Boost Steps

[0173] Four groups of HHD mice (n=6) were immunized via intra lymph node injection with either pSEM and pCBP as a mixture; or with pSEM in the left inguinal lymph node and pCBP in the right inguinal lymph node, twice, at day 0 and 4 as shown in Figure 3. As a control, mice were immunized with either pSEM or pCBP plasmid. The amount of the plasmid was 25 μ g/plasmid/dose. Two weeks later, the animals were boosted with melan A and/or SSX-2 peptides, mirroring the plasmid immunization dose and combination. Two weeks later, the animals were challenged with splenocytes stained with CFSE and loaded or not with Melan A or SSX-2 peptide, for evaluation of *in vivo* cytotoxicity.

Example 11

Peptide amplification rescues the immunogenicity of the less dominant epitope

[0174] Mice were immunized as described in Example 10 and challenged with HHD littermate splenocytes coated with ELA or SSX-2 peptide, employing a triple peak CFSE *in vivo* cytotoxicity assay that allows the assessment of the specific lysis of two antigen targets simultaneously. Equal numbers of control-CFSE^{lo}, SSX-2₄₁₋₄₉-CFSE^{med}, and ELA-CFSE^{hi} cells were intravenously infused into immunized mice and 18 hours later the mice were sacrificed and target cell elimination was measured in the spleen (Figure 4) by CFSE fluorescence using a flow cytometry. Figure 4 shows the percent specific lysis of the SSX2 and Melan-A antigen targets from individual mice, as well as the mean and SEM for each group.

[0175] The results show that immunizing the animals with a mixture of the two vaccines comprising plasmids followed by peptides generated immunity to both antigens and resulted in the highest immune response, representing an average SSX-2 percent specific lysis in the spleen of 30+/-11, and an average Melan-A percent specific lysis of 97+/-1.

Example 12

Clinical practice for entrain-and-amplify immunization

[0176] The data in figures 2 and 4 suggest two scenarios for achieving a strong multivalent response in the clinic, shown in Figure 5. In the first scenario (A), use of peptides for boosting restores multivalent immune responses even if plasmids and peptides are used as mixtures. In the second scenario (B), segregation of plasmid and peptide components respectively, allows induction of multivalent immune responses.

Example 13

MKC1207: an Entrain-and-Amplify Therapeutic for Melanoma

[0177] MKC1207 comprises the plasmid pSEM (described in U.S. Patent Application No. 10/292,413 (Pub. No. 2003-0228634 A1), filed November 7, 2002, 10/777,053 (Pub. No. 2004-0132088 A1), filed February 10, 2004, 10/837,217 (Pub. No. _____), filed April 30, 2004, each of which is hereby incorporated by reference in its entirety, in which it is referred to as pMA2M) and peptides corresponding to Melan-A 26-35 and tyrosinase 369-377. The plasmid encodes the A27L analogue of the Melan-A epitope and the native tyrosinase epitope sequence. The plasmids encode both of these epitopes in such a manner that they can be expressed and presented by pAPC. In alternate embodiments of the therapeutic, the peptides can comprise the native sequence or be analogues such as those disclosed in U.S. Patent Application No. 11/156,369 (Pub. No. _____), entitled EPITOPE ANALOGUES, filed on June 17, 2005, and incorporated herein by reference in its entirety.

[0178] Briefly, the plasmid is administered intranodally to the inguinal lymph nodes as an entraining immunogen. Subsequently, the peptides are administered intranodally, one to the left node, the other to the right as amplifying immunogens. The entrain-and-amplify protocol is described in greater detail in U.S. Patent Application Nos.

10/871,707 (Pub. No. 2005-0079152 A1), filed on June 17, 2004 and 60/479,393, filed on June 17, 2003, each of which is hereby incorporated by reference in its entirety.

[0179] Melanoma patients can be screened according to the methods disclosed herein and MKC1207 administered to patients whose tumor antigen profile includes Melan-A and/or tyrosinase. In a preferred embodiment, the patient's tumor tissue also expresses HLA-A2, particularly HLA-A*0201.

Example 14

MKC1106: a Tetravalent Entrain-and-Amplify Therapeutic for Carcinoma

[0180] MKC1106 comprises the plasmids pCBP (described in U.S. Patent Application No. 10/292,413 (Pub. No. 2003/0228634 A1), filed November 7, 2002, 10/777,053 (Pub. No. 2004-0132088 A1), filed February 10, 2004, 10/837,217 (Pub. No. _____), filed April 30, 2004, each of which is hereby incorporated by reference in its entirety) and pRP12 (described in U.S. Provisional Application No. 60/691,579, entitled METHODS AND COMPOSITIONS TO ELICIT MULTIVALENT IMMUNE RESPONSES AGAINST DOMINANT AND SUBDOMINANT EPITOPES, EXPRESSED ON CANCER CELLS AND TUMOR STROMA, filed on June 17, 2005, and incorporated herein by reference in its entirety; and peptides corresponding to NY-ESO-1 157-165, SSX-2 41-49, PRAME 425-433 and PSMA 288-297. The plasmids encode both of these epitopes in such a manner that they can be expressed and presented by pAPC. In alternate embodiments of the therapeutic, the peptides can comprise the native sequence or be analogues such as those disclosed in U.S. Patent Application Nos. 11/156,253 (Pub. No. _____), entitled SSX-2 PEPTIDE ANALOGS, and 11/155,929 (Pub. No. _____), entitled NY-ESO-1 PEPTIDE ANALOGS, and 11/156,369 (Pub. No. _____), entitled EPITOPE ANALOGS, and U.S. Provisional Patent Application No. 60/691,889, entitled EPITOPE ANALOGS, each of which was filed on June 17, 2005, and each of which is expressly incorporated by reference in its entirety.

[0181] Briefly, the plasmids are administered intranodally to the inguinal lymph nodes, one to the left side and one to the right, as entraining immunogens. Subsequently the peptides are sequentially administered intranodally, two on separate days to the left node, the other two on separate days to the right as amplifying immunogens. Preferably, the peptides are administered to the same lymph node that received the plasmid encoding the corresponding epitopes. The entrain-and-amplify protocol is described in greater detail

in U.S. Patent Application Nos. 10/871,707 (Pub. No. 2005-0079152 A1), filed on June 17, 2004 and 60/479,393, filed on June 17, 2003, each of which is expressly incorporated by reference in its entirety.

[0182] Carcinoma patients, especially those with ovarian, colorectal, pancreatic, or renal cell carcinoma, can be screened according to the methods disclosed herein and MKC1106 administered to patients whose tumor profile includes PRAME, PSMA, NY-ESO-1, and/or SSX-2. The NY-ESO-1 epitope targeted by MKC1106 is also found in LAGE 1a/s, so the presence of this antigen in a profile would also be considered a match. As tumor antigen expression tends to be heterogeneous, any particular tissue sample is likely not to give a complete indication of all the antigens expressed. Thus, it is not necessary that a patient's profile contain all four of the antigens for that patient to be a candidate for treatment with MKC1106. However, preferably the profile contains 2, 3, or 4 of the antigens.

WHAT IS CLAIMED IS:

1. A method of inducing an anti-cancer immune response comprising immunizing against a first antigen selected from the group consisting of PRAME, PSMA, and tyrosinase, and at least one other tumor-associated antigen.
2. The method of Claim 1, wherein the at least one other tumor-associated antigen is selected from the group consisting of NY-ESO-1, SSX-2, a MAGE protein, MAGE-3, and Melan-A.
3. The method of Claim 1, wherein the cancer is selected from the group consisting of ovarian cancer, colorectal cancer, pancreatic cancer, non-small cell lung cancer, melanoma, and renal cell carcinoma.
4. The method of Claim 1, wherein the method comprises immunizing against PRAME, and wherein the cancer is selected from the group consisting of ovarian cancer, colorectal cancer, pancreatic cancer, melanoma, and renal cell carcinoma.
5. The method of Claim 4, wherein the cancer is pancreatic cancer.
6. The method of Claim 5, wherein the at least one other tumor-associated antigen is selected from the group consisting of SSX-2, NY-ESO-1, and PSMA.
7. The method of Claim 5, wherein the at least one other tumor-associated antigen comprises NY-ESO-1, SSX-2, and PSMA.
8. The method of Claim 1, wherein the method comprises immunizing against PSMA and at least one other tumor-associated antigen, wherein the cancer is selected from the group consisting of non-small cell lung cancer, ovarian cancer, colorectal cancer, pancreatic cancer, and renal cell carcinoma.
9. The method of Claim 8, wherein the cancer is pancreatic cancer.
10. The method of Claim 9, further comprising immunizing against PRAME.
11. The method of Claim 1, wherein a cytolytic T cell response is induced.
12. The method of Claim 1, further comprising immunizing against at least one antigen selected from the group consisting of an antigen associated with tumor neovasculature, a growth factor, and a signal transduction protein.
13. The method of Claim 12, wherein the antigen associated with tumor neovasculature is selected from the group consisting of PSMA, VEGFR2 and Tie-2.
14. The method of Claim 12, wherein said growth factor is VEGF-A.
15. The method of Claim 12, wherein said signal transduction protein is PLK1.

16. The method of Claim 1, further comprising immunizing against a stromal cell antigen.
17. The method of Claim 16, wherein the immunization comprises active immunization.
18. The method of Claim 16, wherein the immunization comprises passive immunization.
19. The method of Claim 1, further comprising a step for causing inflammation in a tumor lesion.
20. The method of Claim 1, further comprising immunizing against an extra-cellular factor.
21. The method of Claim 20, wherein the extra-cellular factor is selected from the group consisting of an autocrine factor, a paracrine factor, a growth factor, chorionic gonadotropin, gastrin, an NF- κ B activating factor, VEGF-A, CXCL1, CXCL8, and CCL2.
22. The method of Claim 1, further comprising a step for immunization against a factor that promotes the growth, survival, invasiveness, or metastasis of a tumor.
23. The method of Claim 1, further comprising immunizing against a non-self antigen.
24. The method of Claim 23, wherein the non-self antigen comprises a B cell epitope.
25. The method of Claim 23, wherein the non-self antigen comprises a Th epitope.
26. The method of Claim 1, further comprising a step for co-inducing a helper response.
27. The method of Claim 26, wherein the helper response comprises a B cell response.
28. The method of Claim 26, wherein the helper response comprises a Th cell response.
29. The method of Claim 1, further comprising a treatment selected from the group consisting of chemotherapy, radiotherapy, chemotherapy, biotherapy, passive immunotherapy, antibody therapy, and surgery.
30. The method of Claim 1, further comprising a step for tumor debulking.
31. The method of Claim 1, further comprising a step for inducing tissue damage, necrosis, or apoptosis within a tumor.

32. The method of Claim 1, further comprising a step for inducing inflammation within a tumor.

33. An immunogenic composition for the treatment of a cancer comprising a first antigen selected from the group consisting of PRAME, PSMA, and tyrosinase; and at least one other tumor-associated antigen.

34. The immunogenic composition of Claim 33, wherein the antigens are provided in the form of 1) whole antigens, 2) fragments of antigens, 3) epitope clusters derived from antigens, 4) epitopes derived from antigens, or 5) nucleic acids encoding any of 1 to 4.

35. The immunogenic composition of Claim 33, wherein the cancer is selected from the group consisting of ovarian cancer, colorectal cancer, pancreatic cancer, non-small cell lung cancer, melanoma, and renal cell carcinoma

36. The composition of claim 33, wherein the at least one other tumor-associated antigen is selected from the group consisting of PRAME, PSMA, NY-ESO-1, SSX-2, a MAGE protein, MAGE-3, and Melan-A.

37. The composition of Claim 33, wherein the composition comprises a PSMA antigen and at least one additional antigen selected from PRAME, NY-ESO and SSX-2.

38. The composition of Claim 33, wherein the composition comprises a PRAME antigen and at least one additional antigen selected from NY-ESO and SSX-2.

39. The composition of Claim 37, further comprising at least one antigen selected from the group consisting of an antigen associated with tumor neovasculature, a growth factor, and a signal transduction protein.

40. The composition of Claim 39, wherein the antigen associated with tumor neovasculature is selected from the group consisting of PSMA, VEGFR2 and Tie-2.

41. The composition of Claim 39, wherein said growth factor is VEGF-A.

42. The composition of Claim 39, wherein said signal transduction protein is PLK1.

43. The composition of Claim 33, wherein the antigens further comprise a neovasculature or other stromal antigen

44. The composition of Claim 33, wherein the antigens further comprise an extra-cellular factor.

45. The composition of Claim 33, wherein the antigens further comprise a non-target antigen.

46. The composition of Claim 33, further comprising means for inducing immunity to a factor that promotes the growth, survival, invasiveness, or metastasis of a tumor.


47. The composition of Claim 33, further comprising means for inducing bystander help for the tumor-associated antigens.

48. The composition of Claim 33, further comprising means for causing inflammation in a tumor lesion.

Figure 1. Schedule of immunization with plasmids (pCBP expressing SSX2 41-49; and pSEM expressing Melan A)

Schedule of immunization

Immunization Schedule:



Experimental Setup:

Group 1: Plasmids separately (pCBP, pSEM)
Group 2: Plasmids admixed (pCBP+pSEM)

Figure 2. Co-administration of different vectors carrying distinct antigens results in establishment of a hierarchy in regard to immunogenicity. Vector segregation rescues the immunogenicity of the less dominant component, resulting in a multivalent response.





Figure 3. Addition of peptide boost steps to the immunization protocol described in Fig. 1.

Schedule of immunization

Immunization Schedule:



Experimental Setup:

- Group 1: Naïve controls
- Group 2: Mixture of plasmids followed by mixture of peptides
- Group 3: Plasmids and peptides into different lymph nodes
- Group 4: pSEM plasmid and melan A peptide only
- Group 5: pCBP plasmid and SSX2 peptide only


Figure 4. Peptide boost rescues the immunogenicity of a less dominant epitope even when the vectors and peptides respectively, are used as a mixture.

Animal #	Treatment	Spleen Specific Lysis (%)	
		<u>SSX2</u>	<u>Melan A</u>
#3505	Control	Control	Control
#3473	Control	6	4
#3481	Control	8	6
#3951	Control	Control	Control
#3474	Control	-4	-8
#3513	Control	-3	-4
		Mean	2
		SEM	4
#3125	pSEM + pCBP	71	95
#3075	pSEM + pCBP	26	93
#3088	pSEM + pCBP	10	94
#3081	pSEM + pCBP	22	100
#3078	pSEM + pCBP	44	100
#3102	pSEM + pCBP	9	100
		Mean	30
		SEM	11
#3076	L=pSEM, R=pCBP	16	37
#3112	L=pSEM, R=pCBP	15	88
#3068	L=pSEM, R=pCBP	7	93
#3051	L=pSEM, R=pCBP	46	100
#3146	L=pSEM, R=pCBP	4	100
#3103	L=pSEM, R=pCBP	13	100
		Mean	17
		SEM	7
#3111	pSEM	3	57
#3036	pSEM	6	94
#3052	pSEM	-1	95
#3067	pSEM		5
#3049	pSEM	1	100
#3039	pSEM		38
		Mean	2
		SEM	1
#3069	pCBP	26	-3
#3037	pCBP	15	3
#3042	pCBP	6	7
#3070	pCBP	11	11
#3046	pCBP	18	17
#3053	pCBP	33	15
		Mean	18
		SEM	4
			8
			3

Figure 5. Methodology to induce strong, multivalent responses: reduction to practice in clinic


A. Schedule of immunization

Immunization Schedule:



B. Schedule of immunization

Immunization Schedule:



MANNK.049A.txt

SEQUENCE LISTING

<110> Chiang, Chih-Sheng
Simard, John J.L.
Diamond, David C.
Bot, Adrian Ion
Liu , Xiping

<120> COMBINATIONS OF TUMOR-ASSOCIATED
ANTIGENS IN COMPOSITIONS FOR VARIOUS TYPES OF CANCERS

<130> MANNK.049VPC

<150> 60/640,598

<151> 2004-12-29

<160> 26

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 529

<212> PRT

<213> Homo sapiens

<400> 1

Met Leu Leu Ala Val Leu Tyr Cys Leu Leu Trp Ser Phe Gln Thr Ser
1 5 10 15
Ala Gly His Phe Pro Arg Ala Cys Val Ser Ser Lys Asn Leu Met Glu
20 25 30
Lys Glu Cys Cys Pro Pro Trp Ser Gly Asp Arg Ser Pro Cys Gly Gln
35 40 45
Leu Ser Gly Arg Gly Ser Cys Gln Asn Ile Leu Leu Ser Asn Ala Pro
50 55 60
Leu Gly Pro Gln Phe Pro Phe Thr Gly Val Asp Asp Arg Glu Ser Trp
65 70 75 80
Pro Ser Val Phe Tyr Asn Arg Thr Cys Gln Cys Ser Gly Asn Phe Met
85 90 95
Gly Phe Asn Cys Gly Asn Cys Lys Phe Gly Phe Trp Gly Pro Asn Cys
100 105 110
Thr Glu Arg Arg Leu Leu Val Arg Arg Asn Ile Phe Asp Leu Ser Ala
115 120 125
Pro Glu Lys Asp Lys Phe Phe Ala Tyr Leu Thr Leu Ala Lys His Thr
130 135 140
Ile Ser Ser Asp Tyr Val Ile Pro Ile Gly Thr Tyr Gly Gln Met Lys
145 150 155 160
Asn Gly Ser Thr Pro Met Phe Asn Asp Ile Asn Ile Tyr Asp Leu Phe
165 170 175
Val Trp Met His Tyr Tyr Val Ser Met Asp Ala Leu Leu Gly Gly Ser
180 185 190
Glu Ile Trp Arg Asp Ile Asp Phe Ala His Glu Ala Pro Ala Phe Leu
195 200 205
Pro Trp His Arg Leu Phe Leu Leu Arg Trp Glu Gln Glu Ile Gln Lys
210 215 220
Leu Thr Gly Asp Glu Asn Phe Thr Ile Pro Tyr Trp Asp Trp Arg Asp
225 230 235 240
Ala Glu Lys Cys Asp Ile Cys Thr Asp Glu Tyr Met Gly Gly Gln His
245 250 255
Pro Thr Asn Pro Asn Leu Leu Ser Pro Ala Ser Phe Phe Ser Ser Trp
260 265 270
Gln Ile Val Cys Ser Arg Leu Glu Glu Tyr Asn Ser His Gln Ser Leu
275 280 285
Cys Asn Gly Thr Pro Glu Gly Pro Leu Arg Arg Asn Pro Gly Asn His
290 295 300
Asp Lys Ser Arg Thr Pro Arg Leu Pro Ser Ser Ala Asp Val Glu Phe
305 310 315 320

MANNK.049A.txt

Cys Leu Ser Leu Thr Gln Tyr Glu Ser Gly Ser Met Asp Lys Ala Ala
 325 330 335
 Asn Phe Ser Phe Arg Asn Thr Leu Glu Gly Phe Ala Ser Pro Leu Thr
 340 345 350
 Gly Ile Ala Asp Ala Ser Gln Ser Ser Met His Asn Ala Leu His Ile
 355 360 365
 Tyr Met Asn Gly Thr Met Ser Gln Val Gln Gly Ser Ala Asn Asp Pro
 370 375 380
 Ile Phe Leu Leu His His Ala Phe Val Asp Ser Ile Phe Glu Gln Trp
 385 390 395 400
 Leu Arg Arg His Arg Pro Leu Gln Glu Val Tyr Pro Glu Ala Asn Ala
 405 410 415
 Pro Ile Gly His Asn Arg Glu Ser Tyr Met Val Pro Phe Ile Pro Leu
 420 425 430
 Tyr Arg Asn Gly Asp Phe Phe Ile Ser Ser Lys Asp Leu Gly Tyr Asp
 435 440 445
 Tyr Ser Tyr Leu Gln Asp Ser Asp Pro Asp Ser Phe Gln Asp Tyr Ile
 450 455 460
 Lys Ser Tyr Leu Glu Gln Ala Ser Arg Ile Trp Ser Trp Leu Leu Gly
 465 470 475 480
 Ala Ala Met Val Gly Ala Val Leu Thr Ala Leu Leu Ala Gly Leu Val
 485 490 495
 Ser Leu Leu Cys Arg His Lys Arg Lys Gln Leu Pro Glu Glu Lys Gln
 500 505 510
 Pro Leu Leu Met Glu Lys Glu Asp Tyr His Ser Leu Tyr Gln Ser His
 515 520 525
 Leu

<210> 2
 <211> 118
 <212> PRT
 <213> Homo sapiens

<400> 2
 Met Pro Arg Glu Asp Ala His Phe Ile Tyr Gly Tyr Pro Lys Lys Gly
 1 5 10 15
 His Gly His Ser Tyr Thr Thr Ala Glu Glu Ala Ala Gly Ile Gly Ile
 20 25 30
 Leu Thr Val Ile Leu Gly Val Leu Leu Leu Ile Gly Cys Trp Tyr Cys
 35 40 45
 Arg Arg Arg Asn Gly Tyr Arg Ala Leu Met Asp Lys Ser Leu His Val
 50 55 60
 Gly Thr Gln Cys Ala Leu Thr Arg Arg Cys Pro Gln Glu Gly Phe Asp
 65 70 75 80
 His Arg Asp Ser Lys Val Ser Leu Gln Glu Lys Asn Cys Glu Pro Val
 85 90 95
 Val Pro Asn Ala Pro Pro Ala Tyr Glu Lys Leu Ser Ala Glu Gln Ser
 100 105 110
 Pro Pro Pro Tyr Ser Pro
 115

<210> 3
 <211> 223
 <212> PRT
 <213> Homo sapiens

<400> 3
 Met Asn Gly Asp Asp Ala Phe Ala Arg Arg Pro Thr Val Gly Ala Gln
 1 5 10 15
 Ile Pro Glu Lys Ile Gln Lys Ala Phe Asp Asp Ile Ala Lys Tyr Phe
 20 25 30
 Ser Lys Glu Glu Trp Glu Lys Met Lys Ala Ser Glu Lys Ile Phe Tyr
 35 40 45
 Val Tyr Met Lys Arg Lys Tyr Glu Ala Met Thr Lys Leu Gly Phe Lys
 50 55 60

MANNK.049A.txt

Ala Thr Leu Pro Pro Phe Met Cys Asn Lys Arg Ala Glu Asp Phe Gln
 65 70 75 80
 Gly Asn Asp Leu Asp Asn Asp Pro Asn Arg Gly Asn Gln Val Glu Arg
 85 90 95
 Pro Gln Met Thr Phe Gly Arg Leu Gln Gly Ile Ser Pro Lys Ile Met
 100 105 110
 Pro Lys Lys Pro Ala Glu Glu Gly Asn Asp Ser Glu Glu Val Pro Glu
 115 120 125
 Ala Ser Gly Pro Gln Asn Asp Gly Lys Glu Leu Cys Pro Pro Gly Lys
 130 135 140
 Pro Thr Thr Ser Glu Lys Ile His Glu Arg Ser Gly Asn Arg Glu Ala
 145 150 155 160
 Gln Glu Lys Glu Glu Arg Arg Gly Thr Ala His Arg Trp Ser Ser Gln
 165 170 175
 Asn Thr His Asn Ile Gly Arg Phe Ser Leu Ser Thr Ser Met Gly Ala
 180 185 190
 Val His Gly Thr Pro Lys Thr Ile Thr His Asn Arg Asp Pro Lys Gly
 195 200 205
 Gly Asn Met Pro Gly Pro Thr Asp Cys Val Arg Glu Asn Ser Trp
 210 215 220

<210> 4
 <211> 750
 <212> PRT
 <213> Homo sapiens

<400> 4
 Met Trp Asn Leu Leu His Glu Thr Asp Ser Ala Val Ala Thr Ala Arg
 1 5 10 15
 Arg Pro Arg Trp Leu Cys Ala Gly Ala Leu Val Leu Ala Gly Gly Phe
 20 25 30
 Phe Leu Leu Gly Phe Leu Phe Gly Trp Phe Ile Lys Ser Ser Asn Glu
 35 40 45
 Ala Thr Asn Ile Thr Pro Lys His Asn Met Lys Ala Phe Leu Asp Glu
 50 55 60
 Leu Lys Ala Glu Asn Ile Lys Lys Phe Leu Tyr Asn Phe Thr Gln Ile
 65 70 75 80
 Pro His Leu Ala Gly Thr Glu Gln Asn Phe Gln Leu Ala Lys Gln Ile
 85 90 95
 Gln Ser Gln Trp Lys Glu Phe Gly Leu Asp Ser Val Glu Leu Ala His
 100 105 110
 Tyr Asp Val Leu Leu Ser Tyr Pro Asn Lys Thr His Pro Asn Tyr Ile
 115 120 125
 Ser Ile Ile Asn Glu Asp Gly Asn Glu Ile Phe Asn Thr Ser Leu Phe
 130 135 140
 Glu Pro Pro Pro Gly Tyr Glu Asn Val Ser Asp Ile Val Pro Pro
 145 150 155 160
 Phe Ser Ala Phe Ser Pro Gln Gly Met Pro Glu Gly Asp Leu Val Tyr
 165 170 175
 Val Asn Tyr Ala Arg Thr Glu Asp Phe Phe Lys Leu Glu Arg Asp Met
 180 185 190
 Lys Ile Asn Cys Ser Gly Lys Ile Val Ile Ala Arg Tyr Gly Lys Val
 195 200 205
 Phe Arg Gly Asn Lys Val Lys Asn Ala Gln Leu Ala Gly Ala Lys Gly
 210 215 220
 Val Ile Leu Tyr Ser Asp Pro Ala Asp Tyr Phe Ala Pro Gly Val Lys
 225 230 235 240
 Ser Tyr Pro Asp Gly Trp Asn Leu Pro Gly Gly Val Gln Arg Gly
 245 250 255
 Asn Ile Leu Asn Leu Asn Gly Ala Gly Asp Pro Leu Thr Pro Gly Tyr
 260 265 270
 Pro Ala Asn Glu Tyr Ala Tyr Arg Arg Gly Ile Ala Glu Ala Val Gly
 275 280 285
 Leu Pro Ser Ile Pro Val His Pro Ile Gly Tyr Tyr Asp Ala Gln Lys
 290 295 300
 Leu Leu Glu Lys Met Gly Gly Ser Ala Pro Pro Asp Ser Ser Trp Arg
 305 310 315 320

MANNK.049A.txt

Gly Ser Leu Lys Val Pro Tyr Asn Val Gly Pro Gly Phe Thr Gly Asn
 325 330 335
 Phe Ser Thr Gln Lys Val Lys Met His Ile His Ser Thr Asn Glu Val
 340 345 350
 Thr Arg Ile Tyr Asn Val Ile Gly Thr Leu Arg Gly Ala Val Glu Pro
 355 360 365
 Asp Arg Tyr Val Ile Leu Gly Gly His Arg Asp Ser Trp Val Phe Gly
 370 375 380
 Gly Ile Asp Pro Gln Ser Gly Ala Ala Val Val His Glu Ile Val Arg
 385 390 395 400
 Ser Phe Gly Thr Leu Lys Glu Gly Trp Arg Pro Arg Arg Thr Ile
 405 410 415
 Leu Phe Ala Ser Trp Asp Ala Glu Glu Phe Gly Leu Leu Gly Ser Thr
 420 425 430
 Glu Trp Ala Glu Glu Asn Ser Arg Leu Leu Gln Glu Arg Gly Val Ala
 435 440 445
 Tyr Ile Asn Ala Asp Ser Ser Ile Glu Gly Asn Tyr Thr Leu Arg Val
 450 455 460
 Asp Cys Thr Pro Leu Met Tyr Ser Leu Val His Asn Leu Thr Lys Glu
 465 470 475 480
 Leu Lys Ser Pro Asp Glu Gly Phe Glu Gly Lys Ser Leu Tyr Glu Ser
 485 490 495
 Trp Thr Lys Ser Pro Ser Pro Glu Phe Ser Gly Met Pro Arg Ile
 500 505 510
 Ser Lys Leu Gly Ser Gly Asn Asp Phe Glu Val Phe Phe Gln Arg Leu
 515 520 525
 Gly Ile Ala Ser Gly Arg Ala Arg Tyr Thr Lys Asn Trp Glu Thr Asn
 530 535 540
 Lys Phe Ser Gly Tyr Pro Leu Tyr His Ser Val Tyr Glu Thr Tyr Glu
 545 550 555 560
 Leu Val Glu Lys Phe Tyr Asp Pro Met Phe Lys Tyr His Leu Thr Val
 565 570 575
 Ala Gln Val Arg Gly Gly Met Val Phe Glu Leu Ala Asn Ser Ile Val
 580 585 590
 Leu Pro Phe Asp Cys Arg Asp Tyr Ala Val Val Leu Arg Lys Tyr Ala
 595 600 605
 Asp Lys Ile Tyr Ser Ile Ser Met Lys His Pro Gln Glu Met Lys Thr
 610 615 620
 Tyr Ser Val Ser Phe Asp Ser Leu Phe Ser Ala Val Lys Asn Phe Thr
 625 630 635 640
 Glu Ile Ala Ser Lys Phe Ser Glu Arg Leu Gln Asp Phe Asp Lys Ser
 645 650 655
 Asn Pro Ile Val Leu Arg Met Met Asn Asp Gln Leu Met Phe Leu Glu
 660 665 670
 Arg Ala Phe Ile Asp Pro Leu Gly Leu Pro Asp Arg Pro Phe Tyr Arg
 675 680 685
 His Val Ile Tyr Ala Pro Ser Ser His Asn Lys Tyr Ala Gly Glu Ser
 690 695 700
 Phe Pro Gly Ile Tyr Asp Ala Leu Phe Asp Ile Glu Ser Lys Val Asp
 705 710 715 720
 Pro Ser Lys Ala Trp Gly Glu Val Lys Arg Gln Ile Tyr Val Ala Ala
 725 730 735
 Phe Thr Val Gln Ala Ala Ala Glu Thr Leu Ser Glu Val Ala
 740 745 750

<210> 5
 <211> 309
 <212> PRT
 <213> Homo sapiens

<400> 5
 Met Ser Leu Glu Gln Arg Ser Leu His Cys Lys Pro Glu Glu Ala Leu
 1 5 10 15
 Glu Ala Gln Gln Glu Ala Leu Gly Leu Val Cys Val Gln Ala Ala Thr
 20 25 30
 Ser Ser Ser Pro Leu Val Leu Gly Thr Leu Glu Glu Val Pro Thr
 35 40 45

MANNK.049A.txt

Ala Gly Ser Thr Asp Pro Pro Gln Ser Pro Gln Gly Ala Ser Ala Phe
 50 55 60
 Pro Thr Thr Ile Asn Phe Thr Arg Gln Arg Gln Pro Ser Glu Gly Ser
 65 70 75 80
 Ser Ser Arg Glu Glu Glu Gly Pro Ser Thr Ser Cys Ile Leu Glu Ser
 85 90 95
 Leu Phe Arg Ala Val Ile Thr Lys Lys Val Ala Asp Leu Val Gly Phe
 100 105 110
 Leu Leu Leu Lys Tyr Arg Ala Arg Glu Pro Val Thr Lys Ala Glu Met
 115 120 125
 Leu Glu Ser Val Ile Lys Asn Tyr Lys His Cys Phe Pro Glu Ile Phe
 130 135 140
 Gly Lys Ala Ser Glu Ser Leu Gln Leu Val Phe Gly Ile Asp Val Lys
 145 150 155 160
 Glu Ala Asp Pro Thr Gly His Ser Tyr Val Leu Val Thr Cys Leu Gly
 165 170 175
 Leu Ser Tyr Asp Gly Leu Leu Gly Asp Asn Gln Ile Met Pro Lys Thr
 180 185 190
 Gly Phe Leu Ile Ile Val Leu Val Met Ile Ala Met Glu Gly Gly His
 195 200 205
 Ala Pro Glu Glu Glu Ile Trp Glu Glu Leu Ser Val Met Glu Val Tyr
 210 215 220
 Asp Gly Arg Glu His Ser Ala Tyr Gly Glu Pro Arg Lys Leu Leu Thr
 225 230 235 240
 Gln Asp Leu Val Gln Glu Lys Tyr Leu Glu Tyr Arg Gln Val Pro Asp
 245 250 255
 Ser Asp Pro Ala Arg Tyr Glu Phe Leu Trp Gly Pro Arg Ala Leu Ala
 260 265 270
 Glu Thr Ser Tyr Val Lys Val Leu Glu Tyr Val Ile Lys Val Ser Ala
 275 280 285
 Arg Val Arg Phe Phe Phe Pro Ser Leu Arg Glu Ala Ala Leu Arg Glu
 290 295 300
 Glu Glu Glu Gly Val
 305

<210> 6
 <211> 314
 <212> PRT
 <213> Homo sapiens

<400> 6
 Met Pro Leu Glu Gln Arg Ser Gln His Cys Lys Pro Glu Glu Gly Leu
 1 5 10 15
 Glu Ala Arg Gly Glu Ala Leu Gly Leu Val Gly Ala Gln Ala Pro Ala
 20 25 30
 Thr Glu Glu Gln Glu Ala Ala Ser Ser Ser Ser Thr Leu Val Glu Val
 35 40 45
 Thr Leu Gly Glu Val Pro Ala Ala Glu Ser Pro Asp Pro Pro Gln Ser
 50 55 60
 Pro Gln Gly Ala Ser Ser Leu Pro Thr Thr Met Asn Tyr Pro Leu Trp
 65 70 75 80
 Ser Gln Ser Tyr Glu Asp Ser Ser Asn Gln Glu Glu Glu Gly Pro Ser
 85 90 95
 Thr Phe Pro Asp Leu Glu Ser Glu Phe Gln Ala Ala Leu Ser Arg Lys
 100 105 110
 Val Ala Glu Leu Val His Phe Leu Leu Leu Lys Tyr Arg Ala Arg Glu
 115 120 125
 Pro Val Thr Lys Ala Glu Met Leu Gly Ser Val Val Gly Asn Trp Gln
 130 135 140
 Tyr Phe Phe Pro Val Ile Phe Ser Lys Ala Ser Ser Ser Leu Gln Leu
 145 150 155 160
 Val Phe Gly Ile Glu Leu Met Glu Val Asp Pro Ile Gly His Leu Tyr
 165 170 175
 Ile Phe Ala Thr Cys Leu Gly Leu Ser Tyr Asp Gly Leu Leu Gly Asp
 180 185 190
 Asn Gln Ile Met Pro Lys Ala Gly Leu Leu Ile Ile Val Leu Ala Ile
 195 200 205

MANNK.049A.txt

Ile Ala Arg Glu Gly Asp Cys Ala Pro Glu Glu Lys Ile Trp Glu Glu
 210 215 220
 Leu Ser Val Leu Glu Val Phe Glu Gly Arg Glu Asp Ser Ile Leu Gly
 225 230 235 240
 Asp Pro Lys Lys Leu Leu Thr Gln His Phe Val Gln Glu Asn Tyr Leu
 245 250 255
 Glu Tyr Arg Gln Val Pro Gly Ser Asp Pro Ala Cys Tyr Glu Phe Leu
 260 265 270
 Trp Gly Pro Arg Ala Leu Val Glu Thr Ser Tyr Val Lys Val Leu His
 275 280 285
 His Met Val Lys Ile Ser Gly Gly Pro His Ile Ser Tyr Pro Pro Leu
 290 295 300
 His Glu Trp Val Leu Arg Glu Gly Glu Glu
 305 310

<210> 7
 <211> 180
 <212> PRT
 <213> Homo sapiens

<400> 7
 Met Gln Ala Glu Gly Arg Gly Thr Gly Gly Ser Thr Gly Asp Ala Asp
 1 5 10 15
 Gly Pro Gly Gly Pro Gly Ile Pro Asp Gly Pro Gly Gly Asn Ala Gly
 20 25 30
 Gly Pro Gly Glu Ala Gly Ala Thr Gly Gly Arg Gly Pro Arg Gly Ala
 35 40 45
 Gly Ala Ala Arg Ala Ser Gly Pro Gly Gly Ala Pro Arg Gly Pro
 50 55 60
 His Gly Gly Ala Ala Ser Gly Leu Asn Gly Cys Cys Arg Cys Gly Ala
 65 70 75 80
 Arg Gly Pro Glu Ser Arg Leu Leu Glu Phe Tyr Leu Ala Met Pro Phe
 85 90 95
 Ala Thr Pro Met Glu Ala Glu Leu Ala Arg Arg Ser Leu Ala Gln Asp
 100 105 110
 Ala Pro Pro Leu Pro Val Pro Gly Val Leu Leu Lys Glu Phe Thr Val
 115 120 125
 Ser Gly Asn Ile Leu Thr Ile Arg Leu Thr Ala Ala Asp His Arg Gln
 130 135 140
 Leu Gln Leu Ser Ile Ser Ser Cys Leu Gln Gln Leu Ser Leu Leu Met
 145 150 155 160
 Trp Ile Thr Gln Cys Phe Leu Pro Val Phe Leu Ala Gln Pro Pro Ser
 165 170 175
 Gly Gln Arg Arg
 180

<210> 8
 <211> 509
 <212> PRT
 <213> Homo sapiens

<400> 8
 Met Glu Arg Arg Arg Leu Trp Gly Ser Ile Gln Ser Arg Tyr Ile Ser
 1 5 10 15
 Met Ser Val Trp Thr Ser Pro Arg Arg Leu Val Glu Leu Ala Gly Gln
 20 25 30
 Ser Leu Leu Lys Asp Glu Ala Leu Ala Ile Ala Ala Leu Glu Leu Leu
 35 40 45
 Pro Arg Glu Leu Phe Pro Leu Phe Met Ala Ala Phe Asp Gly Arg
 50 55 60
 His Ser Gln Thr Leu Lys Ala Met Val Gln Ala Trp Pro Phe Thr Cys
 65 70 75 80
 Leu Pro Leu Gly Val Leu Met Lys Gly Gln His Leu His Leu Glu Thr
 85 90 95
 Phe Lys Ala Val Leu Asp Gly Leu Asp Val Leu Leu Ala Gln Glu Val
 100 105 110

MANNK.049A.txt

Arg Pro Arg Arg Trp Lys Leu Gln Val Leu Asp Leu Arg Lys Asn Ser
 115 120 125
 His Gln Asp Phe Trp Thr Val Trp Ser Gly Asn Arg Ala Ser Leu Tyr
 130 135 140
 Ser Phe Pro Glu Pro Glu Ala Ala Gln Pro Met Thr Lys Lys Arg Lys
 145 150 155 160
 Val Asp Gly Leu Ser Thr Glu Ala Glu Gln Pro Phe Ile Pro Val Glu
 165 170 175
 Val Leu Val Asp Leu Phe Leu Lys Glu Gly Ala Cys Asp Glu Leu Phe
 180 185 190
 Ser Tyr Leu Ile Glu Lys Val Lys Arg Lys Lys Asn Val Leu Arg Leu
 195 200 205
 Cys Cys Lys Lys Leu Lys Ile Phe Ala Met Pro Met Gln Asp Ile Lys
 210 215 220
 Met Ile Leu Lys Met Val Gln Leu Asp Ser Ile Glu Asp Leu Glu Val
 225 230 235 240
 Thr Cys Thr Trp Lys Leu Pro Thr Leu Ala Lys Phe Ser Pro Tyr Leu
 245 250 255
 Gly Gln Met Ile Asn Leu Arg Arg Leu Leu Ser His Ile His Ala
 260 265 270
 Ser Ser Tyr Ile Ser Pro Glu Lys Glu Glu Gln Tyr Ile Ala Gln Phe
 275 280 285
 Thr Ser Gln Phe Leu Ser Leu Gln Cys Leu Gln Ala Leu Tyr Val Asp
 290 295 300
 Ser Leu Phe Phe Leu Arg Gly Arg Leu Asp Gln Leu Leu Arg His Val
 305 310 315 320
 Met Asn Pro Leu Glu Thr Leu Ser Ile Thr Asn Cys Arg Leu Ser Glu
 325 330 335
 Gly Asp Val Met His Leu Ser Gln Ser Pro Ser Val Ser Gln Leu Ser
 340 345 350
 Val Leu Ser Leu Ser Gly Val Met Leu Thr Asp Val Ser Pro Glu Pro
 355 360 365
 Leu Gln Ala Leu Leu Glu Arg Ala Ser Ala Thr Leu Gln Asp Leu Val
 370 375 380
 Phe Asp Glu Cys Gly Ile Thr Asp Asp Gln Leu Leu Ala Leu Leu Pro
 385 390 395 400
 Ser Leu Ser His Cys Ser Gln Leu Thr Thr Leu Ser Phe Tyr Gly Asn
 405 410 415
 Ser Ile Ser Ile Ser Ala Leu Gln Ser Leu Leu Gln His Leu Ile Gly
 420 425 430
 Leu Ser Asn Leu Thr His Val Leu Tyr Pro Val Pro Leu Glu Ser Tyr
 435 440 445
 Glu Asp Ile His Gly Thr Leu His Leu Glu Arg Leu Ala Tyr Leu His
 450 455 460
 Ala Arg Leu Arg Glu Leu Leu Cys Glu Leu Gly Arg Pro Ser Met Val
 465 470 475 480
 Trp Leu Ser Ala Asn Pro Cys Pro His Cys Gly Asp Arg Thr Phe Tyr
 485 490 495
 Asp Pro Glu Pro Ile Leu Cys Pro Cys Phe Met Pro Asn
 500 505

<210> 9
 <211> 1255
 <212> PRT
 <213> Homo sapiens

<400> 9
 Met Glu Leu Ala Ala Leu Cys Arg Trp Gly Leu Leu Leu Ala Leu Leu
 1 5 10 15
 Pro Pro Gly Ala Ala Ser Thr Gln Val Cys Thr Gly Thr Asp Met Lys
 20 25 30
 Leu Arg Leu Pro Ala Ser Pro Glu Thr His Leu Asp Met Leu Arg His
 35 40 45
 Leu Tyr Gln Gly Cys Gln Val Val Gln Gly Asn Leu Glu Leu Thr Tyr
 50 55 60
 Leu Pro Thr Asn Ala Ser Leu Ser Phe Leu Gln Asp Ile Gln Glu Val
 65 70 75 80

MANNK.049A.txt

Gln Gly Tyr Val Leu Ile Ala His Asn Gln Val Arg Gln Val Pro Leu
 85 90 95
 Gln Arg Leu Arg Ile Val Arg Gly Thr Gln Leu Phe Glu Asp Asn Tyr
 100 105 110
 Ala Leu Ala Val Leu Asp Asn Gly Asp Pro Leu Asn Asn Thr Thr Pro
 115 120 125
 Val Thr Gly Ala Ser Pro Gly Gly Leu Arg Glu Leu Gln Leu Arg Ser
 130 135 140
 Leu Thr Glu Ile Leu Lys Gly Gly Val Leu Ile Gln Arg Asn Pro Gln
 145 150 155 160
 Leu Cys Tyr Gln Asp Thr Ile Leu Trp Lys Asp Ile Phe His Lys Asn
 165 170 175
 Asn Gln Leu Ala Leu Thr Leu Ile Asp Thr Asn Arg Ser Arg Ala Cys
 180 185 190
 His Pro Cys Ser Pro Met Cys Lys Gly Ser Arg Cys Trp Gly Glu Ser
 195 200 205
 Ser Glu Asp Cys Gln Ser Leu Thr Arg Thr Val Cys Ala Gly Gly Cys
 210 215 220
 Ala Arg Cys Lys Gly Pro Leu Pro Thr Asp Cys Cys His Glu Gln Cys
 225 230 235 240
 Ala Ala Gly Cys Thr Gly Pro Lys His Ser Asp Cys Leu Ala Cys Leu
 245 250 255
 His Phe Asn His Ser Gly Ile Cys Glu Leu His Cys Pro Ala Leu Val
 260 265 270
 Thr Tyr Asn Thr Asp Thr Phe Glu Ser Met Pro Asn Pro Glu Gly Arg
 275 280 285
 Tyr Thr Phe Gly Ala Ser Cys Val Thr Ala Cys Pro Tyr Asn Tyr Leu
 290 295 300
 Ser Thr Asp Val Gly Ser Cys Thr Leu Val Cys Pro Leu His Asn Gln
 305 310 315 320
 Glu Val Thr Ala Glu Asp Gly Thr Gln Arg Cys Glu Lys Cys Ser Lys
 325 330 335
 Pro Cys Ala Arg Val Cys Tyr Gly Leu Gly Met Glu His Leu Arg Glu
 340 345 350
 Val Arg Ala Val Thr Ser Ala Asn Ile Gln Glu Phe Ala Gly Cys Lys
 355 360 365
 Lys Ile Phe Gly Ser Leu Ala Phe Leu Pro Glu Ser Phe Asp Gly Asp
 370 375 380
 Pro Ala Ser Asn Thr Ala Pro Leu Gln Pro Glu Gln Leu Gln Val Phe
 385 390 395 400
 Glu Thr Leu Glu Glu Ile Thr Gly Tyr Leu Tyr Ile Ser Ala Trp Pro
 405 410 415
 Asp Ser Leu Pro Asp Leu Ser Val Phe Gln Asn Leu Gln Val Ile Arg
 420 425 430
 Gly Arg Ile Leu His Asn Gly Ala Tyr Ser Leu Thr Leu Gln Gly Leu
 435 440 445
 Gly Ile Ser Trp Leu Gly Leu Arg Ser Leu Arg Glu Leu Gly Ser Gly
 450 455 460
 Leu Ala Leu Ile His His Asn Thr His Leu Cys Phe Val His Thr Val
 465 470 475 480
 Pro Trp Asp Gln Leu Phe Arg Asn Pro His Gln Ala Leu Leu His Thr
 485 490 495
 Ala Asn Arg Pro Glu Asp Glu Cys Val Gly Glu Gly Leu Ala Cys His
 500 505 510
 Gln Leu Cys Ala Arg Gly His Cys Trp Gly Pro Gly Pro Thr Gln Cys
 515 520 525
 Val Asn Cys Ser Gln Phe Leu Arg Gly Gln Glu Cys Val Glu Glu Cys
 530 535 540
 Arg Val Leu Gln Gly Leu Pro Arg Glu Tyr Val Asn Ala Arg His Cys
 545 550 555 560
 Leu Pro Cys His Pro Glu Cys Gln Pro Gln Asn Gly Ser Val Thr Cys
 565 570 575
 Phe Gly Pro Glu Ala Asp Gln Cys Val Ala Cys Ala His Tyr Lys Asp
 580 585 590
 Pro Pro Phe Cys Val Ala Arg Cys Pro Ser Gly Val Lys Pro Asp Leu
 595 600 605
 Ser Tyr Met Pro Ile Trp Lys Phe Pro Asp Glu Glu Gly Ala Cys Gln
 610 615 620

MANNK.049A.txt

Pro Cys Pro Ile Asn Cys Thr His Ser Cys Val Asp Leu Asp Asp Lys
 625 630 635 640
 Gly Cys Pro Ala Glu Gln Arg Ala Ser Pro Leu Thr Ser Ile Ile Ser
 645 650 655
 Ala Val Val Gly Ile Leu Leu Val Val Val Leu Gly Val Val Phe Gly
 660 665 670
 Ile Leu Ile Lys Arg Arg Gln Gln Lys Ile Arg Lys Tyr Thr Met Arg
 675 680 685
 Arg Leu Leu Gln Glu Thr Glu Leu Val Glu Pro Leu Thr Pro Ser Gly
 690 695 700
 Ala Met Pro Asn Gln Ala Gln Met Arg Ile Leu Lys Glu Thr Glu Leu
 705 710 715 720
 Arg Lys Val Lys Val Leu Gly Ser Gly Ala Phe Gly Thr Val Tyr Lys
 725 730 735
 Gly Ile Trp Ile Pro Asp Gly Glu Asn Val Lys Ile Pro Val Ala Ile
 740 745 750
 Lys Val Leu Arg Glu Asn Thr Ser Pro Lys Ala Asn Lys Glu Ile Leu
 755 760 765
 Asp Glu Ala Tyr Val Met Ala Gly Val Gly Ser Pro Tyr Val Ser Arg
 770 775 780
 Leu Leu Gly Ile Cys Leu Thr Ser Thr Val Gln Leu Val Thr Gln Leu
 785 790 795 800
 Met Pro Tyr Gly Cys Leu Leu Asp His Val Arg Glu Asn Arg Gly Arg
 805 810 815
 Leu Gly Ser Gln Asp Leu Leu Asn Trp Cys Met Gln Ile Ala Lys Gly
 820 825 830
 Met Ser Tyr Leu Glu Asp Val Arg Leu Val His Arg Asp Leu Ala Ala
 835 840 845
 Arg Asn Val Leu Val Lys Ser Pro Asn His Val Lys Ile Thr Asp Phe
 850 855 860
 Gly Leu Ala Arg Leu Leu Asp Ile Asp Glu Thr Glu Tyr His Ala Asp
 865 870 875 880
 Gly Gly Lys Val Pro Ile Lys Trp Met Ala Leu Glu Ser Ile Leu Arg
 885 890 895
 Arg Arg Phe Thr His Gln Ser Asp Val Trp Ser Tyr Gly Val Thr Val
 900 905 910
 Trp Glu Leu Met Thr Phe Gly Ala Lys Pro Tyr Asp Gly Ile Pro Ala
 915 920 925
 Arg Glu Ile Pro Asp Leu Leu Lys Gly Glu Arg Leu Pro Gln Pro
 930 935 940
 Pro Ile Cys Thr Ile Asp Val Tyr Met Ile Met Val Lys Cys Trp Met
 945 950 955 960
 Ile Asp Ser Glu Cys Arg Pro Arg Phe Arg Glu Leu Val Ser Glu Phe
 965 970 975
 Ser Arg Met Ala Arg Asp Pro Gln Arg Phe Val Val Ile Gln Asn Glu
 980 985 990
 Asp Leu Gly Pro Ala Ser Pro Leu Asp Ser Thr Phe Tyr Arg Ser Leu
 995 1000 1005
 Leu Glu Asp Asp Asp Met Gly Asp Leu Val Asp Ala Glu Glu Tyr Leu
 1010 1015 1020
 Val Pro Gln Gln Gly Phe Phe Cys Pro Asp Pro Ala Pro Gly Ala Gly
 1025 1030 1035 1040
 Gly Met Val His His Arg His Arg Ser Ser Thr Arg Ser Gly Gly
 1045 1050 1055
 Gly Asp Leu Thr Leu Gly Leu Glu Pro Ser Glu Glu Glu Ala Pro Arg
 1060 1065 1070
 Ser Pro Leu Ala Pro Ser Glu Gly Ala Gly Ser Asp Val Phe Asp Gly
 1075 1080 1085
 Asp Leu Gly Met Gly Ala Ala Lys Gly Leu Gln Ser Leu Pro Thr His
 1090 1095 1100
 Asp Pro Ser Pro Leu Gln Arg Tyr Ser Glu Asp Pro Thr Val Pro Leu
 1105 1110 1115 1120
 Pro Ser Glu Thr Asp Gly Tyr Val Ala Pro Leu Thr Cys Ser Pro Gln
 1125 1130 1135
 Pro Glu Tyr Val Asn Gln Pro Asp Val Arg Pro Gln Pro Pro Ser Pro
 1140 1145 1150
 Arg Glu Gly Pro Leu Pro Ala Ala Arg Pro Ala Gly Ala Thr Leu Glu
 1155 1160 1165

MANNK.049A.txt

Arg Pro Lys Thr Leu Ser Pro Gly Lys Asn Gly Val Val Lys Asp Val
 1170 1175 1180
 Phe Ala Phe Gly Gly Ala Val Glu Asn Pro Glu Tyr Leu Thr Pro Gln
 1185 1190 1195 1200
 Gly Gly Ala Ala Pro Gln Pro His Pro Pro Ala Phe Ser Pro Ala
 1205 1210 1215
 Phe Asp Asn Leu Tyr Tyr Trp Asp Gln Asp Pro Pro Glu Arg Gly Ala
 1220 1225 1230 1235
 Pro Pro Ser Thr Phe Lys Gly Thr Pro Thr Ala Glu Asn Pro Glu Tyr
 1235 1240 1245
 Leu Gly Leu Asp Val Pro Val
 1250 1255

<210> 10
 <211> 622
 <212> PRT
 <213> Homo sapiens

<400> 10
 Met Ala Leu Pro Thr Ala Arg Pro Leu Leu Gly Ser Cys Gly Thr Pro
 1 5 10 15
 Ala Leu Gly Ser Leu Leu Phe Leu Leu Phe Ser Leu Gly Trp Val Gln
 20 25 30
 Pro Ser Arg Thr Leu Ala Gly Glu Thr Gly Gln Glu Ala Ala Pro Leu
 35 40 45
 Asp Gly Val Leu Ala Asn Pro Pro Asn Ile Ser Ser Leu Ser Pro Arg
 50 55 60
 Gln Leu Leu Gly Phe Pro Cys Ala Glu Val Ser Gly Leu Ser Thr Glu
 65 70 75 80
 Arg Val Arg Glu Leu Ala Val Ala Leu Ala Gln Lys Asn Val Lys Leu
 85 90 95
 Ser Thr Glu Gln Leu Arg Cys Leu Ala His Arg Leu Ser Glu Pro Pro
 100 105 110
 Glu Asp Leu Asp Ala Leu Pro Leu Asp Leu Leu Phe Leu Asn Pro
 115 120 125
 Asp Ala Phe Ser Gly Pro Gln Ala Cys Thr Arg Phe Phe Ser Arg Ile
 130 135 140
 Thr Lys Ala Asn Val Asp Leu Leu Pro Arg Gly Ala Pro Glu Arg Gln
 145 150 155 160
 Arg Leu Leu Pro Ala Ala Leu Ala Cys Trp Gly Val Arg Gly Ser Leu
 165 170 175
 Leu Ser Glu Ala Asp Val Arg Ala Leu Gly Gly Leu Ala Cys Asp Leu
 180 185 190
 Pro Gly Arg Phe Val Ala Glu Ser Ala Glu Val Leu Leu Pro Arg Leu
 195 200 205
 Val Ser Cys Pro Gly Pro Leu Asp Gln Asp Gln Gln Glu Ala Ala Arg
 210 215 220
 Ala Ala Leu Gln Gly Gly Pro Pro Tyr Gly Pro Pro Ser Thr Trp
 225 230 235 240
 Ser Val Ser Thr Met Asp Ala Leu Arg Gly Leu Leu Pro Val Leu Gly
 245 250 255
 Gln Pro Ile Ile Arg Ser Ile Pro Gln Gly Ile Val Ala Ala Trp Arg
 260 265 270
 Gln Arg Ser Ser Arg Asp Pro Ser Trp Arg Gln Pro Glu Arg Thr Ile
 275 280 285
 Leu Arg Pro Arg Phe Arg Arg Glu Val Glu Lys Thr Ala Cys Pro Ser
 290 295 300
 Gly Lys Lys Ala Arg Glu Ile Asp Glu Ser Leu Ile Phe Tyr Lys Lys
 305 310 315 320
 Trp Glu Leu Glu Ala Cys Val Asp Ala Ala Leu Leu Ala Thr Gln Met
 325 330 335
 Asp Arg Val Asn Ala Ile Pro Phe Thr Tyr Glu Gln Leu Asp Val Leu
 340 345 350
 Lys His Lys Leu Asp Glu Leu Tyr Pro Gln Gly Tyr Pro Glu Ser Val
 355 360 365
 Ile Gln His Leu Gly Tyr Leu Phe Leu Lys Met Ser Pro Glu Asp Ile
 370 375 380

MANNK.049A.txt

Arg Lys Trp Asn Val Thr Ser Leu Glu Thr Leu Lys Ala Leu Leu Glu
 385 390 395 400
 Val Asn Lys Gly His Glu Met Ser Pro Gln Val Ala Thr Leu Ile Asp
 405 410 415
 Arg Phe Val Lys Gly Arg Gly Gln Leu Asp Lys Asp Thr Leu Asp Thr
 420 425 430
 Leu Thr Ala Phe Tyr Pro Gly Tyr Leu Cys Ser Leu Ser Pro Glu Glu
 435 440 445
 Leu Ser Ser Val Pro Pro Ser Ser Ile Trp Ala Val Arg Pro Gln Asp
 450 455 460
 Leu Asp Thr Cys Asp Pro Arg Gln Leu Asp Val Leu Tyr Pro Lys Ala
 465 470 475 480
 Arg Leu Ala Phe Gln Asn Met Asn Gly Ser Glu Tyr Phe Val Lys Ile
 485 490 495
 Gln Ser Phe Leu Gly Gly Ala Pro Thr Glu Asp Leu Lys Ala Leu Ser
 500 505 510
 Gln Gln Asn Val Ser Met Asp Leu Ala Thr Phe Met Lys Leu Arg Thr
 515 520 525
 Asp Ala Val Leu Pro Leu Thr Val Ala Glu Val Gln Lys Leu Leu Gly
 530 535 540
 Pro His Val Glu Gly Leu Lys Ala Glu Glu Arg His Arg Pro Val Arg
 545 550 555 560
 Asp Trp Ile Leu Arg Gln Arg Gln Asp Asp Leu Asp Thr Leu Gly Leu
 565 570 575
 Gly Leu Gln Gly Gly Ile Pro Asn Gly Tyr Leu Val Leu Asp Leu Ser
 580 585 590
 Met Gln Glu Ala Leu Ser Gly Thr Pro Cys Leu Leu Gly Pro Gly Pro
 595 600 605
 Val Leu Thr Val Leu Ala Leu Leu Leu Ala Ser Thr Leu Ala
 610 615 620

<210> 11
 <211> 630
 <212> PRT
 <213> Homo sapiens

<400> 11
 Met Ala Leu Pro Thr Ala Arg Pro Leu Leu Gly Ser Cys Gly Thr Pro
 1 5 10 15
 Ala Leu Gly Ser Leu Leu Phe Leu Leu Phe Ser Leu Gly Trp Val Gln
 20 25 30
 Pro Ser Arg Thr Leu Ala Gly Glu Thr Gly Gln Glu Ala Ala Pro Leu
 35 40 45
 Asp Gly Val Leu Ala Asn Pro Pro Asn Ile Ser Ser Leu Ser Pro Arg
 50 55 60
 Gln Leu Leu Gly Phe Pro Cys Ala Glu Val Ser Gly Leu Ser Thr Glu
 65 70 75 80
 Arg Val Arg Glu Leu Ala Val Ala Leu Ala Gln Lys Asn Val Lys Leu
 85 90 95
 Ser Thr Glu Gln Leu Arg Cys Leu Ala His Arg Leu Ser Glu Pro Pro
 100 105 110
 Glu Asp Leu Asp Ala Leu Pro Leu Asp Leu Leu Phe Leu Asn Pro
 115 120 125
 Asp Ala Phe Ser Gly Pro Gln Ala Cys Thr Arg Phe Phe Ser Arg Ile
 130 135 140
 Thr Lys Ala Asn Val Asp Leu Leu Pro Arg Gly Ala Pro Glu Arg Gln
 145 150 155 160
 Arg Leu Leu Pro Ala Ala Leu Ala Cys Trp Gly Val Arg Gly Ser Leu
 165 170 175
 Leu Ser Glu Ala Asp Val Arg Ala Leu Gly Gly Leu Ala Cys Asp Leu
 180 185 190
 Pro Gly Arg Phe Val Ala Glu Ser Ala Glu Val Leu Leu Pro Arg Leu
 195 200 205
 Val Ser Cys Pro Gly Pro Leu Asp Gln Asp Gln Gln Glu Ala Ala Arg
 210 215 220
 Ala Ala Leu Gln Gly Gly Pro Pro Tyr Gly Pro Pro Ser Thr Trp
 225 230 235 240

MANNK.049A.txt

Ser Val Ser Thr Met Asp Ala Leu Arg Gly Leu Leu Pro Val Leu Gly
 245 250 255
 Gln Pro Ile Ile Arg Ser Ile Pro Gln Gly Ile Val Ala Ala Trp Arg
 260 265 270
 Gln Arg Ser Ser Arg Asp Pro Ser Trp Arg Gln Pro Glu Arg Thr Ile
 275 280 285
 Leu Arg Pro Arg Phe Arg Arg Glu Val Glu Lys Thr Ala Cys Pro Ser
 290 295 300
 Gly Lys Lys Ala Arg Glu Ile Asp Glu Ser Leu Ile Phe Tyr Lys Lys
 305 310 315 320
 Trp Glu Leu Glu Ala Cys Val Asp Ala Ala Leu Leu Ala Thr Gln Met
 325 330 335
 Asp Arg Val Asn Ala Ile Pro Phe Thr Tyr Glu Gln Leu Asp Val Leu
 340 345 350
 Lys His Lys Leu Asp Glu Leu Tyr Pro Gln Gly Tyr Pro Glu Ser Val
 355 360 365
 Ile Gln His Leu Gly Tyr Leu Phe Leu Lys Met Ser Pro Glu Asp Ile
 370 375 380
 Arg Lys Trp Asn Val Thr Ser Leu Glu Thr Leu Lys Ala Leu Leu Glu
 385 390 395 400
 Val Asn Lys Gly His Glu Met Ser Pro Gln Ala Pro Arg Arg Pro Leu
 405 410 415
 Pro Gln Val Ala Thr Leu Ile Asp Arg Phe Val Lys Gly Arg Gly Gln
 420 425 430
 Leu Asp Lys Asp Thr Leu Asp Thr Leu Thr Ala Phe Tyr Pro Gly Tyr
 435 440 445
 Leu Cys Ser Leu Ser Pro Glu Glu Leu Ser Ser Val Pro Pro Ser Ser
 450 455 460
 Ile Trp Ala Val Arg Pro Gln Asp Leu Asp Thr Cys Asp Pro Arg Gln
 465 470 475 480
 Leu Asp Val Leu Tyr Pro Lys Ala Arg Leu Ala Phe Gln Asn Met Asn
 485 490 495
 Gly Ser Glu Tyr Phe Val Lys Ile Gln Ser Phe Leu Gly Gly Ala Pro
 500 505 510
 Thr Glu Asp Leu Lys Ala Leu Ser Gln Gln Asn Val Ser Met Asp Leu
 515 520 525
 Ala Thr Phe Met Lys Leu Arg Thr Asp Ala Val Leu Pro Leu Thr Val
 530 535 540
 Ala Glu Val Gln Lys Leu Leu Gly Pro His Val Glu Gly Leu Lys Ala
 545 550 555 560
 Glu Glu Arg His Arg Pro Val Arg Asp Trp Ile Leu Arg Gln Arg Gln
 565 570 575
 Asp Asp Leu Asp Thr Leu Gly Leu Gln Gly Gly Ile Pro Asn
 580 585 590
 Gly Tyr Leu Val Leu Asp Leu Ser Met Gln Glu Ala Leu Ser Gly Thr
 595 600 605
 Pro Cys Leu Leu Gly Pro Gly Pro Val Leu Thr Val Leu Ala Leu Leu
 610 615 620
 Leu Ala Ser Thr Leu Ala
 625 630

<210> 12
 <211> 232
 <212> PRT
 <213> Homo sapiens

<400> 12
 Met Asn Phe Leu Leu Ser Trp Val His Trp Ser Leu Ala Leu Leu Leu
 1 5 10 15
 Tyr Leu His His Ala Lys Trp Ser Gln Ala Ala Pro Met Ala Glu Gly
 20 25 30
 Gly Gly Gln Asn His His Glu Val Val Lys Phe Met Asp Val Tyr Gln
 35 40 45
 Arg Ser Tyr Cys His Pro Ile Glu Thr Leu Val Asp Ile Phe Gln Glu
 50 55 60
 Tyr Pro Asp Glu Ile Glu Tyr Ile Phe Lys Pro Ser Cys Val Pro Leu
 65 70 75 80

MANNK.049A.txt

Met Arg Cys Gly Gly Cys Cys Asn Asp Glu Gly Leu Glu Cys Val Pro
 85 90 95
 Thr Glu Glu Ser Asn Ile Thr Met Gln Ile Met Arg Ile Lys Pro His
 100 105 110
 Gln Gly Gln His Ile Gly Glu Met Ser Phe Leu Gln His Asn Lys Cys
 115 120 125
 Glu Cys Arg Pro Lys Lys Asp Arg Ala Arg Gln Glu Lys Lys Ser Val
 130 135 140
 Arg Gly Lys Gly Lys Gln Lys Arg Lys Arg Lys Ser Arg Tyr
 145 150 155 160
 Lys Ser Trp Ser Val Tyr Val Gly Ala Arg Cys Cys Leu Met Pro Trp
 165 170 175
 Ser Leu Pro Gly Pro His Pro Cys Gly Pro Cys Ser Glu Arg Arg Lys
 180 185 190
 His Leu Phe Val Gln Asp Pro Gln Thr Cys Lys Cys Ser Cys Lys Asn
 195 200 205
 Thr Asp Ser Arg Cys Lys Ala Arg Gln Leu Glu Leu Asn Glu Arg Thr
 210 215 220
 Cys Arg Cys Asp Lys Pro Arg Arg
 225 230

<210> 13
 <211> 603
 <212> PRT
 <213> Homo sapiens

<400> 13
 Met Ser Ala Ala Val Thr Ala Gly Lys Leu Ala Arg Ala Pro Ala Asp
 1 5 10 15
 Pro Gly Lys Ala Gly Val Pro Gly Val Ala Ala Pro Gly Ala Pro Ala
 20 25 30
 Ala Ala Pro Pro Ala Lys Glu Ile Pro Glu Val Leu Val Asp Pro Arg
 35 40 45
 Ser Arg Arg Arg Tyr Val Arg Gly Arg Phe Leu Gly Lys Gly Phe
 50 55 60
 Ala Lys Cys Phe Glu Ile Ser Asp Ala Asp Thr Lys Glu Val Phe Ala
 65 70 75 80
 Gly Lys Ile Val Pro Lys Ser Leu Leu Lys Pro His Gln Arg Glu
 85 90 95
 Lys Met Ser Met Glu Ile Ser Ile His Arg Ser Leu Ala His Gln His
 100 105 110
 Val Val Gly Phe His Gly Phe Phe Glu Asp Asn Asp Phe Val Phe Val
 115 120 125
 Val Leu Glu Leu Cys Arg Arg Ser Leu Leu Glu Leu His Lys Arg
 130 135 140
 Arg Lys Ala Leu Thr Glu Pro Glu Ala Arg Tyr Tyr Leu Arg Gln Ile
 145 150 155 160
 Val Leu Gly Cys Gln Tyr Leu His Arg Asn Arg Val Ile His Arg Asp
 165 170 175
 Leu Lys Leu Gly Asn Leu Phe Leu Asn Glu Asp Leu Glu Val Lys Ile
 180 185 190
 Gly Asp Phe Gly Leu Ala Thr Lys Val Glu Tyr Asp Gly Glu Arg Lys
 195 200 205
 Lys Thr Leu Cys Gly Thr Pro Asn Tyr Ile Ala Pro Glu Val Leu Ser
 210 215 220
 Lys Lys Gly His Ser Phe Glu Val Asp Val Trp Ser Ile Gly Cys Ile
 225 230 235 240
 Met Tyr Thr Leu Leu Val Gly Lys Pro Pro Phe Glu Thr Ser Cys Leu
 245 250 255
 Lys Glu Thr Tyr Leu Arg Ile Lys Lys Asn Glu Tyr Ser Ile Pro Lys
 260 265 270
 His Ile Asn Pro Val Ala Ala Ser Leu Ile Gln Lys Met Leu Gln Thr
 275 280 285
 Asp Pro Thr Ala Arg Pro Thr Ile Asn Glu Leu Leu Asn Asp Glu Phe
 290 295 300
 Phe Thr Ser Gly Tyr Ile Pro Ala Arg Leu Pro Ile Thr Cys Leu Thr
 305 310 315 320

MANNK.049A.txt

Ile Pro Pro Arg Phe Ser Ile Ala Pro Ser Ser Leu Asp Pro Ser Asn
 325 330 335
 Arg Lys Pro Leu Thr Val Leu Asn Lys Gly Leu Glu Asn Pro Leu Pro
 340 345 350
 Glu Arg Pro Arg Glu Lys Glu Glu Pro Val Val Arg Glu Thr Gly Glu
 355 360 365
 Val Val Asp Cys His Leu Ser Asp Met Leu Gln Gln Leu His Ser Val
 370 375 380
 Asn Ala Ser Lys Pro Ser Glu Arg Gly Leu Val Arg Gln Glu Glu Ala
 385 390 395 400
 Glu Asp Pro Ala Cys Ile Pro Ile Phe Trp Val Ser Lys Trp Val Asp
 405 410 415
 Tyr Ser Asp Lys Tyr Gly Leu Gly Tyr Gln Leu Cys Asp Asn Ser Val
 420 425 430
 Gly Val Leu Phe Asn Asp Ser Thr Arg Leu Ile Leu Tyr Asn Asp Gly
 435 440 445
 Asp Ser Leu Gln Tyr Ile Glu Arg Asp Gly Thr Glu Ser Tyr Leu Thr
 450 455 460
 Val Ser Ser His Pro Asn Ser Leu Met Lys Lys Ile Thr Leu Leu Lys
 465 470 475 480
 Tyr Phe Arg Asn Tyr Met Ser Glu His Leu Leu Lys Ala Gly Ala Asn
 485 490 495
 Ile Thr Pro Arg Glu Gly Asp Glu Leu Ala Arg Leu Pro Tyr Leu Arg
 500 505 510
 Thr Trp Phe Arg Thr Arg Ser Ala Ile Ile Leu His Leu Ser Asn Gly
 515 520 525
 Ser Val Gln Ile Asn Phe Phe Gln Asp His Thr Lys Leu Ile Leu Cys
 530 535 540
 Pro Leu Met Ala Ala Val Thr Tyr Ile Asp Glu Lys Arg Asp Phe Arg
 545 550 555 560
 Thr Tyr Arg Leu Ser Leu Leu Glu Glu Tyr Gly Cys Cys Lys Glu Leu
 565 570 575
 Ala Ser Arg Leu Arg Tyr Ala Arg Thr Met Val Asp Lys Leu Leu Ser
 580 585 590
 Ser Arg Ser Ala Ser Asn Arg Leu Lys Ala Ser
 595 600

<210> 14
 <211> 2384
 <212> DNA
 <213> Homo sapiens

<400> 14
 tattgagttc ttcaaacatt gtagccttct tatggctctct gagaataaac taccttaaac 60
 ccataatctt taatacttcc taaaactttct taataagaga agctctattc ctgacactac 120
 ctctcatttgc caaggtcaaa tcatcatttag tttttagtgc tattaactgg gtttgcttag 180
 gtcaggcattt attattacta accttattgt taatattcta accataagaa ttaaaactatt 240
 aatggtaat agagttttc actttaacat aggcctatcc cactgggtggg atacgagcc 300
 attcgaaaga aaagtcaagtc atgtgctttt cagaggatga aagcttaaga taaagactaa 360
 aagtgtttga tgctggaggt gggagtggta ttatataaggt ctcagccaag acatgtgata 420
 atcaactgttag tagtagctgg aaagagaaat ctgtgactcc aattagccag ttccctgcaga 480
 ccttgtgagg actagagaa gaatgctcct ggctgttttgc tactgcctgc tggagttt 540
 ccagacctcc gctggccatt tccctagagc ctgtgtctcc tctaagaacc tgatggagaa 600
 ggaatgtctgt ccaccgttgc gcggggacag gagtccctgt ggccagctt cagggcagg 660
 ttccctgtcag aatatccctc tgccaaatgc accacttggg cctcaatttc cttcacagg 720
 ggtggatgac cgggagtcgt ggccttccgt ctttataat aggacctgcc agtgctctgg 780
 caacttcatg ggatcaact gtggaaactg caagtttggc ttttgggac caaactgcac 840
 agagagacga ctcttggta gaagaaacat ctgcatttg agtgcggcag agaaggacaa 900
 attttttgcc tacctcaact tagccaaagca taccatcagc tcagactatg tcatccccat 960
 agggacctat ggccaaatga aaaatggatc aacacccatg tttaacgaca tcaatattta 1020
 tgacccctttt gtctggatgc attattatgt gtcaatggat gcactgcttg ggggatctga 1080
 aatctggaga gacattgatt ttgcccattga agcaccagct ttctgcctt ggcataagact 1140
 cttcttggtg cggtggaaac aagaaatcca gaagctgaca ggagatgaaa acttcactat 1200
 tccatattgg gactggcggg atgcagaaaa gtgtgacatt tgccatcgat agtacatggg 1260
 aggtcagcac cccacaatac ctaacttact cagccatcgat tcattctt cctcttgca 1320
 gattgtctgt agccgattgg aggagtacaa cagccatcgat tctttatgca atggaacgcc 1380
 cgagggacct ttacggcgta atcctggaaa ccatgacaaa tccagaaccc caaggctccc 1440

MANNK.049A.txt

ctcttcagct	gatgtagaat	tttgccctgag	tttgacccaa	tatgaatctg	gttccatgga	1500
taaagctgcc	aatttcagct	ttagaaaatac	actggaaagga	tttgcttagtc	cacttaactgg	1560
gatagcggat	gcctctcaaa	gcagcatgca	caatgccttg	cacatctata	tgaatggAAC	1620
aatgtcccag	gtacaggat	ctgccaacga	tcctatcttc	cttcttcacc	atgcatttgt	1680
tgacagttt	tttgagcagt	ggctccgaag	gcaccgtcct	cttcaagaag	tttatccaga	1740
agccaatgca	cccattggac	ataaccggga	atcctacatg	gttcccttta	taccactgtA	1800
cagaatgggt	gatttctta	tttcatccaa	agatctggc	tatgactata	gctatctaca	1860
agattcagac	ccagactctt	ttcaagacta	cattaagtcc	tatttggAAC	aagcgagtgc	1920
gatctggtca	tggctccctt	gggcggcgat	ggtaggggcc	gtccctactg	ccctgctggc	1980
agggcttgtg	agcttgctgt	gtcgtcacaa	gagaaagcag	cttccctgaag	aaaaggcagcc	2040
actccatcg	gagaaagagg	attaccacag	cttgatctag	agccatttat	aaaaggctta	2100
ggcaatagag	tagggccaaa	aagcctgacc	tcactctaa	tcaaaagtaat	gtccaggttc	2160
ccagagaata	tctgctggta	ttttctgtta	aagaccattgt	gcaaaattgt	aacctaatac	2220
aaagtgttagc	cttcttccaa	ctcaggtaga	acacacctgt	ctttgtcttg	ctgtttcac	2280
tcagcccttt	taacattttc	ccctaagccc	atatgtctaa	ggaaaggatg	ctatttggta	2340
atgaggaact	gttattttgt	tgtgaattaa	agtgtcttta	tttt		2384

<210> 15

<211> 1524

<212> DNA

<213> Homo sapiens

<400> 15

agcagacaga	ggactctcat	taaggaaggt	gtcctgtgcc	ctgaccctac	aagatgcca	60
gagaagatgc	tcacttcatc	tatggttacc	ccaagaaggg	gcacggccac	tcttacacca	120
cggctgaaga	ggccgctggg	atcggcatcc	tgacagtgt	cctgggagtc	ttactgctca	180
tcggctgttg	gtattgtaga	agacgaaatg	gatacagagc	cttgcgtggat	aaaagtcttc	240
atgttggcac	tcaatgtgcc	ttaacaagaa	gatcccaca	agaagggttt	gatcatcg	300
acagcaaagt	gtctcttcaa	gagaaaaact	gtgaacctgt	ggttcccaat	gttccacctg	360
ctttaggaa	actctctgca	gaacagtcac	caccaccta	ttcaccttaa	gagccagcga	420
gacacctgag	acatgctgaa	attatttctc	tcacacttt	gcttgaattt	aatacagaca	480
tctaattgttc	tcctttggaa	tgggttagga	aaaatgcaag	ccatctctaa	taataagtca	540
gtgttaaaat	tttagtaggt	ccgctagcag	tactaatcat	gtgagggaaat	gtgagaaat	600
attaaattgg	gaaaactcca	tcaataaaatg	ttgcaatgca	tgatactatc	tgtgccagag	660
gtaatgttag	taaatccatg	gtgttatttt	ctgagagaca	gaattcaagt	gggtattctg	720
gggccatcca	atttctctt	acttgaattt	tggctaataa	caaactagtc	aggtttcga	780
accttgaccg	acatgaactg	tacacagaat	tgttccagta	ctatggagt	ctcacaaagg	840
atactttac	aggttaagac	aaagggttga	ctggcctatt	tatctgtatca	agaacatgtc	900
agcaatgtct	ctttgtgctc	taaaattctt	ttatactaca	ataatatattt	gtaaagatcc	960
tatagtctt	tttttttgag	atggagttt	gtttttgtt	cccaggctgg	agtgcata	1020
cgcgatcttg	gctcaccata	accccgct	cccagggtca	agaattctc	ctgccttagc	1080
ctccctgatg	gctggggatta	caggcgtgc	ccactatgcc	tgactaattt	tgtgtttt	1140
gttagagacgg	ggtttctcca	tgttggtcag	gctgggtc	aactcctgac	ctcagggtat	1200
ctgccccct	cagccctcca	aagtgtggaa	attacaggcg	tgagccacca	cgccctggctg	1260
gatccatata	cttaggttaag	acatataacg	cagtctaatt	acatttact	tcaaggctca	1320
atgctattct	aactaatgac	aagtattttc	tactaaacca	gaaattggta	gaaggattta	1380
aataagtaaa	agctactatg	tactgcctt	gtgctgatgc	ctgtgtactg	ccttaaatgt	1440
acctatggca	atttagctct	cttgggttcc	caaattccctc	tcacaagaat	gtgcagaaga	1500
aatcataaaag	gatcagagat	tctg				1524

<210> 16

<211> 1466

<212> DNA

<213> Homo sapiens

<400> 16

gcatgctcg	actttctctc	tcttcgatt	cttccatact	cagagtacgc	acgggtctgat	60
tttcttttg	gattcttcca	aaatcagagt	cagactgctc	ccgggtccat	gaacggagac	120
gacgccttg	caaggagacc	cacgggttgt	gctcaataac	cagagaagat	ccaaaaggcc	180
ttcgtatgata	ttgccaaata	cttctctaa	gaagagttgg	aaaagatgaa	agcctcgag	240
aaaatcttct	atgtgtatata	gaagagaaag	tatgaggcta	tgactaaact	aggtttcaag	300
gccaccctcc	cacccctcat	gtgtataaaa	cgggccgaag	acttccaggg	gaatgattt	360
gataatgacc	ctaaccgtgg	gaatcagggtt	gaacgtcctc	agatgactt	cggcaggctc	420
cagggaatct	ccccgaagat	catgccccaa	aagccagcag	aggaaggaaa	tgattcggag	480
gaagtgccag	aagcatctgg	cccacaaaat	gatggaaaag	agctgtgccc	cccgggaaaa	540
ccaaactacct	ctgagaagat	tcacgagaga	tctggaaata	gggaggccca	agaaaaggaa	600
gagagacgcg	gaacagctca	tcgggtggagc	agtcaaaaa	cacacaacat	tggtcgattc	660
agtttgtcaa	cttctatggg	tgcagttcat	ggtacccca	aaacaattac	acacaacagg	720

MANNK.049A.txt

gacccaaagg	gggggaacat	gcctggaccc	acagactgcg	tgagagaaaa	cagctggta	780
tttatgaaga	gatcagcgac	cctgaggaag	atgacgagta	actccctca	gggatacgac	840
acatgcccatt	gatgagaagc	agaacgtgg	gacctttcac	gaacatgggc	atggctgcgg	900
acccttcgtc	atcaggtgca	tagcaagtga	aagaagtgt	tcacaacagt	aaaagttga	960
gcgtcattt	tcttagtgg	ccaagagttc	gatgttagcg	tttacgttgt	attttcttac	1020
actgtgtcat	tctgttagat	actaacattt	tcattgtatg	gcaagacata	cttaatgcac	1080
attttggttt	gtgtatccat	gcacccatct	tagaaaaacaa	gtattgtcg	ttacctctgc	1140
atggAACAGC	attaccctcc	tctctccca	gatgtgacta	ctgagggcag	ttctgagtgt	1200
ttaatttcag	atttttctct	ctgcattttac	acacacacgc	acacaaacca	caccacacac	1260
acacacacac	acacacacac	acacacacac	acacaccaag	taccagtata	agcatctgcc	1320
atctgctttt	cccattgcca	tgcgtccctgg	tcaagctccc	ctcactctgt	ttcctggta	1380
gcatgtactc	ccctcatccg	attccctgt	agcagtcaact	gacagttaat	aaacctttgc	1440
aaacgttcaa	aaaaaaaaaa	aaaaaaa				1466

<210> 17

<211> 2653

<212> DNA

<213> Homo sapiens

<400> 17

ctcaaaaagg	gccggatttc	cttctcctgg	aggcagatgt	tgcctctctc	tctcgctcg	60
attggttcag	tgcactctag	aaacactgct	gtgggtggaga	aactggaccc	caggcttgaa	120
gcgaattcca	gcctgcaggg	ctgataagcg	aggcattagt	gagattgaga	gagactttac	180
cccggcgtgg	tggttggagg	gcccgcgacta	gagcagcagc	acaggcgcgg	gtcccgggag	240
gcccgcgtcg	ctcgcgcccga	gatgtggaat	ctccctcacg	aaaccgactc	ggctgtggcc	300
accgcgcgcc	gcccgcgtcg	gctgtgcgt	ggggcgcgtgg	tgctggcggg	tggcttcttt	360
ctccctcggt	tcctcttgcg	gtggtttata	aaatccctcca	atgaagctac	taacattact	420
ccaaagcata	atatgaaagc	atttttggat	gaattgaaag	ctgagaacat	caagaagttc	480
ttatataattt	ttacacagat	accacattt	gcaggaacag	aacaaaactt	ttagcttgca	540
aagcaaattt	aatcccagt	gaaagaattt	ggcctggat	cttggagact	agcacattat	600
gatgtcctgt	tgtccttaccc	aaataagact	catcccaact	acatctcaat	aattaatgaa	660
gatgaaatgt	agattttcaa	cacatcatta	tttgaaccac	ctccctccagg	atatgaaaat	720
gtttcgata	ttgttaccacc	tttcagtgt	ttctctctc	aaggaatgcc	agagggcgat	780
ctagtgtatg	ttaactatgc	acgaactgaa	gacttctta	aatttggaaacg	ggacatgaaa	840
atcaattgtct	ctggaaaat	tgtaatttgc	agatatggga	aagttttcag	agggaaaataag	900
gttaaaaatgt	cccagctggc	aggggcaaa	ggagtcattc	tctactccga	ccctgctgac	960
tactttgttc	ctgggggtgaa	gtccatccaa	gatgggttgg	atcttcctgg	aggtgggtgc	1020
cagcgtggaa	atatccctaa	tctgtatgg	gcaggagacc	ctctcacacc	aggttaccca	1080
gcaaataaat	atgcttatag	gctgttgcatt	gcagaggctg	ttgttcttcc	aagtatttcc	1140
gttcatccaa	ttggataacta	tgtgtcacag	aagcttccat	aaaaaatggg	tggctcagca	1200
ccaccagata	gcagctggag	aggaagtc	aaagtgcctt	acaatgttgg	acctggcttt	1260
actgaaactt	tttctacaca	aaaatgtcaag	atgcacatcc	actctacaa	tgaagtgaca	1320
agaatttaca	atgtgtatgg	tactctcaga	ggagcagtgg	aaccagacag	atatgtcatt	1380
ctggggagg	accggggactc	atgggtgtt	ggtggattt	accctcagag	tggagcagct	1440
gtttttcatg	aaatttgttag	gagctttgg	acactgtaaa	aggaagggtg	gagacctaga	1500
agaacaattt	tgttttgcag	ctgggatgc	gaagaatttt	gtcttcttgg	ttctacttgag	1560
tggcagagg	agaatttcaag	acttcttca	gagcgtggcg	tggcttataat	taatgctgac	1620
tcatctatag	aggaaaacta	cactctcaga	gttattgt	caccgcgtat	gtacagcttg	1680
gtacacaacc	taacaaaaga	gctgaaaagc	cctgatgaag	gctttgaagg	caaatcttt	1740
tatgaaagtt	ggactaaaaaa	aatgccttcc	ccagagttca	gtggcatgcc	caggataagc	1800
aaatttggat	ctggaaatgt	ttttgagggt	ttcttccaac	gacttggaaat	tgctttaggc	1860
agagcacgg	atactaaaaa	ttggaaaca	aacaattca	gcggctatcc	actgtatcac	1920
agtgtctatg	aaacatatga	gttgggtgg	aagttttatg	atccaatgtt	taaatatcac	1980
ctcaactgtgg	cccagggtcg	aggaggatg	gtgtttgagc	tagccatttc	catagtgc	2040
ccttttgatt	gtcgagat	tgtgttagt	ttaagaaatgt	atgtgtacaa	aatctacagt	2100
atttctatg	aacatccaca	ggaaatgtag	acatactgt	tatcattttg	ttcactttt	2160
tctcgat	agaattttac	agaaattgt	tccaagg	gtgagagact	ccaggacttt	2220
gacaaaagca	acccaatagt	attaagaatg	atgaatgtac	aactcatgtt	tctggaaaga	2280
gcatttattt	atccatttgg	gttaccagac	aggcctttt	ataggcatgt	catctatgct	2340
ccaaggcagcc	acaacaatgt	tgcaggggag	tcatttccag	gaatttatg	tgctctgttt	2400
gatattgaaa	gcaaaatgtt	cccttccaa	gcctggggag	aagtgaagag	acagatttat	2460
gttgcagcct	tcacagtgc	ggcagctgc	gagacttga	gtgaagttagc	ctaagaggat	2520
tcttttagaga	atccgtattt	aatttgggt	gtatgtact	cagaaagaat	cgtaatgggt	2580
atattgataa	attttaaaat	tggtatattt	gaaataaaatgt	tgaatattat	atataaaaaaa	2640
aaaaaaaaaa	aaa					2653

<210> 18

<211> 2420

MANNK.049A.txt

<212> DNA
 <213> Homo sapiens

<400> 18

ggatccaggc	cctgccagga	aaaatataag	ggccctgcgt	gagaacagag	ggggtcatcc	60
actgcatgag	agtggggatg	tcacagagtc	cagccccccc	tcctggtagc	actgagaagc	120
cagggctgtg	cttgcggctt	gcaccctgag	ggcccggtga	ttccttcc	tggagctcca	180
ggaaccaggc	agtgaggcct	tggctctgaga	cagtatcctc	aggtcacaga	gcagaggatg	240
cacagggtgt	gccagcagtg	aatgtttgcc	ctgaatgcac	accaagggcc	ccacctgcca	300
caggacacat	aggactccac	agagtctggc	ctcacctccc	tactgtcagt	cctgtagaat	360
cgacctctgc	tggccggctg	taccctgagt	accctctcac	ttccctcctc	aggttttcag	420
gggacaggcc	aaccaggagg	acaggattcc	ctggagggcc	cagaggagca	ccaaggagaa	480
gatctgttaag	taggccttg	ttagagtctc	caaggttcag	tttcagctg	aggcctctca	540
cacactccct	ctctcccccag	gcctgtgggt	cttcattgcc	cagctctgc	ccacactcct	600
gcctgctgcc	ctgacgagag	tcatcatgtc	tctttagcc	aggagtctgc	actgcaagcc	660
tgaggaaagcc	cttgaggccc	aacaagaggc	cctggggctg	gtgtgtgtgc	aggctgccac	720
ctccctctcc	tccctctgg	tcctgggcac	cctggaggag	gtggccactg	ctgggtcaac	780
agatccctcc	cagagtccctc	agggagcctc	cgccctttcc	actaccatca	acttcactcg	840
acagaggcaa	cccagtggagg	gttccagcag	ccgtgaagag	gagggggccaa	gcaccttgg	900
tatcctggag	tccttgcgttcc	gagcagtaat	cactaagaag	gtggctgatt	tggttgggtt	960
tctgcctc	aaatatcgag	ccagggagcc	agtcacaaag	gcagaaatgc	tggagagtgt	1020
catcaaaaat	tacaaggact	gtttccctga	gatcttcggc	aaagcctctg	agtccttgca	1080
gctggctttt	ggcatttgcac	tgaaggaagc	agacccccc	ggccactctt	atgtccctgt	1140
cacctgccta	ggtctctcct	atgatggcct	gctgggtgtat	aatcagatca	tgcccaagac	1200
aggcttcctg	ataattgtcc	tggctatgtat	tgcaatggag	ggccggccatg	ctcctgagga	1260
ggaaatctgg	gaggagctga	gtgtgtatgg	ggtgtatgtat	gggaggggagc	acagtgccta	1320
tggggagccc	aggaagctgc	tcacccaaga	tttgggtgcag	gaaaagtacc	tggagtaccg	1380
gcaggggtccg	gacagtgtatc	ccgcacgcata	tgagttcctg	tgggttccaa	gggcccctcgc	1440
tgaaccaccg	tatgtgaaag	tcctttagata	tgtgatcaag	gtcagtgcata	gagttcgctt	1500
tttcttccca	tccctgcgtg	aaggcagttt	gagagaggag	gaagagggag	tctgagcatg	1560
agttcagcc	aaggccatgt	ggggggggac	tggggccatg	caccccccac	ggccgcgtcc	1620
agcagcttcc	cctgcctctgt	gtgacatgag	ggccattttt	cactctgaag	agagcggta	1680
gtgttctcag	tagtaggttt	ctgttctatt	gggtgacttg	gagattttatc	tttggttctt	1740
tttggaaattt	ttcaaatgtt	tttttttaag	ggatgggtga	atgaacttca	gcatccaat	1800
ttatgaatga	cagcagtcac	acagttctgt	gtatatagtt	taagggttaag	agtcttggt	1860
tttattcaga	ttgggaaatc	cattctattt	tgtgaatttgg	gataataaca	gcagtgaaat	1920
aagtacttag	aaatgtaaa	aatgagcagt	aaaatagatg	agataaagaa	ctaaagaaat	1980
taagagatag	tcaattcttg	ccttatacct	cagtctattc	tgtaaaattt	ttaaagatat	2040
atgcataacct	ggatttcctt	ggcttcttgc	agaatgttaag	agaaattaaa	tctgaataaa	2100
gaattcttcc	tgttcaactgg	ctttttctt	ctccatgcac	tgacatctg	ctttttggaa	2160
gcccctgggt	tagtagtgg	gatgctaagg	taagccagac	tcataccac	ccatagggtc	2220
gtagagtcta	ggagctgcag	tcacgtatc	gagggtggaa	gatgtccctt	aaagatgtag	2280
ggaaaagtga	gagaggggtt	agggtgtgg	gctccgggtt	agagttgggg	agtgtcaat	2340
ccctgagctg	gggcattttt	ggcttgggaa	aactgcagtt	ccttctgggg	gagctgattt	2400
taatgatctt	gggtggatcc					2420

<210> 19
 <211> 4204
 <212> DNA
 <213> Homo sapiens

<400> 19

acgcaggccg	tgtatgtcacc	cagaccacac	cccttcccccc	aatgccactt	caggggggtac	60
tcagagtccat	agacttggtc	tgagggggagc	agaagcaatc	tgacaggat	ggcggtccag	120
gctcagccag	gcatcaactt	caggaccctg	aggatgatc	gaaggccccg	cccacccacc	180
cccaactccc	ccgaccaccc	caggatctac	agccctcagga	cccccggtcc	aatccttacc	240
ccttgcccca	tcaccatctt	catgttacc	tccaccccca	tccgatcccc	atccaggcag	300
aatccagttc	cacccctgtcc	cgaaacccag	ggttagtacc	ttgcccaggat	gtgacgcccac	360
tgacttgcgc	attggaggtc	agaagaccgc	gagatttctg	ccctgagcaaa	cgagcgtac	420
cctgacgtcg	gcggaggggaa	gcccggccac	gctcgggtag	gaggcaaggt	aagacgctga	480
gggaggactg	aggcgggcct	cacccatcagac	agagggcctc	aaataatcca	tgctgcctc	540
tgctgcccgg	cctggccac	cccgccagggg	aagacttcca	ggctgggtcg	ccactacctc	600
accccgccga	ccccccgcgc	tttagccac	gggaactctg	ggacagagac	ttaatgtggc	660
cagggcaggg	ctggtttagaa	gaggtcaggg	cccacgtgt	ggcaggaatc	aaggtcagga	720
ccccgaggg	gaactgaggg	cacccatcacc	accaccctca	ccaccatttc	cgtccccaa	780
cacccaaccc	caccccccattc	ccccatttccc	atccccaccc	ccacccctat	cctggcagaa	840
tccgggcttt	gccccctggta	tcaagtcaac	gaagctccgg	gaatggcggc	caggcacgtg	900
agtccctgagg	ttcacatcta	cggctaaagg	agggaagggg	ttcggatatcg	cgagtatggc	960

MANNK.049A.txt

cgttgggagg	cagcgaaagg	gcccaggcct	cctggaagac	agtggagtcc	tgaggggacc	1020
cagcatgcca	ggacaggggg	cccactgtac	ccctgtctca	aaccgaggca	cttttcatt	1080
cggctacggg	atcctaggg	atgcagaccc	acttcagcag	ggggttgggg	cccagccctg	1140
cgaggagtca	tggggaggaa	gaagagggag	gactgaggggg	accttggagt	ccagatcagt	1200
ggcaaccttg	ggctggggg	tgctgggcac	agtggccaaa	tgtgtctgt	gctcattgcg	1260
ccttcagggt	gaccagagag	ttgagggctg	tggtctgaag	agtgggactt	caggtcagca	1320
gagggaggaa	tcccaggatc	tgcagggccc	aagggttacc	cccaaggggc	ccctatgtgg	1380
tggacagatg	cagtggctc	aggatctgcc	aagcatccag	gtgaagagac	tgagggagga	1440
ttgagggta	ccctgggaca	gaatcgccac	tgggggcccc	ataaaaatct	gcccgtctcc	1500
tgctgttacc	tcagagagcc	tggcaggggc	tgtcagctga	ggtccttcca	ttatcctagg	1560
atcactgtat	tcagggaaagg	ggaagccttg	gtctgaggggg	gctgcactca	ggcagtaga	1620
gggagggctct	cagaccctac	taggagtgg	ggtgaggacc	aagcgtctc	ctcaccagg	1680
gtacatggac	tcaataaat	ttggacatct	ctcggttcc	ttttccggag	gacctgggaa	1740
tgtatggca	gatgtgggtc	ccctcatgtt	tttctgtacc	atatcaggta	tgtgagttct	1800
tgacatgaga	gatttcagg	ccacccggaa	ggagggatata	ggccctataa	ggagaaaggt	1860
gagggccctg	agtgagcaca	gaggggatcc	tccaccccg	tagagtgggg	acctcacaga	1920
gtctggccaa	ccctccgtac	agttctggga	atccgtgtct	gcgtttgctg	tctgcacatt	1980
ggggggccgt	ggattccct	cccaagggatc	aggagcttca	ggaacaaggc	agtgaggact	2040
ttgtctgagg	cagtgtccct	aggtcacaga	gtagaggggg	ctcagatagt	gccaacgggt	2100
aaggtttgc	ttggattcaa	accaagggcc	ccacctgccc	cagaacacat	ggactccaga	2160
gcccctggcc	tcaccctcaa	tacttcagt	cctgcagct	cagcatgcgc	tggccggatg	2220
taccctgagg	tgcctctca	cttcctcctt	caggttctga	ggggacaggc	tgacctggag	2280
gaccagaggc	ccccggagga	gcactgaagg	agaagatctg	taagtaagcc	tttgttagag	2340
cctccaaggt	tccattcagt	actcagctga	ggtctctcac	atgcctccct	tctcccccagg	2400
ccagtggtc	tccattgccc	agctctgccc	cacactcccg	cctgttgc	tgaccagagt	2460
catcatgcct	cttgagcaga	ggagtccagca	ctgcgaagct	gaagaaggcc	ttgaggcccg	2520
aggagaggcc	ctgggcctgg	tgggtgcgc	ggctcctgt	actgaggagc	aggaggtgc	2580
ctcctctct	tctactctag	ttgaagtctc	cttggggggag	gtgcctgctg	ccgagtcacc	2640
agatcctccc	cagagtcc	aggagccctc	cagcctcccc	actaccatga	actaccctct	2700
ctggagccaa	tcctatgagg	actccagcaa	ccaagaagag	gaggggccaa	gcaccttccc	2760
tgacctggag	tccgagttcc	aagcagcact	cagtaggaag	gtggccgagt	tggttcattt	2820
tctgctctc	aagtatcgag	ccagggagcc	ggtcacaaag	gcagaaatgc	tggggagtgt	2880
cgtcgaaat	tggcagtatt	tcttcctgt	gatcttcagc	aaagcttcca	gttccttgca	2940
gctggtctt	ggcattcgagc	tgatggaagt	ggaccccatc	ggccacttgt	acatcttgc	3000
cacccctctg	ggcctctct	acgatggcct	gctgggtgac	aatcagatca	tgcccaggc	3060
aggccctctg	ataatcgcc	tggccataat	cgcaagagag	ggcactgtg	ccccctgagga	3120
gaaaatctgg	gaggagctga	gtgtgttaga	ggtgttttag	ggaggggaag	acagtatctt	3180
gggggatccc	aagaagctgc	tcacccaaca	tttctgtcag	gaaaactacc	tggagtaccg	3240
gcaggtcccc	ggcagtgtac	ctgcattgtta	tgaattccgt	tgggttccaa	ggggccctcg	3300
tgaaccaggc	tatgtgaaag	tccgtccacca	tatggtaaag	atcagtggag	gacctcacat	3360
ttccatccca	cccctgcatg	agtgggggtt	gagagagggg	gaagagttag	tctgagcacg	3420
agttgcagcc	aggggccatgt	ggaggggggtc	tggggccatgt	cacccctccgg	ggccgcaccc	3480
cttagttcc	actgcctct	tgacgtgtag	gcccattctt	cactctttga	agcgagcagt	3540
cagcatttt	agtagtgggt	ttctgttctg	tttggatgact	tttggatatt	tctttgtttc	3600
ctgttgagt	tgttcaaatg	ttccctttaa	cggtatggtt	aatgagcgtc	agcatccagg	3660
tttatgaatg	acagtagtca	cacatagtgc	tgtttatata	gttttaggagt	aagagtcttg	3720
tttttactc	aaattggaa	atccattcca	ttttgtgaat	tgtgacataa	taatagcagt	3780
ggtaaaagta	tttgcttaaa	attgtgagcg	aattagcaat	aacatacatg	agataactca	3840
agaaaatcaa	agatagttga	ttcttgcctt	gtacctcaat	ctattctgt	aaattaaaca	3900
aatatgc	ccaggattt	cttgcattct	ttgagaatgc	aagcggaaatt	aaatctgaat	3960
aaataattct	tcctcttcac	tggctcggtt	cttttccgtt	cactcagcat	ctgctctgt	4020
ggaggccctg	ggttagtagt	ggggatgctt	aggtaaagcc	gactcacgcc	tacccatagg	4080
gctgttagac	ctaggacctg	cagtcatata	attaagggtt	tgagaagtc	tgtaagatgt	4140
agagggaaatg	taagagaggg	gtgagggtgt	ggcgctccgg	gtgagagtag	tggagtgtca	4200
						4204

<210> 20
 <211> 752
 <212> DNA
 <213> Homo sapiens

<400> 20
 atccctcggtt gcccgtaccc tctctctgag agccggcag aggctccgga gccatgcagg 60
 ccgaaggccg gggcacaggg ggttcgacgg gcgatgtca tggcccgagg gggccctggca 120
 ttccctgtgg cccaggggggc aatgtggcg gcccaggaga ggggggtgtcc acggggcggca 180
 gaggtccccgg gggcgcaggg gcagcaaggc ctcggggcc gggaggaggcc gccccggcggg 240
 gtcccgatgg cggcgcggct tcagggtctg atggatgtc cagatgcggg gccagggggc 300
 cggagagccg cctgcttgcg ttctaccctcg ccatgcctt cgcgcacacc atggaagcag 360

MANNK.049A.txt

agctggcccg	caggagccctg	gccaggatg	ccccaccgct	tcccggtccca	gggggtgccttc	420
tgaaggagtt	cactgtgtcc	ggcaacatac	tgactatccg	actgactgct	gcagaccacc	480
gccaactgca	gctctccatc	agctctgtc	tccagcagct	ttccctgttg	atgtggatca	540
cgcagtgctt	tctgcccgtg	ttttggctc	agcctccctc	agggcagagg	cgctaagccc	600
agcctggcgc	cctttcctag	gtcatgcctc	ctcccccattt	gaatggtccc	agcacgagtg	660
gccaggatcat	tgtggggggcc	tgattgtttt	tcgctggagg	aggacggctt	acatgtttgt	720
ttctgttagaa	aataaaaactg	agctacgaaa	aa			752

<210> 21
<211> 2148

<212> DNA

<213> Homo sapiens

<400> 21

gcttcagggt	acagctcccc	cgcagccaga	agccgggcct	gcagcgcctc	agcaccgctc	60
cgggacaccc	cacccgcctt	ccaggcgtga	cctgtcaaca	gcaacttcgc	ggtgtggtga	120
actctctgag	aaaaaaaccat	tttgattatt	actctcagac	gtgcgtggca	acaagtgact	180
gagacctaga	aatccaagcg	ttggagggtcc	tgaggccagc	ctaagtcgct	tcaaaaatgga	240
acgaaggcgt	tttgtgggtt	ccattcagag	ccgatacatc	agcatgagtg	tgtggacaag	300
cccacggaga	cttgcggagc	tggcagggca	gagcctgctg	aaggatgagg	ccctggccat	360
tgccgcctg	gagttgctgc	ccagggagct	cttccgccttca	ctttcatgg	cagcctttga	420
cgggagacac	agccagaccc	tgaaggcaat	gggtcaggcc	tggcccttca	cctgcctccc	480
tctgggagtg	ctgtatgggg	gacaacatct	tcacctggag	accttcaaag	ctgtgccttga	540
tggacttgat	gtgccttgc	cccaggaggt	tcgcccagg	aggtggaaac	ttcaagtgct	600
ggatttacgg	aagaactctc	atcaggactt	ctggactgtt	tggctggaa	acagggccag	660
tctgtactca	tttccagagc	cagaagcagc	tcagcccatg	acaaaagaagc	aaaaagtaga	720
tggttttagc	acagaggcag	agcagccctt	cattccagta	gaggtgctcg	tagacctgtt	780
cctcaaggaa	ggtgcctgtg	atgaattttt	ctcctaccc	atttggaaa	tgaagcgaaa	840
aaaaaaatgta	ctacgcctgt	gctgttaagaa	gctgaagatt	tttgcattgc	ccatgcagga	900
tatcaagatg	atctgtaaaa	tggtcagct	ggacttcat	gaagattttgg	aagtacttg	960
tacctggaaag	ctaccctaccc	tggcgaaattt	ttctcccttac	ctggggccaga	tgattaaatct	1020
gcgttagactc	ctcctcttcc	acatccatgc	atcttcctac	atttccccgg	agaaggaaga	1080
gcagtagatc	gcccagttca	ccttcagtt	cctcagtcgt	cagtgcctgc	aggctctcta	1140
tgtggactct	ttatttttcc	ttagaggccg	cctggatctc	ttgctcaggc	acgtgatgaa	1200
ccccctggaa	accctctcaa	taactaactg	ccggctttcg	gaagggggatg	tgtatgcatt	1260
gtcccagagt	cccagcgtca	gtcagctaa	tgtccttgagt	ctaagtgggg	tcatgctgac	1320
cgatgttaat	cccgagcccc	tccaaagctct	gctggagaga	gcctctgcca	ccctccagga	1380
cctgtgtctt	gatgagtgtt	ggatcacgg	tgatcagtc	cttgcccttcc	tgccttccct	1440
gagccactgc	tcccagctta	caaccttaag	cttctacggg	aattccatct	ccatatctgc	1500
cttgcagagt	ctcctgcagc	accatcatcg	gctgagcaat	ctgacccacg	tgctgtatcc	1560
tgtccccctg	gagagttat	aggacatcca	tggtaccc	cacccggaga	ggcttgccta	1620
tctgcattgc	aggctcagg	agttgtgtt	tgagttgggg	cggcccagca	tggctggct	1680
tagtgccaa	ccctgttcc	actgtgggg	cagaaccttc	tatgacccgg	agcccatcct	1740
gtccccctgt	ttcatgccta	actagctgg	tgcacatatc	aaatgtttca	ttctgcatac	1800
ttggacacta	aaggccaggat	gtgcattgc	tttgaagcaa	caaaggcagcc	acagtttcag	1860
acaatgttc	agtgtgagtg	agaaaaacat	gttcagtgag	aaaaaaacat	tcagacaat	1920
gttcagtgag	aaaaaaaagg	ggaagttggg	gataggcaga	tgttacttg	aggagttat	1980
gtgatctttg	ggggagataca	tcttatacg	tttagaaatag	aatctgaatt	tctaaaggga	2040
gattctggct	tgggaagttac	atgttaggat	taatccctgt	gtagactgtt	gtaaagaaac	2100
tgttggaaat	aaagagaagc	aatgtgaagc	aaaaaaaaaa	aaaaaaaaaa		2148

<210> 22
<211> 4530
<212> DNA
<213> Homo sapiens

<400> 22

aattctcgag	ctcgtcgacc	ggtcgacgag	ctcgagggtc	gacgagctcg	agggcgcgcg	60
cccgcccccc	acccctcgca	gcaccccgcg	cccccgcccc	tcccagccgg	gtccagccgg	120
agccatgggg	ccggagccgc	agtggagcacc	atggagctgg	cgcccttgg	ccgctgggggg	180
ctcctctcg	ccctcttgcc	ccccggagcc	gcgagcaccc	aagtgtgcac	cggcacagac	240
atgaagctgc	ggctccctgc	cagtcccgg	acccacccgg	acatgctccg	ccacctctac	300
cagggctgcc	aggtggtgca	ggggaaacctg	gaactcacct	acctgcccac	caatgccagc	360
ctgtccttcc	tgcaggatat	ccaggaggtt	cagggctacg	tgcctcatcg	tcacaaccaa	420
gtgaggcagg	tcccactgca	gaggctgcgg	attgtgcag	gcacccagct	ctttgaggac	480
aactatgccc	tggccgtgtt	agacaatgga	gaccgcgtga	acaataccac	ccctgtcaca	540
ggggcctccc	caggaggcct	gcgggagctg	cagttcgaa	gcctcacaga	gatcttgaaa	600
ggaggggtct	tgatccagcg	gaaccccccag	ctctgttacc	aggacacgat	tttgcggaaag	660

MANNK.049A.txt

gacatcttcc	acaagaacaa	ccagctggct	ctcacactga	tagacaccaa	ccgctctcg	720
gcctgccacc	cctgttctcc	gatgtgtaa	ggctcccgt	gctggggaga	gagttctgag	780
gattgtcaga	gcctgacg	cactgtctgt	gcccgtg	gtgcccgt	caaggggcca	840
ctgcccactg	actgctgcca	tgagcagtgt	gctgcccgt	gcacggggcc	caagcactct	900
gactgctgg	cctgcctcca	cttcaaccac	agtggcatct	gtgagctgca	ctgcccagcc	960
ctggtcac	acaacacaga	cacgttgag	tccatgccc	atcccgggg	ccggatataca	1020
ttcggcgcca	gctgtgtgac	tgccgttccc	tacaactacc	tttctacgga	cgtggatcc	1080
tgcaccctcg	tctgccccct	gcacaaccaa	gaggtgacag	cagaggatgg	aacacagcg	1140
tgtgagaagt	gcagcaagcc	ctgtcccga	gtgtgctatg	gtctgggcat	ggagcacttg	1200
cgagagggtga	gggcagttac	cagtccaa	atccaggagt	ttgctggctg	caagaagatc	1260
tttggggagcc	tgccatttct	gccggagagc	tttgcattggg	accagccct	caacactg	1320
ccgctccagc	cagagcagt	ccaagtgttt	gagactctgg	aagagatcac	aggttaccta	1380
tacatctcag	catggccgga	cagcctgcct	gacctcagcg	tcttccagaa	cctgcaagta	1440
atccggggac	gaattctgca	caatggcgcc	tactcgtg	ccctgcaagg	gctgggcattc	1500
agctgctgg	ggctgcgtc	actgaggggaa	ctgggcgtg	gactggccct	catccaccat	1560
aacacccacc	tctgttctgt	gcacacgggt	ccctgggacc	agcttcttcg	gaacccgcac	1620
caagctctgc	tccacactgc	caacccggca	gaggacgagt	gtgtggcga	gggcctggcc	1680
tgccaccagc	tgtgcggcc	agggcactgc	ttgggtccag	ggcccaccca	gtgtgtcaac	1740
tgcagccagt	tccttcgggg	ccagagatgc	ttggaggaaat	gcccagatact	gcaggggctc	1800
cccagggagt	atgtgaatgc	caggcactgt	ttggcgtg	accctgatgt	tcagccccag	1860
aatggctcag	tgacctgtt	tggaccggag	gctgaccagt	gtgtggcctg	tgcccactat	1920
aaggaccctc	ccttctgctg	ggccgctgc	cccagcgtg	tgaacactga	cctctcttac	1980
atgcccattc	ggaagtttcc	agatgaggag	ggcgcattcc	agccttgc	catcaactgc	2040
acccactcct	gtgtggacct	ggatgacaag	ggctgccc	ccgagcagag	agccagccct	2100
ctgacgttca	tcgtctctgc	ggtgttggc	attctgctgg	tcgtggctt	gggggtggc	2160
tttgggatcc	tcatcaagcg	acggcagcag	aagatccgg	agtagacatg	gcccggactg	2220
ctgcaggaaa	cggagctgg	ggagccgtg	acacactcg	gagcgtatcc	caaccaggcg	2280
cagatgcgga	tcctgaaaga	gacggagatg	aggaagggtg	aggtgttgg	atctggcgct	2340
tttggcagag	tctacaagg	catctggatc	cctgtatgggg	agaatgtgaa	aattccatgt	2400
gccatcaaag	tgttgaggaa	aaacacatcc	cccaaaggcc	acaaagaaat	cttagacgaa	2460
gcatacgtca	tggctgggt	gggctccca	tatgtctcc	gccttctggg	catctgcctg	2520
acatccacgg	tgcagctgtt	gacacagctt	atgcccatt	gctgcctctt	agaccatgtc	2580
cggggaaaacc	gcggacgcct	gggctccca	gaccgtgt	actgtgttat	gcagattg	2640
aaggggatga	gctacctgga	ggatgtgcgg	ctcgatcaca	gggacttggc	cgctcgaac	2700
gtgctggta	agagtccaa	ccatgtcaaa	attacagact	tcgggctggc	tcggctgctg	2760
gacattgacg	agacagagta	ccatgcagat	gggggcaagg	tgcccattcaa	gtggatggcg	2820
ctggagtcca	ttctccggc	gcccgttacc	caccagatg	atgtgtggag	ttatggtgt	2880
actgtgtggg	agctgatgac	ttttggggcc	aaaccttacg	atgggatccc	agcccgggag	2940
atccctgacc	tgctggaaaa	gggggagcg	ctgcccacgt	ccccatgtc	caccatgtat	3000
gtctacatga	tcatgttca	atgttggatg	attgactctg	aatgtcgcc	aagattccgg	3060
gagttgggt	ctgaatttctc	ccgcattggc	agggacccc	agcgtttgt	gtcattccag	3120
aatgaggact	tgggcccacg	cagtccctt	gacagcacct	tctaccgctc	actgctggag	3180
gacgatgaca	tggggggac	gttggatgt	gaggagatc	tggtacccca	gcagggtt	3240
ttctgtccag	accctgcccc	gggcgttgg	ggcatggtcc	accacaggca	ccgcagctca	3300
tctaccagg	tgggcggtt	ggacctgaca	ctagggctgg	agccctctg	agaggaggcc	3360
cccaggtctc	cactggcacc	ctccgaaagg	gctggctcc	atgtatttga	tggtaccc	3420
ggaatgggggg	cagccaagg	gctgcaaagc	ctccccacac	atgacccac	ccctctacag	3480
cggtagactg	aggacccac	agtacccctg	ccctctgaga	ctgatggcta	cggtgcccc	3540
ctgacctgca	ccccccagcc	tgaatatgt	aaccagccag	atgttgcgg	ccagccccct	3600
tcgccccgag	agggccctt	gcctgcttcc	cgacctgctg	gtgccactct	ggaaaggggcc	3660
aagactctct	ccccagggaa	gaatggggtc	gtcaaagacg	ttttgcctt	tgggggtg	3720
gtggagaacc	ccgagtactt	gacacccac	ggaggagct	ccctctagcc	ccacccctt	3780
cctgccttca	gcccagcctt	cgacaaccc	tattactgg	accaggaccc	accagagcg	3840
ggggctccac	ccagcacctt	caaagggaca	cctacgcag	agaacccaga	gtacctgggt	3900
ctggacgtgc	cagtgttac	cagaaggcc	agtccgcaga	agccctgtat	tgtcctcagg	3960
gaggcaggaa	ggcctgactt	ctgtggcat	caagagggtg	gagggccctc	cgaccactt	4020
caggggaaacc	tgccatgca	ggaacctgtc	ctaaggaaacc	ttccttcctg	tttgagttcc	4080
cagatggctg	gaaggggttcc	agcctgtt	gaagaggaaac	agcactgggg	agtcttgt	4140
gatttgcagg	ccctgcccc	tgagactct	gggtccatgt	gatgccacag	cccagcttgg	4200
cccttcctt	ccagatctt	ggtaactgaaa	gccttaggg	agctggctg	agaggggaag	4260
cggccctaag	ggagtgtcta	agaacaaaag	cgaccattt	agagactgtc	cctgaaacct	4320
agtactgccc	cccatgagga	aggaacacgca	atggtgcag	tatccaggct	ttgtacagag	4380
tgctttctg	tttagtttt	actttttttt	ttttgtttt	ttaaagacga	aataaagacc	4440
cagggggagaa	tgggtgtt	atggggaggc	aagtgtggg	ggtccttctc	cacacccact	4500
ttgtccattt	gcaaatatat	tttggaaaac				4530

MANNK.049A.txt

<212> DNA
 <213> Homo sapiens

<400> 23

ggaaaccgag	gcagaggagg	ctcaggtgt	gccaatcacc	ctgcacatca	gagttaccct	60
gggcagggcc	cactgagacc	tgggagggc	cactcgggac	ctggagggct	gggggctgcc	120
cgggcgttag	gggttaaagct	ccctacccaa	ctgcgcagaa	ggcctcagag	gcctggggc	180
tgggcttccc	ctttcacatc	gccctttaga	ggcccacgtg	tgggcattgg	cccgcgatct	240
gaaaggggct	gtcctgttcc	tcatggcgc	tgccagcgc	acgcactcct	ctttctgcct	300
ggccggccac	tcccgtctgc	tgtgacgcgc	ggacagagag	ctaccggtgg	acccacggtg	360
cctccctccc	tggatctac	acagaccatg	gcctgccaa	cggctcgcacc	cctgttggg	420
tcctgtggga	cccccgccct	cggcgcgc	ctgttctgc	tcttcagcct	cggatgggtg	480
cagccctcga	gjacccctgc	tggagagaca	gggcaggagg	ctgcgcctc	ggacggagtc	540
ctggccaacc	cacctaact	ttccagcctc	tcccctcgc	aactccttgg	cttcccggt	600
gcggaggtgt	ccggcgttag	cacggagct	gtccgggagc	tggctgtggc	cttggcacag	660
aagaatgtca	agctctcaac	agagcagctg	cgctgtctgg	ctcaccggct	ctctgagccc	720
cccggggacc	ttggacgccc	cccattggc	ctgctgtat	tcccaaccc	agatgcgttc	780
tcggggccccc	aggccctgcac	ccgttcttc	tcccgcac	cgaaggccaa	tgtggacctg	840
ctcccggaggg	gggctcccg	gjacccgcgg	ctgctgcct	cggctctggc	ctgctgggt	900
gtgcgggggt	ctctgcttag	cgaggctgat	gtgcgggct	tggaggccct	ggcttgcac	960
ctgcttgggc	gctttgtggc	cgagtgcgc	gaagtgc	tacccggct	gttgagctgc	1020
ccgggacccc	tggaccagga	ccagcaggag	gcagccagg	cggctctgc	gggcggggga	1080
ccccccctacg	gccccccgtc	gacatggct	gtctccacga	tggacgc	gcggggcctg	1140
ctgcccgtgc	tgggccagcc	catcatccgc	agcatccgc	agggcatcg	ggccgcgtgg	1200
cggcaacgct	cctctcg	cccattcctgg	cggcagcctg	aacggaccat	cctccggccg	1260
cggttccggc	gggaagtgg	gaagacagcc	tgtccttc	gcaagaaggc	ccgcgagata	1320
gacgagagcc	tcatcttca	caagaagtgg	gagctggaa	cctgcgtgg	tgcggccctg	1380
ctggccaccc	agatggacc	cgtjaccc	atcccctca	cctacgagca	gctggacgtc	1440
ctaaagcata	aactggatg	gctctaccca	caaggttacc	ccgagtctgt	gatccagcac	1500
ctgggttacc	tcttcctca	gatggaccc	gaggacattc	gcaagtggaa	tgtgacgtcc	1560
ctggagaccc	tgaaggctt	gcttgaagtc	aacaaagg	acgaaatgag	tcctcaggtg	1620
gccaccctga	tcgaccgctt	tgtgaaggga	agggggccag	tagacaaga	caccctagac	1680
accctgaccg	ccttctaccc	tgggtacctg	tgctccctca	gccccgagga	gctgagctcc	1740
gtgcccccca	gcagcatctg	ggcggtcagg	ccccaggacc	tggacacgt	tgacccaagg	1800
cagctggacg	tcctctatcc	caaggcccgc	tttgcttcc	agaacatgaa	cggttccgaa	1860
tactctgtga	agatccagtc	cttccctgggt	ggggccccc	cgaggatt	gaaggcgctc	1920
agtca	caga	atgtgagcat	ggacttggcc	acgttcatga	agtcgcggac	1980
ctgcccgtga	ctgtggctga	ggtgcagaaa	tttctggac	cccacgtgg	gggcctgaag	2040
gcggaggagc	ggcacccccc	ggtgcgggac	ttgatctac	ggcagcggca	ggacgacc	2100
gacacgctgg	ggctggggct	acagggcgc	atcccaac	gctacctgg	cctagac	2160
agcatgcaag	aggccctctc	ggggacgc	tgcctcc	gac	tgttctacc	2220
gtccctggcac	tgctccttagc	ctccaccc	gcctgagggc	cccactcc	tgctggccc	2280
agccctgctg	gggatcccc	cctggccagg	agcaggac	gggtggccccc	gttccacccc	2340
aagagaactc	g	gcgtcagta	aacgggaaca	tgccccctgc	agacacgt	2388

<210> 24

<211> 2412
 <212> DNA
 <213> Homo sapiens

<400> 24

ggaaaccgag	gcagaggagg	ctcaggtgt	gccaatcacc	ctgcacatca	gagttaccct	60
gggcagggcc	cactgagacc	tgggagggc	cactcgggac	ctggagggct	gggggctgcc	120
cgggcgttag	gggttaaagct	ccctacccaa	ctgcgcagaa	ggcctcagag	gcctggggc	180
tgggcttccc	ctttcacatc	gccctttaga	ggcccacgt	tgggcattgg	cccgcgatct	240
gaaaggggct	gtcctgttcc	tcatggcgc	tgccagcgc	acgcactcct	ctttctgcct	300
ggccggccac	tcccgtctgc	tgtgacgcgc	ggacagagag	ctaccggtgg	acccacggtg	360
cctccctccc	tggatctac	acagaccatg	gcctgccaa	cggctcgcacc	cctgttggg	420
tcctgtggga	cccccgccct	cggcgcgc	ctgttctgc	tcttcagcct	cggatgggtg	480
cagccctcga	ggaccctggc	tggagagaca	gggcaggagg	ctgcgcctc	ggacggagtc	540
ctggccaacc	cacctaact	ttccagcctc	tcccctcgc	aactccttgg	cttcccggt	600
gcggaggtgt	ccggcgttag	cacggagc	gtccgggagc	tggctgtgg	cttggcacag	660
aagaatgtca	agctctcaac	agagcagctg	cgctgtctgg	ctcaccggct	ctctgagccc	720
cccgaggacc	tggacgc	cccattggc	ctgctgtat	tcccaaccc	agatgcgttc	780
tcggggccccc	aggcctgcac	ccgttcttc	tcccgatca	cgaaggccaa	tgtggac	840
ctcccgaggg	gggctcccg	gjacccgcgg	ctgctgcct	cggctctggc	ctgctgggt	900
gtgcgggggt	ctctgcttag	cgaggctgat	gtgcgggct	tggaggccct	ggcttgcac	960
ctgcttgggc	gctttgtggc	cgagtcgc	gaagtgc	tacccggct	gttgagctgc	1020

MANNK_049A.txt

ccgggacccc	tggaccagga	ccagcaggag	gcagccagg	cggctctgca	gggcggggga	1080
ccccccctacg	gccccccgtc	gacatggct	gtctccacga	tggacgctct	gcggggcctg	1140
ctgcccgtgc	tggccagcc	catcatccgc	agcatcccg	aggcatcg	ggccgcgtgg	1200
cggaacgct	cctctcgga	cccattcctgg	cggcagcctg	aacggaccat	cctccggccg	1260
cggttccggc	gggaagtgg	gaagacagcc	tgtccttcag	gcaagaaggc	ccgcgagata	1320
gacgagagcc	tcatcttca	caagaagtgg	gagctggaa	cctgcgtgga	tgcggccctg	1380
ctggccaccc	agatggaccg	cgtgaacgccc	atcccctca	cctacgagca	gctggacgtc	1440
ctaaagata	aactggatga	gctctaccca	caaggttacc	ccgagtctgt	gatccagcac	1500
ctgggctacc	tcttcctcaa	gatgagccct	gaggacattc	gcaagtggaa	tgtgacgtcc	1560
ctggagaccc	tgaaggctt	gcttgaagtc	aacaaaggc	acgaaatgag	tcctcaggct	1620
cctccggcgc	ccctccca	ggtgccacc	ctgatcgacc	gcttggtaa	ggaaaggggc	1680
cagctagaca	aagacaccc	agacaccctg	accgcctct	accctggta	cctgtgtcc	1740
ctcagccccc	aggagctg	ctccgtgccc	cccagcaga	tctggcggt	caggccccag	1800
gacctggaca	cgtgtgaccc	aaggcagctg	gacgtcctct	atcccaaggc	ccgccttgct	1860
ttccagaaca	tgaacgggtc	cgaatacttc	gtgaagatcc	agtcccttc	gggtggggcc	1920
cccacggagg	atttgaaggc	gctcagtcag	cagaatgtga	gcatggactt	ggccacgttc	1980
atgaagctgc	ggacggatgc	ggtgcgtgccc	ttgactgtgg	ctgaggtgca	gaaacttctg	2040
ggacccacg	tggagggcct	gaaggcggag	gagcggcacc	gcccggtgcg	ggactggatc	2100
ctacggcagc	ggcaggacga	cctggacacg	ctggggctgg	ggctacaggg	cggcacatccc	2160
aacggctacc	tggtcctaga	cctcagcatg	caagaggccc	tctcggggac	gccctgcctc	2220
ctaggacctg	gacctgttct	caccgtcctg	gcactgctcc	tagcctccac	cctggcctga	2280
gggccccact	ccctgtctgg	ccccagccct	gctggggatc	ccgcctgtgg	caggagcagg	2340
cacgggttgt	ccccgttcca	ccccaaagaga	actcgcgctc	agtaaacggg	aacatgcccc	2400
ctgcagacac	gt					2412

<210> 25

<211> 3665

<212> DNA

<213> Homo sapiens

<400> 25

ggctggggc	agccgggtag	ctcggaggtc	gtggcgtgg	gggctagcac	cagcgctctg	60
tcggaggcg	cagcggttag	gtggaccgg	cagcggactc	accggccagg	gcgcgtcggt	120
ctggaatttg	atattcattg	atccgggtt	tatcccttct	cttttttctt	aaacattttt	180
ttttaaaact	gtattgttc	tcgttttaat	ttatttttgc	ttgccattcc	ccacttgaat	240
cggggcgcg	gcttggggag	attgtctac	ttccccaaat	cactgtggat	tttggaaacc	300
agcagaaaga	ggaaagaggt	agcaagagct	ccagagagaa	gtcgaggaag	agagagacgg	360
ggtcagagag	agcgcgcggg	cgtgcgagca	gcaaaagcga	cagggccaaa	tgagtgacc	420
tgcttttggg	ggtgaccggc	ggagcgcggc	gtgagccctc	ccccttggga	tcccgagct	480
gaccagtgc	gctgacggac	agacagacag	acaccggccc	cagccccagc	taccacctcc	540
tccccggccg	gcggcggaca	gtggacgcgg	cgcgagccg	cgggcaggggg	ccggagcccg	600
cggccggagg	cgggggtggag	ggggtcgggg	ctcgcggcgt	cgcaactgaaa	ctttctgtcc	660
aacttctggg	ctgttctcgc	ttcggaggag	ccgtggtccg	cgcgggggaa	gccgagccga	720
gcggagccgc	gagaagtgtc	agctcgggccc	gggaggagcc	gcagccggag	gagggggagg	780
aggaagaaga	gaaggaagag	gagagggggc	cgcagtggcg	actcggcgct	cggaagccgg	840
gctcatggac	gggtgaggcg	gcgggtgtgc	cagacagtgc	tccagccgcg	cgcgctcccc	900
aggccctggc	ccgggcctcg	ggccggggag	gaagagtagc	tcgcccggagc	gccgaggaga	960
gcggggccgc	ccacagcccg	agccggagag	ggagcgcgag	ccgcgcggc	cccggtcg	1020
cctccgaaac	catgaacttt	ctgtgtctt	gggtgcattt	gaccccttgc	ttgctgtct	1080
acctccacca	tgccaagtgg	tccaggctg	cacccatggc	agaaggagga	ggcagaatc	1140
atcacgaagt	ggtaaggatc	atgatgtct	atcagcgcag	ctactgcct	ccaatcgaga	1200
cccttgcgtt	cattttcag	gagtaccctg	atgagatcga	gtacatctt	aagccatctt	1260
gtgtccccct	gatgcgtatc	gggggtctgt	gcaatgcga	ggcccttgag	tgtgtgc	1320
ctgaggagtc	caacatcacc	atgcagat	tgcggatcaa	acctcacc	ggccagcaca	1380
taggagat	gagcttcata	cagcacaaca	aatgtaatg	cagaccaaag	aaagatagag	1440
caagacaaga	aaaaaaatca	gttcgaggaa	agggaaagg	gcaaaaacga	aagcgaaga	1500
aatcccgtt	taagtctgg	agcggtatc	ttgggtcccc	ctgctgtcta	atgcccctgga	1560
gcctccctgg	cccccatccc	tgtggccctt	gctcagagcg	gagaaagcat	ttgtttgtac	1620
aagatccgca	gacgtgtaaa	tgttcctgca	aaaacacaga	ctcgcgttgc	aaggcgaggc	1680
agtttgagtt	aaacgaacgt	acttgcagat	gtgacaagcc	gaggcggtga	gccggggcagg	1740
aggaaggagc	ctccctcagg	gtttcgggaa	ccagatctct	caccaggaaa	gactgataca	1800
gaacgatcga	tacagaaacc	acgctgccc	caccacacca	tccacatcga	cagaacagtc	1860
cttaatccag	aaacctgaaa	tgaaggaaaga	ggagactctg	cgagagacac	tttgggtccg	1920
gagggcgaga	ctccggcgg	agcattcccg	ggcgggtgac	ccagcacgg	ccctcttgg	1980
attggattcg	ccattttatt	tttcttgc	ctaaatcacc	gagcccgaa	gatttagagag	2040
ttttatttct	gggattccctg	tagacacacc	caccacata	catacatata	tatataatata	2100
tattatata	atataaaaaat	aaatatctt	attttatata	tataaaaaat	atatattctt	2160
tttttaaatt	aacagtgtca	atgttattgg	tgtcttact	ggatgtattt	gactgtgt	2220

MANNK.049A.txt

gacttgagtt	gggaggggaa	tgttccact	cagatcctga	caggaaagag	gaggagatga	2280
gagactctgg	catgatcttt	tttttgc	acttgggtgg	gccagggtcc	tctccctgc	2340
ccaggaatgt	gcaaggccag	ggcatgggg	caaataatgac	ccagtttgg	gaacaccgac	2400
aaaccaggcc	ctggcgtga	gcctctctac	cccaggtcag	acggacagaa	agacagatca	2460
caggtacagg	gatgaggaca	ccggctctga	ccaggagttt	ggggagctc	aggacattgc	2520
tgtgcttgg	ggattccctc	cacatgctgc	acgcgcac	cgc	ggcactgcct	2580
ggaagattca	ggagcctggg	cgcccttc	ttactctcac	ctgcttctga	tttgcccagg	2640
agaccactgg	cagatgtccc	ggcgaagaga	agagacacat	tgttggaaaga	agcagcccat	2700
gacagctccc	cttcctggg	ctcgccctca	tccttctctt	gctccccttc	ctggggtgca	2760
gcctaaaagg	acctatgtcc	tcacaccatt	gaaaccacta	gttctgtccc	cccaggagac	2820
ctggttgtgt	gtgtgtgagt	gttgcac	cctccatccc	ctggcccttc	ccttcccttc	2880
ccgaggcaca	gagagacagg	gcaggatcca	cgtgc	gtggaggcag	agaaaaagaga	2940
aagtgttta	tatacggtac	ttatataa	tcccttttta	attagaaatt	aaaacagtt	3000
attnaattaa	agagtaggtt	ttttttcag	tattcttgg	taatatttaa	tttcaactat	3060
ttatgatgt	tatctttgc	tctcttgc	tctcttattt	gtaccgg	ttgtatataa	3120
aattcatgtt	tccaatctct	ctctccctga	tcggtgacag	tcactagctt	atcttgaaca	3180
gatatttaat	tttgcataaca	ctcagctc	ccctcccg	tcccctggct	ccccagcaca	3240
cattccttgc	aaataaggtt	tcaatataca	tctacatact	atataatata	ttggcaactt	3300
gtatttgtgt	gtatataat	atataatatgt	ttatgtat	atgtgattct	gataaaatag	3360
acattgctat	tctgtttttt	atatgtaaaa	acaaaacaag	aaaaaaataga	gaattctaca	3420
tactaaatct	ctctcccttt	ttaattttaa	tatttgtat	catttattt	ttggtgctac	3480
tgttatccg	taataattgt	ggggaaaaga	tattaacatc	acgtctttgt	ctctagtgca	3540
gttttgcag	atattccgt	gtacatattt	atttttaaac	aacgacaaag	aaatacagat	3600
atatcttaaa	aaaaaaaaaaag	catttgc	taaagaattt	aattctgtac	tcaaaaaaaaaa	3660
						3665
						aaaaa

<210> 26

<211> 2204

<212> DNA

<213> Homo sapiens

<400> 26

gagcgggtgc	gaggctctgc	tcggatcgag	gtctgcagcg	cagttcggg	agcatgagt	60
ctgcagtgc	tgcagggaa	ctggcacggg	caccggccga	ccctgggaaa	gccgggggtcc	120
ccggagg	agctcccgga	gctccggcg	cggctccacc	ggcgaagag	atcccgagg	180
tccttagtgg	cccacgc	cgccggcgct	atgtgcgggg	ccgcttgg	ggcaaggcg	240
gctttgc	gtgcttcgag	atctcgac	cggacaccaa	ggaggtgttc	gcgggcaaga	300
ttgtgcctaa	gtctctgtc	ctcaagccgc	accagaggg	gaagatgtcc	atggaaatat	360
ccattcaccg	cagcctcgcc	caccagc	tctaggatt	ccacggctt	tgcaggaca	420
acgacttcgt	gttcgtgg	ttggagct	gccgcggag	gtctctc	gagctgcaca	480
agaggaggaa	agccctgt	gaggctgagg	cccgatacta	cctacggcaa	attgtgtt	540
gctgc	ctgcacccga	aaccgagtt	ttcatcgaga	cctcaagctg	ggcaac	600
tcctgaatga	agatctggag	gtggaaatag	gggattttgg	actggcaacc	aaagtcaat	660
atgacgggaa	gaggaagaag	accctgtgt	ggactctaa	ttacatagct	cccgagg	720
tgagaagaa	agggcacagt	ttcgagg	atgtgtgg	cattgggt	atcatgtata	780
ccttgttagt	gggcaaa	cctttgaga	cttctgc	aaaagagacc	taccc	840
tcaagaagaa	tgaatacagt	attccaa	acatcaac	cgtggcc	tccctcatcc	900
agaagatgct	tcagacagat	cccactgccc	gcccac	taacgagct	cttaatgac	960
agtttttac	ttctggctat	atccctgccc	gtctcc	cacctgc	accattcc	1020
caagttttc	gattgtccc	agcagctgg	acccac	ccgga	ctcacat	1080
tcaataaaagg	cttggagaac	ccctgc	agcgtcccc	ggaaaaagaa	gaaccagt	1140
ttcgagagac	agggtgg	gtcgact	acctc	catgtgc	cagctgc	1200
gtgtcaatgc	cttcaagcc	tcggagc	ggctgg	gcaagaggag	gctgagg	1260
ctgcctgc	ccccatcttc	tggtc	atgtgg	ctattcg	aagtac	1320
ttgggtatca	gctctgt	aaacgc	gggtgc	caatgact	acacgc	1380
tccttacaa	tgtatgg	agcctgc	acatag	tgacgg	gatcct	1440
tcaccgtg	ttcccatt	aactc	tga	cacc	aaatattt	1500
gcaattat	gagcgac	ttgt	cagg	catc	ccgc	1560
atgagctgc	ccggctgccc	tac	gtcc	cacc	gccat	1620
tgcacctcg	caacggc	gtc	actt	ggat	aagct	1680
tgtgccc	gatggc	gta	tcg	ac	cacat	1740
gcctg	cttgg	act	ca	gg	cc	1800
cccgactat	gggg	ac	gc	cc	cc	1860
cctaata	gggg	gg	ca	ca	cc	1920
ccataact	gggg	gg	cc	cc	cc	1980
ggcagagctg	cat	cat	ctg	ccc	cc	2040
cgggtgtgg	ttct	ca	cc	cc	cc	2100
gaatatttct	att	act	tc	cc	cc	2160

tgaatattca aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaa

MANNK.049A.txt

2204